var title_f4_25_4496="Normal arterial Doppler waveform";
var content_f4_25_4496=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F61122&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F61122&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Normal arterial Doppler waveform",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 373px; height: 266px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The normal Doppler waveform has a rapid upstroke, sharp peak, rapid downstroke, flow reversal and resumption of forward flow.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of the Division of Vascular Surgery at OHSU.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_25_4496=[""].join("\n");
var outline_f4_25_4496=null;
var title_f4_25_4497="Acute dysphagia child fever";
var content_f4_25_4497=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F75648&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F75648&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 630px\">",
"   <div class=\"ttl\">",
"    Acute dysphagia in children with fever",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 610px; height: 768px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     CNS: central nervous system; TEN: toxic epidermal necrolysis.",
"     <br/>",
"     * Presence of fever may be variable.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_25_4497=[""].join("\n");
var outline_f4_25_4497=null;
var title_f4_25_4498="Asthma daily diary PI";
var content_f4_25_4498=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F74684&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F74684&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 619px\">",
"   <div class=\"ttl\">",
"    Asthma diary",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 599px; height: 771px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Use the symptom severity key to give a numerical value to the severity of your asthma. In the notes section, note any triggers that seem to affect your asthma on the day it occurs. Triggers can include colds or infections, exercise, irritants, allergens, and cold air.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_25_4498=[""].join("\n");
var outline_f4_25_4498=null;
var title_f4_25_4499="Iothalamate meglumine: Drug information";
var content_f4_25_4499=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Iothalamate meglumine: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?7/19/7476?source=see_link\">",
"    see \"Iothalamate meglumine: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F183983\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Conray&reg;;",
"     </li>",
"     <li>",
"      Conray&reg; 30;",
"     </li>",
"     <li>",
"      Conray&reg; 43;",
"     </li>",
"     <li>",
"      Cysto-Conray&trade; II",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F15793707\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Conray&reg; 30;",
"     </li>",
"     <li>",
"      Conray&reg; 43;",
"     </li>",
"     <li>",
"      Conray&reg; 60;",
"     </li>",
"     <li>",
"      Cysto-Conray&trade; II",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F183986\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Iodinated Contrast Media;",
"     </li>",
"     <li>",
"      Radiological/Contrast Media (Ionic, High Osmolality)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F15962272\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling. Use caution in severe impairment and in setting of combined renal and hepatic disease.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F15962273\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling. Use caution in patients with combined hepatic and renal disease.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F183975\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Conray&reg; 30: 30% (50 mL [DSC], 150 mL) [contains edetate calcium disodium; provides organically-bound iodine 141 mg/mL]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Conray&reg; 43: 43% (50 mL, 100 mL [DSC], 200 mL [DSC], 250 mL) [contains edetate calcium disodium; provides organically-bound iodine 202 mg/mL]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Conray&reg;: 60% (30 mL, 50 mL, 100 mL, 150 mL) [contains edetate calcium disodium; provides organically-bound iodine 282 mg/mL]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution for instillation:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cysto-Conray&trade; II: 17.2% (250 mL) [contains edetate calcium disodium; provides organically-bound iodine 81 mg/mL]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F183971\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F13791581\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Compatibility in syringe: Compatible:",
"     </b>",
"     Ampicillin, chloramphenicol, cimetidine, dimenhyrinate, diphenhydramine, epinephrine, gentamicin, heparin, hyaluronidase, hydrocortisone sodium succinate, methylprednisolone sodium succinate, papaverine, protamine.",
"     <b>",
"      Incompatible:",
"     </b>",
"     Promethazine.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F183976\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Solution for injection: Arthrography, cerebral angiography, cranial computerized angiotomography, digital subtraction angiography, direct cholangiography, endoscopic retrograde cholangiopancreatography, excretory urography, peripheral arteriography, urography, venography; contrast enhancement of computed tomographic images",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Solution for instillation: Retrograde cystography and cystourethrography",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F5174551\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      High alert medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       The Institute for Safe Medication Practices (ISMP) includes this medication among its list of drugs which have a heightened risk of causing significant patient harm when used in error.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F183978\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to any component of the formulation; intrathecal administration; solution for instillation should not be used intravascularly",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Refer to product labeling for product and procedure specific contraindications",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299533\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F6221105\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MetFORMIN: Iodinated Contrast Agents may enhance the adverse/toxic effect of MetFORMIN. Renal dysfunction that may be caused by iodinated contrast agents may lead to metformin-associated lactic acidosis.  Management: Withhold metformin from all patients receiving intravascular iodinated contrast agents prior to or at the time of the procedure and for at least 48 hrs thereafter.  Document adequate renal function before restarting metformin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F183973\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     B/C (product dependent) (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F183980\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     In general, iodinated contrast media agents are avoided during pregnancy unless essential for diagnosis.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F183984\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Enters breast milk/use caution",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F183981\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Bottle feedings are recommended for 24 hours after administration.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16323207\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Conray 30 Intravenous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     30% (150 mL): $24.00",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Conray 43 Intravenous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     43% (50 mL): $13.20",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Conray Injection)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     60% (50 mL): $17.40",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Cysto-Conray II Urethral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     17.2% (250 mL): $27.60",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F6038660\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Conray (AU)",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      ACOG Committee on Obstetric Practice, &ldquo;ACOG Committee Opinion. Guidelines for Diagnostic Imaging During Pregnancy,&rdquo;",
"      <i>",
"       Obstet Gynecol",
"      </i>",
"      , 2004, 104(3):647-51.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?4/25/4499/abstract-text/15339791/pubmed\" id=\"15339791\" target=\"_blank\">",
"        15339791",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8960 Version 35.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-183.1.191.153-09F22AFDA5-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_25_4499=[""].join("\n");
var outline_f4_25_4499=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F183983\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15793707\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F183986\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15962272\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15962273\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F183975\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F183971\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13791581\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F183976\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5174551\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F183978\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299533\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6221105\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F183973\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F183980\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F183984\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F183981\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16323207\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6038660\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8960\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8960|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?7/19/7476?source=related_link\">",
"      Iothalamate meglumine: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f4_25_4500="Solvent detergent treated fresh frozen plasma: Drug information";
var content_f4_25_4500=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"13\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Solvent detergent treated fresh frozen plasma: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F16225140\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Octaplas&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F16225142\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Blood Product Derivative",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F16225347\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;margin-left:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Administer based on ABO-blood compatibility.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Replacement of multiple coagulation factors in patients with acquired deficiencies due to liver disease or when undergoing cardiac surgery or liver transplantation:",
"     </b>",
"     I.V.: Initial: 10-15 mL/kg.",
"     <b>",
"      Note:",
"     </b>",
"     Initial dose should increase plasma coagulation factors by ~15% to 25%; if hemostasis is not attained, may use higher doses.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Plasma exchange in patients with thrombotic thrombocytopenic purpura (TTP):",
"     </b>",
"     I.V.: 40-60 mL/kg.",
"     <b>",
"      Note:",
"     </b>",
"     Dose amount corresponds to 1-1.5 plasma volumes. Completely replace plasma volume removed during plasmapheresis with pooled plasma (human).",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F16225348\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F16225349\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer's labeling.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F16225350\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer's labeling; use with caution.",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F16225141\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F16225351\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Visually inspect for particulate matter or discoloration prior to administration. Do not use if turbid. Administer I.V. at a rate &le;1 mL/kg/minute using an infusion set with a filter.",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F16225342\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Do not combine with other drugs; inactivation and precipitation may occur.",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Y-site administration: Incompatible:",
"     </b>",
"     Calcium containing solutions",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F16225146\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Replacement of multiple coagulation factors in patients with acquired deficiencies due to liver disease or when undergoing cardiac surgery or liver transplantation; plasma exchange in patients with thrombotic thrombocytopenic purpura (TTP)",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F16225139\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Octaplas&reg; may be confused with Octaplex&reg;",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F16225174\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Central nervous system: Headache (&ge;1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dermatologic: Pruritus (&ge;1%), urticaria (&ge;1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Gastrointestinal: Nausea (&ge;1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Neuromuscular &amp; skeletal: Paresthesia (&ge;1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Postmarketing and/or case reports: Abdominal pain, allergic reaction, alkalosis, anaphylactoid reaction, bronchospasm, cardiac arrest, chest discomfort/pain, chills, circulatory overload, citrate toxicity, dyspnea, erythema, fever, hyperfibrinolysis, hypersensitivity reactions, pulmonary edema, rash, respiratory arrest/failure, seroconversions (passive transfer of antibodies), tachycardia, tachypnea, thromboembolism, vomiting",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F16225151\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     History of hypersensitivity to pooled plasma (human), fresh frozen plasma (FFP), or to plasma-derived products including any plasma protein; IgA deficiency; severe protein S deficiency",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F16225171\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Citrate toxicity: Hypocalcemia and associated symptoms (eg, fatigue, paresthesia, muscle spasm) due to citrate toxicity may occur with infusion rates &gt;1 mL/kg/minute (or 0.02-0.025 mmol citrate/kg/minute) especially in patients with hepatic dysfunction. If administering calcium gluconate to minimize citrate toxicity, administer calcium gluconate via another vein.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Hyperfibrinolysis: Due to reduced concentrations of alpha-2 antiplasmin, a physiologic inhibitor of t-PA-induced fibrinolysis, in solvent-detergent treated plasma, an increase in the incidence of hyperfibrinolysis has been observed in patients undergoing liver transplantation; monitor for signs of excessive bleeding (de Jonge, 2002).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Hypersensitivity reactions: Hypersensitivity (including and anaphylactoid or allergic reactions) has been reported.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Hypervolemia: High infusion rates may induce hypervolemia and subsequent pulmonary edema or heart failure. Monitor patients for signs and symptoms of pulmonary edema or heart failure and begin appropriate therapy if necessary.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Thrombosis: Solvent-detergent treated plasma contains low concentrations of protein S; during therapy, monitor for signs and symptoms of thrombosis in patients at risk. Use is contraindicated in patients with severe protein S deficiency.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Transfusion reactions: Administer pooled plasma (human) based on ABO compatibility; transfusion reactions may occur if ABO is mismatched.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Hepatic impairment: Use with caution in patients with hepatic impairment; may be at increased risk of citrate toxicity.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Dosage form specific issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Human plasma: Product of human plasma; may potentially contain infectious agents which could transmit disease, including a theoretical risk of Creutzfeldt-Jakob disease transmission. Infections thought to be transmitted by this product should be reported to the manufacturer.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F16265547\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F16265545\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no known significant interactions.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F16225147\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F16225148\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Animal reproduction studies have not been conducted. Treatment of thrombotic thrombocytopenic purpura (TTP) during pregnancy is generally the same as in nonpregnant women (Hunt, 2013; McCrae, 2010; Scully, 2012).",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F16225149\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F16225150\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Immunoglobulins, albumin and other components of pooled human plasma are endogenous components of breast milk (IOM 1991).",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F16225355\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Monitor response including activated partial thromboplastin time (aPTT), prothrombin time (PT), and/or specific coagulation factors. Monitor for signs of excessive bleeding (patients undergoing liver transplantation); signs and symptoms of pulmonary edema or heart failure; signs and symptoms of thrombosis (in patients at risk).",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F16225343\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Replaces human plasma proteins (eg, albumin, immunoglobulin and other globulins, coagulation factors, complement proteins, protease inhibitors)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      de Jonge J, Groenland TH, Metselaar HJ, et al, &ldquo;Fibrinolysis During Liver Transplantation is Enhanced by Using Solvent/Detergent Virus-Inactivated Plasma (ESDEP&reg;),&rdquo;",
"      <i>",
"       Anesth Analg",
"      </i>",
"      , 2002, 94(5):1127-31.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?4/25/4500/abstract-text/11973173/pubmed\" id=\"11973173\" target=\"_blank\">",
"        11973173",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Doyle S, O&rsquo;Brien P, Murphy K, et al, &ldquo;Coagulation Factor Content of Solvent/Detergent Plasma Compared with Fresh Frozen Plasma,&rdquo;",
"      <i>",
"       Blood Coagul Fibrinolysis",
"      </i>",
"      , 2003, 14(30):283-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?4/25/4500/abstract-text/12695752/pubmed\" id=\"12695752\" target=\"_blank\">",
"        12695752",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Guyatt GH, Akl EA, Crowther M, et al, &ldquo;Executive Summary: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines,&rdquo;",
"      <i>",
"       Chest",
"      </i>",
"      , 2012, 141(2 Suppl):7-47.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?4/25/4500/abstract-text/22315257/pubmed\" id=\"22315257\" target=\"_blank\">",
"        22315257",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hunt BJ, Thomas-Dewing RR, Bramham K, et al, \"Preventing Maternal Deaths Due to Acquired Thrombotic Thrombocytopenic Purpura,\"",
"      <i>",
"       J Obstet Gynaecol Res",
"      </i>",
"      , 2013, 9(1):347-50.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?4/25/4500/abstract-text/22690700/pubmed\" id=\"22690700\" target=\"_blank\">",
"        22690700",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      IOM (Institute of Medicine), &ldquo;Nutrition During Lactation,&rdquo; National Academy of Sciences Washington, DC: National Academy Press, 1991. Available at",
"      <a href=\"file://www.nap.edu\" target=\"_blank\">",
"       file://www.nap.edu",
"      </a>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Jilma-Stohlawetz P, Kursten FW, Horvath M, et al, &ldquo;Recovery, Safety, and Tolerability of a Solvent/Detergent-Treated and Prion-Safeguarded Transfusion Plasma in a Randomized, Crossover, Clinical Trial In Healthy Volunteers,&rdquo;",
"      <i>",
"       Transfusion",
"      </i>",
"      , 2013 [epub ahead of print].",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?4/25/4500/abstract-text/23320451/pubmed\" id=\"23320451\" target=\"_blank\">",
"        23320451",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      McCrae KR, \"Thrombocytopenia in Pregnancy,\"",
"      <i>",
"       Hematology Am Soc Hematol Educ Program",
"      </i>",
"      , 2010,  2010:397-402.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?4/25/4500/abstract-text/21239825/pubmed\" id=\"21239825\" target=\"_blank\">",
"        21239825",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Scully M, Hunt BJ, Benjamin S, et al, \"British Committee for Standards in Haematology. Guidelines on the Diagnosis and Management of Thrombotic Thrombocytopenic Purpura and Other Thrombotic Microangiopathies,\"",
"      <i>",
"       Br J Haematol",
"      </i>",
"      ,  2012, 158(3):323-35.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?4/25/4500/abstract-text/22624596/pubmed\" id=\"22624596\" target=\"_blank\">",
"        22624596",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 88325 Version 3.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-115.66.252.144-6720EAAD2F-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_25_4500=[""].join("\n");
var outline_f4_25_4500=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16225140\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16225142\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16225347\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16225348\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16225349\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16225350\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16225141\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16225351\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16225342\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16225146\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16225139\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16225174\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16225151\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16225171\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16265547\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16265545\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16225147\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16225148\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16225149\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16225150\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16225355\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16225343\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/88325\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/88325|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f4_25_4501="Loose anagen syndrome";
var content_f4_25_4501=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F87472&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F87472&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 596px\">",
"   <div class=\"ttl\">",
"    Loose anagen syndrome",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 576px; height: 432px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Diffuse hair thinning is present.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_25_4501=[""].join("\n");
var outline_f4_25_4501=null;
var title_f4_25_4502="Conjunctival injury";
var content_f4_25_4502=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Conjunctival injury",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/25/4502/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/25/4502/contributors\">",
"     Matthew F Gardiner, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/25/4502/contributors\">",
"     Carolyn E Kloek, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/25/4502/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/25/4502/contributors\">",
"     Richard G Bachur, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/25/4502/contributors\">",
"     Maria E Moreira, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/25/4502/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/25/4502/contributors\">",
"     James F Wiley, II, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?4/25/4502/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 6, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H4258320\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Trauma to the ocular surface often involves the conjunctiva. Mechanisms of injury to the conjunctiva include thermal and chemical burns and blunt or penetrating trauma. While injuries can be isolated to the conjunctiva, conjunctival injury can be the presenting sign of underlying intraocular trauma, including open globe injury. Careful evaluation, initial management, and triage of conjunctival injuries are essential to promote appropriate healing of the conjunctiva and other associated ocular injuries.",
"   </p>",
"   <p>",
"    The approach to subconjunctival hemorrhage, conjunctival abrasions, and conjunctival lacerations will be reviewed here. The treatment of ocular chemical burns is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/33/11801?source=see_link&amp;anchor=H9#H9\">",
"     \"Topical chemical burns\", section on 'Eye exposure'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4258329\">",
"    <span class=\"h1\">",
"     PERTINENT ANATOMY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The conjunctiva is a thin, transparent tissue which covers and is adherent to the anterior portion of the sclera and lines the inside of the eyelids (",
"    <a class=\"graphic graphic_figure graphicRef54272 \" href=\"UTD.htm?1/41/1681\">",
"     figure 1",
"    </a>",
"    ). The conjunctiva is conventionally divided into two sections: bulbar conjunctiva covering the sclera and tarsal conjunctiva covering the inside of the eyelids. The conjunctiva has multiple functions including producing portions of the tear film and serving as a barrier to infection.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3925859\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Subconjunctival hemorrhages are common in the elderly (over 80 years of age), in whom they are most often associated with systemic disease, primarily hypertension. In patients under 40 years of age, ocular rather than systemic conditions, primarily minor trauma or complications from contact lens use, are seen [",
"    <a class=\"abstract\" href=\"UTD.htm?4/25/4502/abstract/1\">",
"     1",
"    </a>",
"    ]. Other causes at any age include coagulopathy (especially in patients receiving anticoagulation therapy), diabetes mellitus, and elevated venous pressure (Valsalva maneuver, coughing, vomiting). Some adult patients report no history of trauma and note the hemorrhage after waking from sleep. Subconjunctival hemorrhage in the setting of significant blunt trauma to the eye may be a sign of globe rupture (",
"    <a class=\"graphic graphic_picture graphicRef65379 \" href=\"UTD.htm?15/57/16287\">",
"     picture 1",
"    </a>",
"    ). &nbsp;",
"   </p>",
"   <p>",
"    Conjunctival lacerations are relatively uncommon and may be associated with an open globe, traumatic hyphema, or other serious ocular injury. In a large prospective study of patients presenting to an ocular trauma department, conjunctival or subconjunctival injuries accounted for 4 percent of the 5671 injuries evaluated [",
"    <a class=\"abstract\" href=\"UTD.htm?4/25/4502/abstract/2\">",
"     2",
"    </a>",
"    ]. Most injuries occurred during work and involved periorbital and superficial ocular structures only. Conjunctival laceration has also resulted from airbag deployment following motor vehicle collisions [",
"    <a class=\"abstract\" href=\"UTD.htm?4/25/4502/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. In addition, several case series and case reports describe conjunctival lacerations in association with penetrating ocular injuries caused by exploded projectiles, eye injury from compressed air hoses, and high velocity blunt trauma from paintball guns [",
"    <a class=\"abstract\" href=\"UTD.htm?4/25/4502/abstract/5-9\">",
"     5-9",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4258343\">",
"    <span class=\"h1\">",
"     CLINICAL FEATURES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4258352\">",
"    <span class=\"h2\">",
"     Subconjunctival hemorrhage",
"    </span>",
"    &nbsp;&mdash;&nbsp;A typical subconjunctival hemorrhage appears as a focal, flat, red region on the ocular surface representing a collection of blood between the sclera and the conjunctiva (",
"    <a class=\"graphic graphic_picture graphicRef51578 \" href=\"UTD.htm?4/24/4495\">",
"     picture 2",
"    </a>",
"    ). In instances of scleral laceration, intraocular blood can leak through the defect and pool in the subconjunctival space, creating a bullous, elevated subconjunctival hemorrhage (",
"    <a class=\"graphic graphic_picture graphicRef62071 \" href=\"UTD.htm?8/59/9137\">",
"     picture 3",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef79392 \" href=\"UTD.htm?14/41/14994\">",
"     figure 2",
"    </a>",
"    ). Patients may note some foreign body sensation in the affected eye, but often have no symptoms.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4258359\">",
"    <span class=\"h2\">",
"     Conjunctival abrasion",
"    </span>",
"    &nbsp;&mdash;&nbsp;Conjunctival abrasions occur from blunt injuries and mild chemical or thermal burns and present as an irregularity of the epithelial surface of the conjunctiva, best seen using",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29108?source=see_link\">",
"     fluorescein",
"    </a>",
"    stain and a cobalt blue light. Regions of denuded epithelium will appear green.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4258366\">",
"    <span class=\"h2\">",
"     Conjunctival laceration",
"    </span>",
"    &nbsp;&mdash;&nbsp;A conjunctival laceration results from a penetrating injury to the ocular surface and clinically presents as a full-thickness defect in the conjunctiva. Often there are associated conjunctival abnormalities including chemosis and subconjunctival hemorrhage (",
"    <a class=\"graphic graphic_figure graphicRef79392 \" href=\"UTD.htm?14/41/14994\">",
"     figure 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/25/4502/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4258373\">",
"    <span class=\"h2\">",
"     Chemosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chemosis is a collection of serous fluid within the substance of the conjunctiva and is a nonspecific sign of conjunctival irritation. Chemosis can be seen in a wide range of conditions affecting the eye and orbit, including trauma, allergic reaction (",
"    <a class=\"graphic graphic_picture graphicRef78585 \" href=\"UTD.htm?30/18/31010\">",
"     picture 4",
"    </a>",
"    ), inflammation, hypoalbuminemic states or anasarca, and infection. It can also be seen in patients on chronic positive pressure ventilation. Rarely, chemosis may be the only conjunctival sign of an occult scleral laceration.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4258380\">",
"    <span class=\"h1\">",
"     PRIMARY EVALUATION AND MANAGEMENT",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4258389\">",
"    <span class=\"h2\">",
"     Initial assessment",
"    </span>",
"    &nbsp;&mdash;&nbsp;The standard trauma evaluation should be followed to evaluate for life-threatening injuries in multiple trauma patients before attention is focused on the eyes. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/11/35002?source=see_link\">",
"     \"Initial management of trauma in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/16/29962?source=see_link\">",
"     \"Trauma management: Approach to the unstable child\"",
"    </a>",
"    .).",
"   </p>",
"   <p>",
"    The key to appropriate care of conjunctival injuries is rapid recognition of serious associated ocular injuries [",
"    <a class=\"abstract\" href=\"UTD.htm?4/25/4502/abstract/10-12\">",
"     10-12",
"    </a>",
"    ]. Any patient who has sustained a conjunctival laceration is at significant risk for an open globe injury or traumatic hyphema. The clinical features and initial management of patients with these ocular injuries are summarized in the rapid overviews (",
"    <a class=\"graphic graphic_table graphicRef50022 \" href=\"UTD.htm?16/28/16845\">",
"     table 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef74146 \" href=\"UTD.htm?28/28/29133\">",
"     table 2",
"    </a>",
"    ) and are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/10/38057?source=see_link&amp;anchor=H12#H12\">",
"     \"Traumatic hyphema: Clinical features and management\", section on 'Initial emergency assessment'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/34/8745?source=see_link&amp;anchor=H22#H22\">",
"     \"Open globe injuries: Emergent evaluation and initial management\", section on 'Initial emergency assessment and treatment'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    If a chemical burn to the ocular surface has occurred, copious irrigation of saline should be performed until the measured pH of the ocular surface is neutral. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/33/11801?source=see_link&amp;anchor=H9#H9\">",
"     \"Topical chemical burns\", section on 'Eye exposure'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Corneal abrasions (",
"    <a class=\"graphic graphic_picture graphicRef77817 \" href=\"UTD.htm?20/21/20816\">",
"     picture 5",
"    </a>",
"    ) and foreign bodies (",
"    <a class=\"graphic graphic_picture graphicRef54709 \" href=\"UTD.htm?3/26/3488\">",
"     picture 6",
"    </a>",
"    ) are also frequently associated with conjunctival injuries and are best seen with slit lamp and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29108?source=see_link\">",
"     fluorescein",
"    </a>",
"    examination. If an open globe is obvious or highly likely, the clinician should not place eye drops or fluorescein in the eye. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/50/34600?source=see_link&amp;anchor=H10#H10\">",
"     \"Corneal abrasions and corneal foreign bodies\", section on 'Fluorescein examination'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    At times, the extent of damage to surrounding structures in a child with a conjunctival injury cannot be determined because the patient is unable to cooperate with the examination. In these situations, if an open globe is considered likely, the child should have an eye shield placed and arrangements be made for examination by an ophthalmologist under procedural sedation in the emergency department or general anesthesia in the operating room.",
"   </p>",
"   <p>",
"    In cooperative patients who do not have signs of an open globe injury, the eye exam should be performed in the standard fashion. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/50/34600?source=see_link&amp;anchor=H6#H6\">",
"     \"Corneal abrasions and corneal foreign bodies\", section on 'Eye examination'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/28/44486?source=see_link&amp;anchor=H13#H13\">",
"     \"Slit lamp examination\", section on 'Performing the exam'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4258396\">",
"    <span class=\"h2\">",
"     Diagnostic tests",
"    </span>",
"    &nbsp;&mdash;&nbsp;If a small bulbar conjunctival laceration is present and there are no other signs of open globe injury (",
"    <a class=\"graphic graphic_table graphicRef50022 \" href=\"UTD.htm?16/28/16845\">",
"     table 1",
"    </a>",
"    ), the laceration can be explored with the aid of the slit lamp. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/28/44486?source=see_link&amp;anchor=H13#H13\">",
"     \"Slit lamp examination\", section on 'Performing the exam'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The eye should be anesthetized with a topical drop (ie,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/12/36032?source=see_link\">",
"     tetracaine",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/57/2963?source=see_link\">",
"     proparacaine",
"    </a>",
"    ) and the conjunctival laceration explored with a cotton-tip applicator, moistened with sterile water of normal saline. With the aid of a slit lamp, effort should be made to visualize the underlying sclera to ensure that it is intact. If a scleral laceration or prolapsed uvea is visible at any point during the exploration, manipulation of the eye should be stopped and treatment for an open globe initiated (",
"    <a class=\"graphic graphic_table graphicRef50022 \" href=\"UTD.htm?16/28/16845\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Although probing of a bulbar conjunctival laceration is ideally performed by an ophthalmologist with the aid of a slit lamp, clinicians with expertise in the use of a slit lamp may perform this test in cases where an ophthalmologist is not readily available, and definitive eye care will require prolonged patient transport. In addition to ocular perforation, large conjunctival lacerations can be an entry site for penetrating orbital injury.",
"   </p>",
"   <p>",
"    If open globe injury or penetrating injury to the orbit cannot be ruled out based on a suspicious conjunctival laceration or a bullous subconjunctival hemorrhage, an orbital CT with thin cuts (&lt;2 mm) should be performed. CT findings of open globe injury include an intraocular foreign body, intraocular air, eye wall deformity, volume loss of the eye, and irregular scleral contour (",
"    <a class=\"graphic graphic_figure graphicRef79392 \" href=\"UTD.htm?14/41/14994\">",
"     figure 2",
"    </a>",
"    ). If radiologic evidence of open globe injury or orbital foreign body is present, an eye shield should be placed and ophthalmology should be urgently consulted. However, ocular CT has limited ability to demonstrate an occult open globe injury and should not be used as the sole determining factor for decisions regarding the need for evaluation by an ophthalmologist. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/34/8745?source=see_link&amp;anchor=H24#H24\">",
"     \"Open globe injuries: Emergent evaluation and initial management\", section on 'Imaging'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3927853\">",
"    <span class=\"h1\">",
"     INDICATIONS FOR OPHTHALMOLOGIC CONSULTATION OR REFERRAL",
"    </span>",
"    &nbsp;&mdash;&nbsp;An ophthalmologist should be urgently consulted in patients with evidence of an open globe (",
"    <a class=\"graphic graphic_table graphicRef50022 \" href=\"UTD.htm?16/28/16845\">",
"     table 1",
"    </a>",
"    ), traumatic hyphema (",
"    <a class=\"graphic graphic_table graphicRef74146 \" href=\"UTD.htm?28/28/29133\">",
"     table 2",
"    </a>",
"    ), intraorbital penetration, or conjunctival lacerations &gt;1 cm in length that will require suturing while limiting potential damage to the eye [",
"    <a class=\"abstract\" href=\"UTD.htm?4/25/4502/abstract/10,11,13\">",
"     10,11,13",
"    </a>",
"    ]. Patients with substantial traumatic subconjunctival hemorrhage, particularly in the setting of bullous conjunctival elevation, warrant prompt referral to an ophthalmologist to evaluate for deeper, underlying trauma and to assess further for an occult open globe injury.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4258403\">",
"    <span class=\"h2\">",
"     Management",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3927931\">",
"    <span class=\"h3\">",
"     Subconjunctival hemorrhage",
"    </span>",
"    &nbsp;&mdash;&nbsp;Spontaneous, nontraumatic causes of subconjunctival hemorrhage self resolve over two to three weeks without ocular sequelae and require no treatment. In elderly patients, the clinician should perform a complete history to determine if any trauma occurred and measure the blood pressure. Coagulation studies should be performed to assess for a bleeding diathesis or overmedication in patients who are anticoagulated if subconjunctival hemorrhages are recurrent.",
"   </p>",
"   <p>",
"    Subconjunctival hemorrhage resulting from trauma (or cases when trauma cannot be ruled out in patients who are poor historians), particularly in the setting of bullous elevation of the conjunctiva, warrants ophthalmology consultation to evaluate for underlying retinal trauma and definitively rule out open globe injury.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3927938\">",
"    <span class=\"h3\">",
"     Conjunctival abrasion or laceration",
"    </span>",
"    &nbsp;&mdash;&nbsp;Conjunctival injury can be a sign of intraocular trauma, including open globe injury or penetration of a foreign body into the eye or orbit (",
"    <a class=\"graphic graphic_table graphicRef50022 \" href=\"UTD.htm?16/28/16845\">",
"     table 1",
"    </a>",
"    ). When these associated conditions cannot be ruled out, ophthalmology consultation should be urgently obtained.",
"   </p>",
"   <p>",
"    Isolated conjunctival abrasions are treated with antibiotic ointment (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/29/36304?source=see_link\">",
"     erythromycin",
"    </a>",
"    ophthalmic ointment or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/20/6469?source=see_link\">",
"     bacitracin",
"    </a>",
"    ophthalmic ointment applied four times daily for one week). Referral to an ophthalmologist for a complete eye examination within one to three days of injury is a reasonable precaution in these patients if all symptoms have not resolved and in contact wearers. These injuries typically heal within two to three days.",
"   </p>",
"   <p>",
"    All patients with conjunctival lacerations should be discussed with an ophthalmologist if available. If a conjunctival laceration is determined to be superficial, not associated with any other serious intraorbital or ocular injury, and is small (&lt;1 cm), the patient may receive treatment with an antibiotic ointment (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/29/36304?source=see_link\">",
"     erythromycin",
"    </a>",
"    ophthalmic ointment) and be referred for ophthalmologic evaluation in one to three days. [",
"    <a class=\"abstract\" href=\"UTD.htm?4/25/4502/abstract/10,13\">",
"     10,13",
"    </a>",
"    ]. Larger lacerations warrant prompt repair by an ophthalmologist.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4258424\">",
"    <span class=\"h1\">",
"     OUTCOMES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with an isolated conjunctival injury typically recover fully without any vision loss. In cases with an associated ocular injury, visual outcome depends on the severity of the intraocular injury. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/34/8745?source=see_link&amp;anchor=H30#H30\">",
"     \"Open globe injuries: Emergent evaluation and initial management\", section on 'Outcomes'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/10/38057?source=see_link&amp;anchor=H29#H29\">",
"     \"Traumatic hyphema: Clinical features and management\", section on 'Outcomes'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4258431\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The conjunctiva is a thin, transparent tissue which covers the anterior portion of the sclera and lines the inside of the eyelids (",
"      <a class=\"graphic graphic_figure graphicRef54272 \" href=\"UTD.htm?1/41/1681\">",
"       figure 1",
"      </a>",
"      ). Trauma to the ocular surface frequently involves the conjunctiva. (See",
"      <a class=\"local\" href=\"#H4258320\">",
"       'Introduction'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H4258329\">",
"       'Pertinent anatomy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Subconjunctival hemorrhage appears as a focal, flat, red region on the ocular surface representing a collection of blood between the sclera and the conjunctiva (",
"      <a class=\"graphic graphic_picture graphicRef51578 \" href=\"UTD.htm?4/24/4495\">",
"       picture 2",
"      </a>",
"      ). Most subconjunctival hemorrhages are not associated with intraocular injury. However, in instances of scleral laceration, intraocular blood or fluid can leak through the defect and pool in the subconjunctival space creating a bullous, elevated subconjunctival hemorrhage which may hide the laceration (",
"      <a class=\"graphic graphic_figure graphicRef79392 \" href=\"UTD.htm?14/41/14994\">",
"       figure 2",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H3925859\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Conjunctival lacerations are frequently associated with intraocular or intraorbital trauma (",
"      <a class=\"graphic graphic_figure graphicRef79392 \" href=\"UTD.htm?14/41/14994\">",
"       figure 2",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H3925859\">",
"       'Epidemiology'",
"      </a>",
"      above.) Patients with these injuries warrant careful evaluation for an open globe (",
"      <a class=\"graphic graphic_table graphicRef50022 \" href=\"UTD.htm?16/28/16845\">",
"       table 1",
"      </a>",
"      ) or traumatic hyphema (",
"      <a class=\"graphic graphic_table graphicRef74146 \" href=\"UTD.htm?28/28/29133\">",
"       table 2",
"      </a>",
"      ). Identification of an open globe may require probing of the conjunctival laceration during slit lamp examination, preferably by an ophthalmologist. Computed tomography of the orbit may also be helpful. (See",
"      <a class=\"local\" href=\"#H4258389\">",
"       'Initial assessment'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H4258396\">",
"       'Diagnostic tests'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      An ophthalmologist should be urgently consulted in patients with evidence of an open globe (",
"      <a class=\"graphic graphic_table graphicRef50022 \" href=\"UTD.htm?16/28/16845\">",
"       table 1",
"      </a>",
"      ), traumatic hyphema (",
"      <a class=\"graphic graphic_table graphicRef74146 \" href=\"UTD.htm?28/28/29133\">",
"       table 2",
"      </a>",
"      ), intraorbital penetration, or conjunctival lacerations &gt;1 cm in length that will require special suturing techniques that avoid eye injury. Patients with traumatic subconjunctival hemorrhage, particularly in the setting of bullous conjunctival elevation, warrant prompt referral to an ophthalmologist to evaluate for deeper injury and to assess further for an occult globe rupture. (See",
"      <a class=\"local\" href=\"#H3927853\">",
"       'Indications for ophthalmologic consultation or referral'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Management of isolated conjunctival injuries are as follows (see",
"      <a class=\"local\" href=\"#H4258403\">",
"       'Management'",
"      </a>",
"      above):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Spontaneous, nontraumatic causes of subconjunctival hemorrhage self resolve over two to three weeks without ocular sequelae and require no treatment. In elderly patients, the clinician should perform a complete history to determine if any trauma occurred and measure the blood pressure. Coagulation studies should be performed to assess for a bleeding diathesis or overmedication in patients who are anticoagulated if subconjunctival hemorrhages are recurrent.",
"     </li>",
"     <li>",
"      Subconjunctival hemorrhage resulting from trauma (or cases when trauma cannot be ruled out in patients who are poor historians), particularly in the setting of bullous elevation of the conjunctiva, warrants ophthalmology consultation to evaluate for underlying retinal trauma and definitively rule out open globe injury.",
"     </li>",
"     <li>",
"      Patients with conjunctival abrasions are treated with antibiotic ointment (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/29/36304?source=see_link\">",
"       erythromycin",
"      </a>",
"      ophthalmic ointment) and in patients whose symptoms have not fully resolved within one to three days or contact wearers, referral to an ophthalmologist. &nbsp;",
"     </li>",
"     <li>",
"      Patients with small (&lt;1 cm) conjunctival lacerations should receive an antibiotic ointment (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/29/36304?source=see_link\">",
"       erythromycin",
"      </a>",
"      ophthalmic ointment) with ophthalmologic follow up arranged for one to three days. Lacerations larger than 1 cm should be promptly referred to an ophthalmologist.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H91331342\">",
"    <span class=\"h1\">",
"     ACKNOWLEDGMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;We are saddened by the untimely death of John Marx, MD, who passed away in July 2012. We wish to acknowledge Dr. Marx's dedication and his many contributions to UpToDate, in particular, his work as editor-in-chief for Emergency Medicine and as a section editor and author for Adult Trauma.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/25/4502/abstract/1\">",
"      Mimura T, Usui T, Yamagami S, et al. Recent causes of subconjunctival hemorrhage. Ophthalmologica 2010; 224:133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/25/4502/abstract/2\">",
"      Macewen CJ. Eye injuries: a prospective survey of 5671 cases. Br J Ophthalmol 1989; 73:888.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/25/4502/abstract/3\">",
"      Ghafouri A, Burgess SK, Hrdlicka ZK, Zagelbaum BM. Air bag-related ocular trauma. Am J Emerg Med 1997; 15:389.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/25/4502/abstract/4\">",
"      Onwuzuruigbo CJ, Fulda GJ, Larned D, Hailstone D. Traumatic blindness after airbag deployment: bilateral lenticular dislocation. J Trauma 1996; 40:314.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/25/4502/abstract/5\">",
"      Sellar PW, Johnston PB. Ocular injuries due to exploding bottles of carbonated drinks. BMJ 1991; 303:176.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/25/4502/abstract/6\">",
"      Mutlukan E, Fleck BW, Cullen JF, Whittle IR. Case of penetrating orbitocranial injury caused by wood. Br J Ophthalmol 1991; 75:374.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/25/4502/abstract/7\">",
"      Yuksel M, Yuksel KZ, Ozdemir G, Ugur T. Bilateral orbital emphysema and pneumocephalus as a result of accidental compressed air exposure. Emerg Radiol 2007; 13:195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/25/4502/abstract/8\">",
"      Jamra FA, Halasa A, Salman S. Letter bomb injuries: a report of three cases. J Trauma 1974; 14:275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/25/4502/abstract/9\">",
"      Yip CC, Tan DT, Balakrishnan V, Choo CT. High-pressure paint gun injury to the orbit and ocular adnexa. Int Ophthalmol 1998; 22:335.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/25/4502/abstract/10\">",
"      Bord SP, Linden J. Trauma to the globe and orbit. Emerg Med Clin North Am 2008; 26:97.",
"     </a>",
"    </li>",
"    <li>",
"     Rhee, DJ. The Wills Eye Manual: Office and Emergency Room Diagnosis and Treatment of Eye Disease, 3rd, Lippincott Williams &amp; Wilkins, Philadelphia 1999.",
"    </li>",
"    <li>",
"     Shingleton, BJ, Hersh, PS, Kenyon, KR. Eye Trauma, Mosby Year Book, St. Louis 1991.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/25/4502/abstract/13\">",
"      Pokhrel PK, Loftus SA. Ocular emergencies. Am Fam Physician 2007; 76:829.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 13904 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-118.195.65.243-298F256B3B-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_25_4502=[""].join("\n");
var outline_f4_25_4502=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H4258431\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4258320\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4258329\">",
"      PERTINENT ANATOMY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3925859\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4258343\">",
"      CLINICAL FEATURES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4258352\">",
"      Subconjunctival hemorrhage",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4258359\">",
"      Conjunctival abrasion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4258366\">",
"      Conjunctival laceration",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4258373\">",
"      Chemosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4258380\">",
"      PRIMARY EVALUATION AND MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4258389\">",
"      Initial assessment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4258396\">",
"      Diagnostic tests",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3927853\">",
"      INDICATIONS FOR OPHTHALMOLOGIC CONSULTATION OR REFERRAL",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4258403\">",
"      Management",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H3927931\">",
"      - Subconjunctival hemorrhage",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H3927938\">",
"      - Conjunctival abrasion or laceration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4258424\">",
"      OUTCOMES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4258431\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H91331342\">",
"      ACKNOWLEDGMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"EM/13904\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/13904|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?1/41/1681\" title=\"figure 1\">",
"      Conjunctival anatomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?14/41/14994\" title=\"figure 2\">",
"      Zone 2 blunt injury",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/13904|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?15/57/16287\" title=\"picture 1\">",
"      Scleral rupture",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?4/24/4495\" title=\"picture 2\">",
"      Subconjunctival hemorrhage",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?8/59/9137\" title=\"picture 3\">",
"      Bullous subconjunctival hemorrhage",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?30/18/31010\" title=\"picture 4\">",
"      Allergic conjunctivitis with chemosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?20/21/20816\" title=\"picture 5\">",
"      Corneal abrasion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?3/26/3488\" title=\"picture 6\">",
"      Linear corneal abrasion",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/13904|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/28/16845\" title=\"table 1\">",
"      Open globe rapid overview",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?28/28/29133\" title=\"table 2\">",
"      Hyphema rapid overview",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/50/34600?source=related_link\">",
"      Corneal abrasions and corneal foreign bodies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/11/35002?source=related_link\">",
"      Initial management of trauma in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/34/8745?source=related_link\">",
"      Open globe injuries: Emergent evaluation and initial management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/28/44486?source=related_link\">",
"      Slit lamp examination",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/33/11801?source=related_link\">",
"      Topical chemical burns",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/16/29962?source=related_link\">",
"      Trauma management: Approach to the unstable child",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/10/38057?source=related_link\">",
"      Traumatic hyphema: Clinical features and management",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f4_25_4503="Repaglinide: Drug information";
var content_f4_25_4503=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Repaglinide: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?34/58/35748?source=see_link\">",
"    see \"Repaglinide: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F217610\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Prandin&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F217611\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      CO-Repaglinide;",
"     </li>",
"     <li>",
"      GlucoNorm&reg;;",
"     </li>",
"     <li>",
"      PMS-Repaglinide;",
"     </li>",
"     <li>",
"      Sandoz-Repaglinide",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F217642\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antidiabetic Agent, Meglitinide Derivative",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F217614\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Type 2 diabetes:",
"     </b>",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Patients not previously treated or whose Hb A",
"      <sub>",
"       1c",
"      </sub>",
"     </i>",
"     is &lt;8%: Initial: 0.5 mg before each meal",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Patients previously treated with blood glucose-lowering agents whose Hb A",
"      <sub>",
"       1c",
"      </sub>",
"     </i>",
"     is &ge;8%: Initial: 1 or 2 mg before each meal.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Dose adjustment:",
"     </i>",
"     Determine dosing adjustments by blood glucose response, usually fasting blood glucose. Double the preprandial dose up to 4 mg until satisfactory blood glucose response is achieved. At least 1 week should elapse to assess response after each dose adjustment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Dose range:",
"     </i>",
"     0.5-4 mg taken with meals. Repaglinide may be dosed preprandially 2, 3, or 4 times/day in response to changes in the patient's meal pattern. Maximum recommended daily dose: 16 mg.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Patients receiving other oral hypoglycemic agents:",
"     </b>",
"     When repaglinide is used to replace therapy with other oral hypoglycemic agents, it may be started the day after the final dose is given. Observe patients carefully for hypoglycemia because of potential overlapping of drug effects. When transferred from longer half-life sulfonylureas (eg, chlorpropamide), close monitoring may be indicated for up to &ge;1 week.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Note: Combination therapy:",
"     </b>",
"     If repaglinide monotherapy does not result in adequate glycemic control, metformin or a thiazolidinedione may be added. Or, if metformin or thiazolidinedione therapy does not provide adequate control, repaglinide may be added. The starting dose and dose adjustments for combination therapy are the same as repaglinide monotherapy. Carefully adjust the dose of each drug to determine the minimal dose required to achieve the desired pharmacologic effect. Failure to do so could result in an increase in the incidence of hypoglycemic episodes. Use appropriate monitoring of FPG and Hb A",
"     <sub>",
"      1c",
"     </sub>",
"     measurements to ensure that the patient is not subjected to excessive drug exposure or increased probability of secondary drug failure. If glucose is not achieved after a suitable trial of combination therapy, consider discontinuing these drugs and using insulin.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F217615\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F217616\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     40-80 mL/minute (mild-to-moderate renal dysfunction): Initial dosage adjustment does not appear to be necessary.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     20-40 mL/minute (severe renal impairment): Initial: 0.5 mg with meals; titrate carefully.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;20 mL/minute: Not studied.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hemodialysis: Not studied",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F217617\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use conservative initial and maintenance doses. Use longer intervals between dosage adjustments.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F217580\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Prandin&reg;: 0.5 mg, 1 mg, 2 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F217565\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F217585\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Administer 15 minutes before meals; however, time may vary from immediately preceding a meal to as long as 30 minutes before a meal. If the patient misses a meal or is unable to take anything by mouth, repaglinide should not be administered to avoid hypoglycemia. Patients consuming extra meals should be instructed to add a dose for the extra meal.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F217584\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Management of type 2 diabetes mellitus (noninsulin dependent, NIDDM) as an adjunct to diet and exercise; may be used in combination with metformin or thiazolidinediones",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F217649\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Prandin&reg; may be confused with Avandia&reg;",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      High alert medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       The Institute for Safe Medication Practices (ISMP) includes this medication among its list of drug classes which have a heightened risk of causing significant patient harm when used in error.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F217640\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Headache (9% to 11%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Hypoglycemia (16% to 31%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Upper respiratory tract infection (10% to 16%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Ischemia (4%), chest pain (2% to 3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Diarrhea (4% to 5%), constipation (2% to 3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Genitourinary: Urinary tract infection (2% to 3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Back pain (5% to 6%), arthralgia (3% to 6%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Sinusitis (3% to 6%), bronchitis (2% to 6%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Allergy (1% to 2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;1% (Limited to important or life-threatening): Anaphylactoid reaction, arrhythmia, hemolytic anemia, hepatic dysfunction (severe), hepatitis, hypertension, leukopenia, MI, pancreatitis, Stevens-Johnson syndrome, thrombocytopenia, visual disturbances (transient)",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F217588\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to repaglinide or any component of the formulation; diabetic ketoacidosis, with or without coma; type 1 diabetes (insulin dependent, IDDM); concurrent gemfibrozil therapy",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F217569\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypoglycemia: May cause hypoglycemia; appropriate patient selection, dosage, and patient education are important to avoid hypoglycemic episodes.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Adrenal/pituitary impairment: Use with caution in patients with adrenal and/or pituitary impairment; may be more susceptible to glucose-lowering effects.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cardiovascular mortality:  Some studies suggest that sulfonylureas may be associated with increased cardiovascular events. Theoretically, repaglinide may also increase cardiovascular events, but there are no long-term studies assessing this concern.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Use with caution in patients with hepatic impairment; may be more susceptible to glucose-lowering effects.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use with caution in patients with severe renal impairment; may be more susceptible to glucose-lowering effects.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Stress-related states: It may be necessary to discontinue repaglinide and administer insulin if the patient is exposed to stress (fever, trauma, infection, surgery).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; NPH insulin: Not indicated for use in combination with NPH insulin; in two studies, reports of myocardial ischemia (6 events) in patients using repaglinide plus insulin have caused concern. Further evaluation  is required to assess the safety of this combination.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Elderly: Use with caution in the elderly; may be more susceptible to glucose-lowering effects.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Malnourished patients: Use with caution in malnourished patients; may be more susceptible to glucose-lowering effects.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F217636\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP2C8 (major), CYP3A4 (major), SLCO1B1;",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F217574\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antifungal Agents (Azole Derivatives, Systemic): May increase the serum concentration of Repaglinide. Management: Concurrent use of an azole antifungal with both repaglinide and gemfibrozil should be avoided.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Conivaptan: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticosteroids (Orally Inhaled): May diminish the hypoglycemic effect of Antidiabetic Agents. In some instances, corticosteroid-mediated HPA axis suppression has led to episodes of acute adrenal crisis, which may manifest as enhanced hypoglycemia, particularly in the setting of insulin or other antidiabetic agent use.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticosteroids (Systemic): May diminish the hypoglycemic effect of Antidiabetic Agents. In some instances, corticosteroid-mediated HPA axis suppression has led to episodes of acute adrenal crisis, which may manifest as enhanced hypoglycemia, particularly in the setting of insulin or other antidiabetic agent use.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CycloSPORINE (Systemic): May increase the serum concentration of Repaglinide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2C8 Inducers (Strong): May increase the metabolism of CYP2C8 Substrates. Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2C8 Inhibitors (Moderate): May decrease the metabolism of CYP2C8 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2C8 Inhibitors (Strong): May decrease the metabolism of CYP2C8 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inducers (Strong): May increase the metabolism of CYP3A4 Substrates. Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Moderate): May decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Strong): May decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dasatinib: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: May increase the serum concentration of Repaglinide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Eltrombopag: May increase the serum concentration of OATP1B1/SLCO1B1 Substrates. Management: According to eltrombopag prescribing information, consideration of a preventative dose reduction may be warranted.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Gemfibrozil: May increase the serum concentration of Repaglinide. The addition of itraconazole may augment the effect of gemfibrozil on repaglinide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (CYP3A4 Inducers): May increase the metabolism of CYP3A4 Substrates. Management: Consider avoiding CYP3A4 inducing herbs in order to avoid therapeutic failure of the substrate. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Hypoglycemic Properties): May enhance the hypoglycemic effect of Hypoglycemic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hypoglycemic Agents: May enhance the adverse/toxic effect of other Hypoglycemic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivacaftor: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Loop Diuretics: May diminish the hypoglycemic effect of Hypoglycemic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Luteinizing Hormone-Releasing Hormone Analogs: May diminish the therapeutic effect of Antidiabetic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Macrolide Antibiotics: May increase the serum concentration of Repaglinide.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Azithromycin (Systemic); Fidaxomicin; Spiramycin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May enhance the hypoglycemic effect of Hypoglycemic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May increase the serum concentration of CYP2C8 Substrates. Management: Use CYP2C8 substrates at the lowest recommended dose, and monitor closely for adverse effects (including myopathy), during and in the 2 weeks following mifepristone treatment.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May increase the serum concentration of CYP3A4 Substrates. Management: Minimize doses of CYP3A4 substrates, and monitor for increased concentrations/toxicity, during and 2 weeks following treatment with mifepristone. Avoid cyclosporine, dihydroergotamine, ergotamine, fentanyl, pimozide, quinidine, sirolimus, and tacrolimus.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pegvisomant: May enhance the hypoglycemic effect of Antidiabetic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rifamycin Derivatives: May increase the metabolism of Repaglinide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Salicylates: May enhance the hypoglycemic effect of Hypoglycemic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Selective Serotonin Reuptake Inhibitors: May enhance the hypoglycemic effect of Hypoglycemic Agents. Selective Serotonin Reuptake Inhibitors may increase the serum concentration of Hypoglycemic Agents. Management: Consider increased monitoring of glycemic control with concomitant use of a hypoglycemic agent and an SSRI. Dosage adjustments of the hypoglycemic agent may be necessary upon SSRI initiation or discontinuation.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Somatropin: May diminish the hypoglycemic effect of Antidiabetic Agents.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Telaprevir: May increase the serum concentration of Repaglinide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Teriflunomide: May increase the serum concentration of Repaglinide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thiazide Diuretics: May diminish the therapeutic effect of Antidiabetic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tocilizumab: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Trimethoprim: May decrease the metabolism of Repaglinide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F217606\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ethanol: Ethanol may increase risk of hypoglycemia. Management: Avoid ethanol.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Food: When given with food, the AUC of repaglinide is decreased. Taking medication without eating may cause hypoglycemia. Management: Administer 15-30 minutes prior to a meal. If a meal is skipped, skip dose for that meal.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Herb/Nutraceutical: St John's wort may decrease the levels/effect of repaglinide. Other herbal medications may enhance the hypoglycemic effects of repaglinide. Management: Avoid St John's wort, alfalfa, aloe, bilberry, bitter melon, burdock, celery, damiana, fenugreek, garcinia, garlic, ginger, ginseng (American), gymnema, marshmallow, and stinging nettle.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F217576\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F217591\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events have been observed in some animal studies; therefore, repaglinide is classified as pregnancy category C. Information describing the effects of repaglinide on pregnancy outcomes is limited. Maternal hyperglycemia can be associated with adverse effects in the fetus, including macrosomia, neonatal hyperglycemia, and hyperbilirubinemia; the risk of congenital malformations is increased when the Hb A",
"     <sub>",
"      1c",
"     </sub>",
"     is above the normal range. Diabetes can also be associated with adverse effects in the mother. Poorly-treated diabetes may cause end-organ damage that may in turn negatively affect obstetric outcomes. Physiologic glucose levels should be maintained prior to and during pregnancy to decrease the risk of adverse events in the mother and the fetus. Until additional safety and efficacy data are obtained, the use of oral agents is generally not recommended as routine management of GDM or type 2 diabetes mellitus during pregnancy. Insulin is the drug of choice for the control of diabetes mellitus during pregnancy.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F217621\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F217592\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     It is not known if repaglinide is excreted in breast milk. Breast-feeding is not recommended by the manufacturer.",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F217593\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Take repaglinide 15-30 minutes before meals. Individualized medical nutrition therapy (MNT) based on ADA recommendations is an integral part of therapy. May cause hypoglycemia. Must be able to recognize symptoms of hypoglycemia (palpitations, tachycardia, sweaty palms, diaphoresis, lightheadedness).",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F217590\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Prandin Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.5 mg (100): $370.43",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1 mg (100): $370.43",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2 mg (100): $370.43",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F217578\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Monitor fasting blood glucose (periodically) and glycosylated hemoglobin (Hb A",
"     <sub>",
"      1c",
"     </sub>",
"     ) levels (every 3 months) with a goal of decreasing these levels towards the normal range. During dose adjustment, fasting glucose can be used to determine response.",
"    </p>",
"   </div>",
"   <div class=\"block rer drugH1Div\" id=\"F217581\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reference Range",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Recommendations for glycemic control in nonpregnant adults with diabetes (ADA, 2012):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hb A",
"     <sub>",
"      1c",
"     </sub>",
"     : &lt;7% (a more aggressive [&lt;6.5%] or less aggressive [&lt;8%] Hb A",
"     <sub>",
"      1c",
"     </sub>",
"     goal may be targeted based on patient-specific characteristics)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Preprandial capillary plasma glucose: 70-130 mg/dL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Peak postprandial capillary blood glucose: &lt;180 mg/dL",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F217594\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Dexanorm (ID);",
"     </li>",
"     <li>",
"      Hipover (PE);",
"     </li>",
"     <li>",
"      Ilgaper (BG);",
"     </li>",
"     <li>",
"      NovoNorm (AE, AR, AT, AU, BE, BF, BH, BJ, BR, CH, CI, CL, CN, CO, CY, CZ, DE, DK, EE, EG, ES, ET, FI, FR, GB, GH, GM, GN, GR, HK, HN, IE, IL, IQ, IR, IT, JO, KE, KP, KW, LB, LR, LY, MA, ML, MR, MT, MU, MW, MX, MY, NE, NG, NL, NO, OM, PH, PK, PL, PT, PY, QA, RU, SA, SC, SD, SE, SG, SK, SL, SN, SY, TH, TN, TR, TW, TZ, UG, UY, VE, YE, ZA, ZM, ZW);",
"     </li>",
"     <li>",
"      Prandin (AT, BE, BG, BR, CH, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HN, IE, IT, MT, NL, NO, PL, PT, RU, SE, SK, TR);",
"     </li>",
"     <li>",
"      Rapilin (IN);",
"     </li>",
"     <li>",
"      Reglinide (TW);",
"     </li>",
"     <li>",
"      Repanorm (TW);",
"     </li>",
"     <li>",
"      Sestrine (AR);",
"     </li>",
"     <li>",
"      Supernide (TW)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F217568\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Nonsulfonylurea hypoglycemic agent which blocks ATP-dependent potassium channels, depolarizing the membrane and facilitating calcium entry through calcium channels. Increased intracellular calcium stimulates insulin release from the pancreatic beta cells. Repaglinide-induced insulin release is glucose-dependent.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F217587\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action: Single dose: Increased insulin levels: ~15-60 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Duration: 4-6 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Rapid and complete",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     : 31 L",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding, plasma: &gt;98% to albumin",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Hepatic via CYP3A4 and CYP2C8 isoenzymes and glucuronidation to inactive metabolites",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bioavailability: ~56%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: ~1 hour",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak, plasma: ~1 hour",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Feces (~90%, &lt;2% as unchanged drug); Urine (~8%, 0.1% as unchanged drug)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      American Diabetes Association, &ldquo;Standards of Medical Care in Diabetes Mellitus -- 2012,&rdquo;",
"      <i>",
"       Diabetes Care",
"      </i>",
"      , 2012, 35(Suppl 1):11-63.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?4/25/4503/abstract-text/22187469/pubmed\" id=\"22187469\" target=\"_blank\">",
"        22187469",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Canadian Diabetes Association Clinical Practice Guidelines Expert Committee, \"Canadian Diabetes Association 2008 Clinical Practice Guidelines for the Prevention and Management of Diabetes in Canada,\"",
"      <i>",
"       Can J Diabetes",
"      </i>",
"      , 20078, 32(suppl 1):1-201.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Furlong NJ, Hulme SA, O'Brien SV, et al, &ldquo;Comparison of Repaglinide vs Gliclazide in Combination With Bedtime NPH Insulin in Patients With Type 2 Diabetes Inadequately Controlled With Oral Hypoglycaemic Agents,&rdquo;",
"      <i>",
"       Diabet Med",
"      </i>",
"      , 2003, 20(11):935-41.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?4/25/4503/abstract-text/14632720/pubmed\" id=\"14632720\" target=\"_blank\">",
"        14632720",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Furlong NJ, Hulme SA, O'Brien SV, et al, &ldquo;Repaglinide Versus Metformin in Combination With Bedtime NPH Insulin in Patients With Type 2 Diabetes Established on Insulin/Metformin Combination Therapy,&rdquo;",
"      <i>",
"       Diabetes Care",
"      </i>",
"      , 2002, 25(10):1685-90.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?4/25/4503/abstract-text/12351462/pubmed\" id=\"12351462\" target=\"_blank\">",
"        12351462",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Handelsman Y, Mechanick JI, Blonde L, et al, &ldquo;American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for Developing a Diabetes Mellitus Comprehensive Care Plan,&rdquo;",
"      <i>",
"       Endocr Pract",
"      </i>",
"      , 2011, 17(Suppl 2):1-53.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?4/25/4503/abstract-text/21474420/pubmed\" id=\"21474420\" target=\"_blank\">",
"        21474420",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kirkman M, Briscoe VJ, Clark N, et al, \"Diabetes in Older Adults: A Consensus Report,\"",
"      <i>",
"       J Am Geriatr Soc",
"      </i>",
"      , 2012; doi: 10.1111/jgs.12035.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?4/25/4503/abstract-text/23106132/pubmed\" id=\"23106132\" target=\"_blank\">",
"        23106132",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Moretto TJ, Milton DR, Ridge TD, et al, &ldquo;Efficacy and Tolerability of Exenatide Monotherapy Over 24 Weeks in Antidiabetic Drug-Na&iuml;ve Patients With Type 2 Diabetes: A Randomized, Double-Bind, Placebo-Controlled, Parallel-Group Study,&rdquo;",
"      <i>",
"       Clin Ther",
"      </i>",
"      , 2008, 30(8):1448-60.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?4/25/4503/abstract-text/18803987/pubmed\" id=\"18803987\" target=\"_blank\">",
"        18803987",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Nathan DM, Buse JB, Davidson MB, et al, &ldquo;Medical Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy: A Consensus Statement of the American Diabetes Association and the European Association for the Study of Diabetes,&rdquo;",
"      <i>",
"       Diabetes Care",
"      </i>",
"      , 2009, 32(1):193-203.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?4/25/4503/abstract-text/18945920/pubmed\" id=\"18945920\" target=\"_blank\">",
"        18945920",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Niemi M, Backman JT, Neuvonen M, et al, &ldquo;Effects of Gemfibrozil, Itraconazole, and Their Combination on the Pharmacokinetics and Pharmacodynamics of Repaglinide: Potentially Hazardous Interaction Between Gemfibrozil and Repaglinide,&rdquo;",
"      <i>",
"       Diabetologia",
"      </i>",
"      , 2003, 46(3):347-51.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?4/25/4503/abstract-text/12687332/pubmed\" id=\"12687332\" target=\"_blank\">",
"        12687332",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Qaseem A, Humphrey LL, Sweet DE, et al,&ldquo;Oral Pharmacologic Treatment of Type 2 Diabetes Mellitus: A Clinical Practice Guideline from the American College of Physicians,&rdquo;",
"      <i>",
"       Ann Intern Med",
"      </i>",
"      , 2012, 156(3):218-31.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?4/25/4503/abstract-text/22312141/pubmed\" id=\"22312141\" target=\"_blank\">",
"        22312141",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Quast U, Stephan D, Bieger S, et al, &ldquo;The Impact of ATP-Sensitive K+ Channel Subtype Selectivity of Insulin Secretagogues for the Coronary Vasculature and the Myocardium,&rdquo;",
"      <i>",
"       Diabetes",
"      </i>",
"      , 2004, 53(Suppl 3):156-64.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Rodbard HW, Jellinger PS, Davidson JA, et al, &ldquo;Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology Consensus Panel on Type 2 Diabetes Mellitus: An Algorithm for Glycemic Control,&rdquo;",
"      <i>",
"       Endocr Pract",
"      </i>",
"      , 2009, 15(6):540-59.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?4/25/4503/abstract-text/19858063/pubmed\" id=\"19858063\" target=\"_blank\">",
"        19858063",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9604 Version 42.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-178.219.2.221-4EAA1F1B94-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_25_4503=[""].join("\n");
var outline_f4_25_4503=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F217610\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F217611\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F217642\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F217614\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F217615\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F217616\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F217617\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F217580\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F217565\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F217585\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F217584\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F217649\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F217640\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F217588\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F217569\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F217636\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F217574\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F217606\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F217576\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F217591\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F217621\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F217592\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F217593\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F217590\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F217578\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F217581\">",
"      Reference Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F217594\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F217568\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F217587\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9604\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9604|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?34/58/35748?source=related_link\">",
"      Repaglinide: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f4_25_4504="Nonmelanoma PI";
var content_f4_25_4504=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F62777&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F62777&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 534px\">",
"   <div class=\"ttl\">",
"    Nonmelanoma skin cancer",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 514px; height: 388px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    (A) A raised or flat area of the skin with a sore that won't heal can be a sign of a basal cell skin cancer.",
"    <br>",
"     (B) Some basal cell skin cancers can look like flat, pink spots on the skin that do not go away.",
"     <br>",
"      (C) This red scaly spot is a squamous cell skin cancer.",
"      <br>",
"       (D) This pink, scaly bump is a squamous cell skin cancer.",
"       <div class=\"footnotes\">",
"       </div>",
"       <div class=\"reference\">",
"        Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"       </div>",
"      </br>",
"     </br>",
"    </br>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_25_4504=[""].join("\n");
var outline_f4_25_4504=null;
var title_f4_25_4505="Clinical manifestations of glucose-6-phosphate dehydrogenase deficiency";
var content_f4_25_4505=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Clinical manifestations of glucose-6-phosphate dehydrogenase deficiency",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/25/4505/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/25/4505/contributors\">",
"     Bertil Glader, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/25/4505/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/25/4505/contributors\">",
"     Stanley L Schrier, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/25/4505/contributors\">",
"     Donald H Mahoney, Jr, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/25/4505/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/25/4505/contributors\">",
"     Stephen A Landaw, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?4/25/4505/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 5, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Glucose 6-phosphate dehydrogenase (G6PD) deficiency, an X-linked disorder, is the most common enzymatic disorder of red blood cells in humans, affecting 400 million people worldwide [",
"    <a class=\"abstract\" href=\"UTD.htm?4/25/4505/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]. The importance of this enzyme for red cell integrity was first recognized following the observation that some African-American soldiers taking the antimalarial drug",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/59/38837?source=see_link\">",
"     primaquine",
"    </a>",
"    developed acute hemolytic anemia with hemoglobinuria. Subsequently, the activity of G6PD, one of the enzymes needed to maintain adequate reduced glutathione (GSH) levels, was found to be deficient in the red cells of subjects developing acute hemolytic anemia following use of this medication [",
"    <a class=\"abstract\" href=\"UTD.htm?4/25/4505/abstract/4\">",
"     4",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/62/13289?source=see_link\">",
"     \"Genetics and pathophysiology of glucose-6-phosphate dehydrogenase deficiency\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The clinical manifestations of G6PD deficiency will be discussed here. The genetics, pathophysiology, diagnosis, and treatment of G6PD deficiency are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/62/13289?source=see_link\">",
"     \"Genetics and pathophysiology of glucose-6-phosphate dehydrogenase deficiency\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/50/39719?source=see_link\">",
"     \"Diagnosis and treatment of glucose-6-phosphate dehydrogenase deficiency\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     OVERVIEW",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Clinical spectrum",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical expression of G6PD variants encompasses a spectrum of hemolytic syndromes. The four forms of symptomatic G6PD deficiency will be reviewed here:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Acute hemolytic anemia",
"     </li>",
"     <li>",
"      Favism",
"     </li>",
"     <li>",
"      Congenital nonspherocytic hemolytic anemia",
"     </li>",
"     <li>",
"      Neonatal hyperbilirubinemia",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    G6PD deficiency is expressed in males carrying a variant gene that results in sufficient enzyme deficiency to lead to symptoms. The mean red blood cell enzyme activity in heterozygous females may be normal, moderately reduced, or grossly deficient depending upon the degree of lyonization and the degree to which the abnormal G6PD variant is expressed [",
"    <a class=\"abstract\" href=\"UTD.htm?4/25/4505/abstract/5\">",
"     5",
"    </a>",
"    ]. A heterozygous female with 50 percent normal G6PD activity, due to inactivation of one X chromosome in each cell via lyonization, has 50 percent normal red cells and 50 percent G6PD-deficient red cells. The deficient cells are as vulnerable to hemolysis as the enzyme-deficient red blood cells in males.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Disease variants",
"    </span>",
"    &nbsp;&mdash;&nbsp;The World Health Organization has classified the different G6PD variants according to the magnitude of the enzyme deficiency and the severity of hemolysis [",
"    <a class=\"abstract\" href=\"UTD.htm?4/25/4505/abstract/6\">",
"     6",
"    </a>",
"    ]. Classes IV and V are of no clinical significance. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/62/13289?source=see_link\">",
"     \"Genetics and pathophysiology of glucose-6-phosphate dehydrogenase deficiency\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Class I variants have severe enzyme deficiency (less than 10 percent of normal) and have chronic (nonspherocytic) hemolytic anemia.",
"     </li>",
"     <li>",
"      Class II variants, such as G6PD Mediterranean, also have severe enzyme deficiency, but there are usually only intermittent episodes of acute hemolysis associated with infection, drugs, or chemicals.",
"     </li>",
"     <li>",
"      Class III variants, such as G6PD A-, have moderate enzyme deficiency (10 to 60 percent of normal) with intermittent episodes of acute hemolysis usually associated with infection, drugs, or chemicals.",
"     </li>",
"     <li>",
"      Class IV variants have no enzyme deficiency or hemolysis.",
"     </li>",
"     <li>",
"      Class V variants have increased enzyme activity.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     ACUTE HEMOLYTIC ANEMIA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Almost all individuals with the most prevalent G6PD variants, G6PD A- and G6PD Mediterranean, are asymptomatic in the steady state. They have neither anemia, evidence of increased red cell destruction, nor an alteration in blood morphology, although a modest shortening of red cell survival can be demonstrated by isotopic techniques [",
"    <a class=\"abstract\" href=\"UTD.htm?4/25/4505/abstract/7,8\">",
"     7,8",
"    </a>",
"    ]. However, sudden destruction of enzyme deficient erythrocytes can be triggered by certain drugs or chemicals (",
"    <a class=\"graphic graphic_table graphicRef74254 \" href=\"UTD.htm?19/22/19821\">",
"     table 1",
"    </a>",
"    ), by selected infections, and rarely by metabolic abnormalities (eg, diabetic ketoacidosis).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Clinical course",
"    </span>",
"    &nbsp;&mdash;&nbsp;The course of an acute hemolytic episode following the administration of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/59/38837?source=see_link\">",
"     primaquine",
"    </a>",
"    to subjects with G6PD A- is an example [",
"    <a class=\"abstract\" href=\"UTD.htm?4/25/4505/abstract/9\">",
"     9",
"    </a>",
"    ]. At two to four days after drug ingestion, there is the sudden onset of jaundice, pallor, and dark urine, with or without abdominal and back pain. This is associated with an abrupt fall in the hemoglobin concentration of 3 to 4",
"    <span class=\"nowrap\">",
"     g/dL,",
"    </span>",
"    during which time the peripheral blood smear reveals red cell fragments, microspherocytes, and eccentrocytes or \"bite\" cells (",
"    <a class=\"graphic graphic_picture graphicRef73790 \" href=\"UTD.htm?25/28/26054\">",
"     picture 1",
"    </a>",
"    ). Special stains document the production of Heinz bodies, which are collections of denatured globin chains often attached to the red cell membrane. Hemolysis is both extravascular and intravascular. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/38/616?source=see_link&amp;anchor=H14#H14\">",
"     \"Unstable hemoglobin variants\", section on 'Heinz body formation'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The anemia induces an appropriate stimulation of erythropoiesis, characterized by an increase in reticulocytes that is apparent within five days and is maximal at 7 to 10 days after the onset of hemolysis. Even with continued drug exposure, the acute hemolytic process ends after about one week, with ultimate reversal of the anemia.",
"   </p>",
"   <p>",
"    This spontaneous recovery reflects replacement of the older, enzyme deficient red cells by younger red cells with sufficient G6PD activity to withstand oxidative injury. As an example, the enzymatic activity of G6PD A- is normal in reticulocytes, but declines rapidly thereafter, with a half-life of 13 days, whereas the half-life of normal G6PD is about 62 days [",
"    <a class=\"abstract\" href=\"UTD.htm?4/25/4505/abstract/10,11\">",
"     10,11",
"    </a>",
"    ]. Although there is continued loss of aging G6PD deficient red cells if the drug is continued, it is compensated by the accompanying erythropoietic marrow response, with the production of younger G6PD-sufficient red cells.",
"   </p>",
"   <p>",
"    In contrast to G6PD A-, G6PD Mediterranean is more unstable, with a half-life measured in hours [",
"    <a class=\"abstract\" href=\"UTD.htm?4/25/4505/abstract/10\">",
"     10",
"    </a>",
"    ]. As a result, acute hemolysis is more severe because there is a larger population of circulating erythrocytes vulnerable to injury (ie, fewer G6PD-sufficient cells are present despite the reticulocytosis). Furthermore, the hemolysis continues until well after the drug is discontinued [",
"    <a class=\"abstract\" href=\"UTD.htm?4/25/4505/abstract/12,13\">",
"     12,13",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Drugs and chemicals",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/59/38837?source=see_link\">",
"     Primaquine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/59/32688?source=see_link\">",
"     dapsone",
"    </a>",
"    , and a number of other drugs can precipitate hemolysis in G6PD deficient subjects (",
"    <a class=\"graphic graphic_table graphicRef74254 \" href=\"UTD.htm?19/22/19821\">",
"     table 1",
"    </a>",
"    ). While hemolysis may be mild and self-limiting in some subjects, the degree of hemolysis can be severe and life-threatening in others [",
"    <a class=\"abstract\" href=\"UTD.htm?4/25/4505/abstract/14\">",
"     14",
"    </a>",
"    ]. The common denominator of these drugs is their interaction with hemoglobin and oxygen, leading to the intracellular formation of H",
"    <sub>",
"     2",
"    </sub>",
"    O",
"    <sub>",
"     2",
"    </sub>",
"    and other oxidizing radicals. As these oxidants accumulate within enzyme-deficient cells with low glutathione levels, hemoglobin and other proteins are oxidized, leading to loss of function and red cell death. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/62/13289?source=see_link&amp;anchor=H9#H9\">",
"     \"Genetics and pathophysiology of glucose-6-phosphate dehydrogenase deficiency\", section on 'Pathophysiology of G6PD deficiency'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Some drugs and chemicals are predictably injurious for all G6PD-deficient subjects (",
"    <a class=\"graphic graphic_table graphicRef74254 \" href=\"UTD.htm?19/22/19821\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/25/4505/abstract/15-17\">",
"     15-17",
"    </a>",
"    ]. However, many hemolytic events that were initially ascribed to drugs actually resulted from infections for which drugs were given. One such drug is",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    . Other drugs may produce a modest shortening of survival of G6PD-deficient red cells and appear on some lists as being unsafe to use in all patients and on other lists as being safe to use when given in usual therapeutic doses to individuals with class II and III G6PD variants. One such example is sulfamethoxazole, a component of the commonly used",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/58/5034?source=see_link\">",
"     trimethoprim-sulfamethoxazole",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?4/25/4505/abstract/17-19\">",
"     17-19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Chemical products commonly causing hemolysis in G6PD deficient individuals include naphthalene (moth balls), aniline dyes, and henna compounds used for hair dyes and tattoos [",
"    <a class=\"abstract\" href=\"UTD.htm?4/25/4505/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Lists of safe and unsafe drugs",
"    </span>",
"    &nbsp;&mdash;&nbsp;Periodically updated lists of drugs and other foods and agents that are felt to be safe or unsafe to use in patients with G6PD deficiency are available on two different websites at",
"    <a class=\"external\" href=\"file://www.g6pd.org/\">",
"     www.g6pd.org",
"    </a>",
"    and",
"    <a class=\"external\" href=\"file://www.g6pddeficiency.org/\">",
"     www.g6pddeficiency.org",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?4/25/4505/abstract/21\">",
"     21",
"    </a>",
"    ]. Interested patients and clinicians should consult these lists, although much of the information (safe versus unsafe) is anecdotal and often conflicting [",
"    <a class=\"abstract\" href=\"UTD.htm?4/25/4505/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Infections",
"    </span>",
"    &nbsp;&mdash;&nbsp;Infection is probably the most common factor inciting hemolysis in G6PD-deficient subjects [",
"    <a class=\"abstract\" href=\"UTD.htm?4/25/4505/abstract/22,23\">",
"     22,23",
"    </a>",
"    ]. In one study, for example, an abrupt fall in hemoglobin concentration occurred in approximately 20 percent of G6PD-deficient subjects with pneumonia [",
"    <a class=\"abstract\" href=\"UTD.htm?4/25/4505/abstract/22\">",
"     22",
"    </a>",
"    ]. The degree of hemolysis is usually mild. However, massive intravascular hemolysis resulting in hemoglobinuric acute renal failure has been described on occasion [",
"    <a class=\"abstract\" href=\"UTD.htm?4/25/4505/abstract/24,25\">",
"     24,25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A variety of infectious agents have been implicated including salmonella [",
"    <a class=\"abstract\" href=\"UTD.htm?4/25/4505/abstract/26-28\">",
"     26-28",
"    </a>",
"    ], Escherichia coli [",
"    <a class=\"abstract\" href=\"UTD.htm?4/25/4505/abstract/22\">",
"     22",
"    </a>",
"    ], beta-hemolytic streptococci [",
"    <a class=\"abstract\" href=\"UTD.htm?4/25/4505/abstract/29\">",
"     29",
"    </a>",
"    ], rickettsiae [",
"    <a class=\"abstract\" href=\"UTD.htm?4/25/4505/abstract/24\">",
"     24",
"    </a>",
"    ], and viral hepatitis [",
"    <a class=\"abstract\" href=\"UTD.htm?4/25/4505/abstract/25,30\">",
"     25,30",
"    </a>",
"    ]. In viral hepatitis, the combination of an increased bilirubin load from hemolysis and a damaged liver unable to process bilirubin normally results in an exaggerated elevation in the serum bilirubin concentration.",
"   </p>",
"   <p>",
"    The factors responsible for accelerated destruction of G6PD-deficient red cells during infection are not known. One possible explanation is that the red cells are damaged by oxidants generated by phagocytosing macrophages, a mechanism similar to that seen with drug-induced hemolysis [",
"    <a class=\"abstract\" href=\"UTD.htm?4/25/4505/abstract/31\">",
"     31",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/31/6650?source=see_link&amp;anchor=H22#H22\">",
"     \"Neutrophil functions other than movement\", section on 'Respiratory burst'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Diabetic ketoacidosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Diabetic ketoacidosis appears to be capable of triggering destruction of G6PD-deficient red cells [",
"    <a class=\"abstract\" href=\"UTD.htm?4/25/4505/abstract/22,32\">",
"     22,32",
"    </a>",
"    ], although one study found no such relationship in patients with G6PD Mediterranean [",
"    <a class=\"abstract\" href=\"UTD.htm?4/25/4505/abstract/33\">",
"     33",
"    </a>",
"    ]. Both acidosis and hyperglycemia are potential precipitating factors [",
"    <a class=\"abstract\" href=\"UTD.htm?4/25/4505/abstract/34\">",
"     34",
"    </a>",
"    ], and correction of the abnormalities is associated with reversal of the hemolytic process. In some diabetic patients, occult infection may be a common trigger for inducing both acute hemolysis and ketoacidosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Foods: fava beans and bitter melon",
"    </span>",
"    &nbsp;&mdash;&nbsp;Favism most often results from the ingestion of fresh fava beans. Consequently, the peak seasonal incidence of favism (April and May) in the Mediterranean coincides with harvesting of the bean [",
"    <a class=\"abstract\" href=\"UTD.htm?4/25/4505/abstract/35\">",
"     35",
"    </a>",
"    ]. Equally severe hemolysis can occur after consuming fried fava beans, a popular Chinese snack. Favism also has been reported in nursing infants whose mothers have eaten fava beans. It is also considered a risk following ingestion of bitter melon.",
"   </p>",
"   <p>",
"    Favism occurs most commonly in children, primarily males, between the ages of 1 and 5. The clinical manifestations begin within 5 to 24 hours after fava bean ingestion and are those of acute intravascular hemolysis [",
"    <a class=\"abstract\" href=\"UTD.htm?4/25/4505/abstract/36\">",
"     36",
"    </a>",
"    ]. Headache, nausea, back pain, chills, and fever are followed by hemoglobinuria and jaundice. The fall in hemoglobin concentration is acute, often severe, and, in the absence of transfusion, can be fatal.",
"   </p>",
"   <p>",
"    Individuals who develop favism are almost invariably deficient in G6PD [",
"    <a class=\"abstract\" href=\"UTD.htm?4/25/4505/abstract/37\">",
"     37",
"    </a>",
"    ]. However, unlike other offending agents capable of inducing hemolysis, only a few G6PD-deficient individuals are sensitive to the fava bean. In addition, the response to the bean by the same individual at different times may not be consistent [",
"    <a class=\"abstract\" href=\"UTD.htm?4/25/4505/abstract/35\">",
"     35",
"    </a>",
"    ]. It is therefore presumed that some other genetic factor contributes, perhaps related to the hepatic metabolism of potentially oxidant compounds within the fava bean [",
"    <a class=\"abstract\" href=\"UTD.htm?4/25/4505/abstract/35,38,39\">",
"     35,38,39",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Two pyrimidine aglycones, divicine and isouramil, have been implicated as the toxic components of fava beans [",
"    <a class=\"abstract\" href=\"UTD.htm?4/25/4505/abstract/40-42\">",
"     40-42",
"    </a>",
"    ]. Both rapidly overwhelm the already diminished GSH-generating capacity of G6PD-deficient cells and may also have direct effects on red cell function. In vitro studies have shown that divicine reduces the activity of catalase which, like the glutathione pathway, contributes to",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?40/41/41617?source=see_link\">",
"     hydrogen peroxide",
"    </a>",
"    removal, and requires NADPH for maintenance of normal activity [",
"    <a class=\"abstract\" href=\"UTD.htm?4/25/4505/abstract/42\">",
"     42",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The G6PD variant most commonly implicated in favism is G6PD Mediterranean. Thus, favism occurs most often in people from Italy, Greece, North Africa and the Mid East [",
"    <a class=\"abstract\" href=\"UTD.htm?4/25/4505/abstract/15\">",
"     15",
"    </a>",
"    ]. It also occurs in Asia. Africans and African-Americans with G6PD deficiency are much less susceptible, although there are rare cases of favism associated with the African variant, G6PD A- [",
"    <a class=\"abstract\" href=\"UTD.htm?4/25/4505/abstract/43\">",
"     43",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     CONGENITAL NONSPHEROCYTIC HEMOLYTIC ANEMIA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with class I G6PD variants have such severe G6PD deficiency that lifelong hemolysis occurs in the absence of infection or drug exposure [",
"    <a class=\"abstract\" href=\"UTD.htm?4/25/4505/abstract/44-48\">",
"     44-48",
"    </a>",
"    ]. Such patients fall under the category of having congenital nonspherocytic hemolytic anemia.",
"   </p>",
"   <p>",
"    These G6PD variants have low in vitro activity",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    marked instability of the molecule, and most have DNA mutations at the glucose&ndash;6-phosphate or NADP binding sites (",
"    <a class=\"graphic graphic_figure graphicRef66818 \" href=\"UTD.htm?28/29/29149\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/25/4505/abstract/15\">",
"     15",
"    </a>",
"    ]. These sites are central to the function of G6PD, which oxidizes glucose-6-phosphate and reduces NADP to NADPH (",
"    <a class=\"graphic graphic_figure graphicRef77081 \" href=\"UTD.htm?18/40/19085\">",
"     figure 2",
"    </a>",
"    ). It is presumed that the functional defect is so severe that the red cells cannot withstand even the normal oxidative stresses encountered in the circulation [",
"    <a class=\"abstract\" href=\"UTD.htm?4/25/4505/abstract/15\">",
"     15",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/46/4841?source=see_link&amp;anchor=H2#H2\">",
"     \"Genetics and pathogenesis of methemoglobinemia\", section on 'Methemoglobin'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Anemia and jaundice are often first noted in the newborn period, and the degree of hyperbilirubinemia is frequently of sufficient severity to require exchange transfusion. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/18/27943?source=see_link&amp;anchor=H15#H15\">",
"     \"Bilirubin metabolism\", section on 'Bilirubin toxicity'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    After infancy, hemolytic manifestations are subtle and inconstant. Most individuals have mild to moderate anemia (hemoglobin 8 to 10",
"    <span class=\"nowrap\">",
"     g/dL)",
"    </span>",
"    with a reticulocyte count of 10 to 15 percent. Pallor is uncommon, scleral icterus is intermittent, splenomegaly is rare, and splenectomy generally is of little benefit [",
"    <a class=\"abstract\" href=\"UTD.htm?4/25/4505/abstract/44,49\">",
"     44,49",
"    </a>",
"    ]. Hemolysis can be exaggerated by exposure to drugs or chemicals with oxidant potential or exposure to fava beans [",
"    <a class=\"abstract\" href=\"UTD.htm?4/25/4505/abstract/48\">",
"     48",
"    </a>",
"    ]. Some drugs with relatively mild oxidant potential that are safe in patients with class II or class III G6PD variants may increase hemolysis in patients with class I variants.",
"   </p>",
"   <p>",
"    The typically mild anemia reflects the ability of increased erythropoiesis to compensate for the hemolysis. Thus, as with other chronic hemolytic anemias, the anemia may be worsened by diminished erythropoietic capacity due to infection or to parvovirus-induced aplastic crises. Such a crisis may be the event that first leads to examination of the blood and establishment of diagnosis of G6PD deficiency. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/54/22377?source=see_link\">",
"     \"Clinical manifestations and pathogenesis of human parvovirus B19 infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Neutrophil dysfunction",
"    </span>",
"    &nbsp;&mdash;&nbsp;A rare associated abnormality in severely deficient patients is neutrophil dysfunction due to G6PD deficiency [",
"    <a class=\"abstract\" href=\"UTD.htm?4/25/4505/abstract/50\">",
"     50",
"    </a>",
"    ]. This defect leads to impaired neutrophil bactericidal activity and recurrent infections with catalase-positive organisms. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/60/14280?source=see_link&amp;anchor=H9#H9\">",
"     \"Myeloperoxidase deficiency and other enzymatic WBC defects causing immunodeficiency\", section on 'Glucose-6-phosphate dehydrogenase deficiency'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     NEONATAL HYPERBILIRUBINEMIA",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical picture of neonatal jaundice due to G6PD deficiency differs from classic Rh-related neonatal jaundice in two main respects:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      G6PD deficiency-related neonatal jaundice is rarely present at birth; the peak incidence of clinical onset is between days two and three [",
"      <a class=\"abstract\" href=\"UTD.htm?4/25/4505/abstract/51\">",
"       51",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      There is more jaundice than anemia, and the anemia is rarely severe. The severity of jaundice varies widely, from being subclinical to imposing the threat of kernicterus if not treated [",
"      <a class=\"abstract\" href=\"UTD.htm?4/25/4505/abstract/52\">",
"       52",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Although neonates with the rare class I variants are at greatest risk, most infants with hyperbilirubinemia due to G6PD deficiency have more common variants and come from the Mediterranean region or Asia [",
"    <a class=\"abstract\" href=\"UTD.htm?4/25/4505/abstract/53-56\">",
"     53-56",
"    </a>",
"    ]. In one series of 43 cases from Italy, for example, 39 had G6PD Mediterranean, one had G6PD A-, and three had other variants [",
"    <a class=\"abstract\" href=\"UTD.htm?4/25/4505/abstract/53\">",
"     53",
"    </a>",
"    ]. Among affected Chinese children, most cases are associated with G6PD Canton [",
"    <a class=\"abstract\" href=\"UTD.htm?4/25/4505/abstract/55\">",
"     55",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although both African-Americans and Africans have the same G6PD A- variant, the risk of neonatal hyperbilirubinemia is less in African-Americans [",
"    <a class=\"abstract\" href=\"UTD.htm?4/25/4505/abstract/57\">",
"     57",
"    </a>",
"    ] compared with African and Jamaican black infants [",
"    <a class=\"abstract\" href=\"UTD.htm?4/25/4505/abstract/58,59\">",
"     58,59",
"    </a>",
"    ]. Untreated hyperbilirubinemia in the latter group frequently leads to kernicterus with severe neurologic injury or death [",
"    <a class=\"abstract\" href=\"UTD.htm?4/25/4505/abstract/58,60\">",
"     58,60",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/18/27943?source=see_link&amp;anchor=H15#H15\">",
"     \"Bilirubin metabolism\", section on 'Bilirubin toxicity'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The difference in risk with the same G6PD variant is thought to be related to local customs and differences in oxidant exposure. In the United States, there is concern that changes in health care delivery with early discharge of newborn infants may increase the risk. One report described four newborn infants with G6PD deficiency (three African-American, and one mixed",
"    <span class=\"nowrap\">",
"     Peruvian/Chinese)",
"    </span>",
"    who developed kernicterus following early hospital discharge, even though there was adherence to the early neonatal discharge guidelines of the American Academy of Pediatrics and the American College of Obstetricians and Gynecologists [",
"    <a class=\"abstract\" href=\"UTD.htm?4/25/4505/abstract/61\">",
"     61",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Data from the USA Kernicterus Registry from 1992 to 2004 indicate that over 30 percent of kernicterus cases are associated with G6PD deficiency [",
"    <a class=\"abstract\" href=\"UTD.htm?4/25/4505/abstract/52\">",
"     52",
"    </a>",
"    ]. These observations have raised the question of whether testing for G6PD deficiency should be included in newborn screening programs worldwide [",
"    <a class=\"abstract\" href=\"UTD.htm?4/25/4505/abstract/62\">",
"     62",
"    </a>",
"    ]. Currently, only the District of Columbia in the United States requires such newborn screening. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/2/2088?source=see_link\">",
"     \"Newborn screening\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The cause of neonatal hyperbilirubinemia in G6PD-deficient infants is not clear. It has been presumed that the combination of increased bilirubin production due to accelerated red cell breakdown and the immature liver is responsible [",
"    <a class=\"abstract\" href=\"UTD.htm?4/25/4505/abstract/58,63,64\">",
"     58,63,64",
"    </a>",
"    ]. Although there is often no obvious external oxidant responsible for red cell injury, indirect evidence supports the importance of local environmental variables. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/3/39992?source=see_link\">",
"     \"Pathogenesis and etiology of unconjugated hyperbilirubinemia in the newborn\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    As examples:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      G6PD-deficient infants born in Australia to Greek immigrants have a lower incidence of neonatal hyperbilirubinemia than deficient infants born in Greece [",
"      <a class=\"abstract\" href=\"UTD.htm?4/25/4505/abstract/65,66\">",
"       65,66",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Herbs used in traditional Chinese medicine and clothing impregnated with naphthalene may be contributing factors.",
"     </li>",
"     <li>",
"      Exposure of the mother to oxidant drugs or chemicals in late gestation has been implicated as the inciting stimulus [",
"      <a class=\"abstract\" href=\"UTD.htm?4/25/4505/abstract/67,68\">",
"       67,68",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    However, most cases of neonatal hyperbilirubinemia occur in the absence of obvious exposure to external oxidants. Furthermore, there is often no evidence of increased red cell breakdown in neonates who develop hyperbilirubinemia compared to deficient neonates [",
"    <a class=\"abstract\" href=\"UTD.htm?4/25/4505/abstract/69,70\">",
"     69,70",
"    </a>",
"    ]. These observations suggest an important role for impaired hepatic clearance of bilirubin. In support of this hypothesis is the observation that neonates with G6PD Mediterranean have a partial defect in bilirubin glucuronide conjugation similar to that seen in Gilbert's disease [",
"    <a class=\"abstract\" href=\"UTD.htm?4/25/4505/abstract/71\">",
"     71",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/62/13289?source=see_link&amp;anchor=H10#H10\">",
"     \"Genetics and pathophysiology of glucose-6-phosphate dehydrogenase deficiency\", section on 'Jaundice in neonates'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The management of neonatal jaundice due to G6PD deficiency does not differ from that recommended for neonatal jaundice arising from other causes. Thus, mild cases do not require treatment, intermediate cases require phototherapy, and severe cases require exchange transfusion. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/59/21434?source=see_link\">",
"     \"Treatment of unconjugated hyperbilirubinemia in term and late preterm infants\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?12/41/12946?source=see_link\">",
"       \"Patient information: Glucose-6-phosphate dehydrogenase deficiency (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Diagnosis of G6PD deficiency",
"    </span>",
"    &nbsp;&mdash;&nbsp;G6PD catalyzes the conversion of glucose-6-phosphate to 6-phosphogluconate. NADP is a cofactor in this reaction and is converted to NADPH. The diagnosis of G6PD deficiency is confirmed by observing the",
"    <strong>",
"     inability",
"    </strong>",
"    of red cell hemolysates to generate NADPH from glucose-6-phosphate and NADP. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/50/39719?source=see_link&amp;anchor=H2#H2\">",
"     \"Diagnosis and treatment of glucose-6-phosphate dehydrogenase deficiency\", section on 'Diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1807524\">",
"    <span class=\"h2\">",
"     Enzyme variants",
"    </span>",
"    &nbsp;&mdash;&nbsp;The World Health Organization has classified G6PD variants according to the magnitude of the enzyme deficiency and the severity of hemolysis. The three most important are:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Class I variants have &lt;10 percent of normal G6PD activity, have chronic hemolytic anemia and are also more likely to develop neonatal hyperbilirubinemia. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Congenital nonspherocytic hemolytic anemia'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H14\">",
"       'Neonatal hyperbilirubinemia'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Class II variants have severe enzyme deficiency, but there is usually only intermittent hemolysis associated with infection, drugs, or chemicals. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Acute hemolytic anemia'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Class III variants have moderate enzyme deficiency (10 to 60 percent of normal) with intermittent hemolysis usually associated with infection, drugs, or chemicals. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Acute hemolytic anemia'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1807531\">",
"    <span class=\"h2\">",
"     Clinical syndromes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Glucose-6-phosphate dehydrogenase (G6PD) deficiency can present with a number of different clinical syndromes. (See",
"    <a class=\"local\" href=\"#H3\">",
"     'Clinical spectrum'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Inciting events",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with class II or III variants develop intermittent hemolysis only after one or more of the following inciting events. (See",
"    <a class=\"local\" href=\"#H5\">",
"     'Acute hemolytic anemia'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Infection",
"     </li>",
"     <li>",
"      Oxidant drugs (",
"      <a class=\"graphic graphic_table graphicRef74254 \" href=\"UTD.htm?19/22/19821\">",
"       table 1",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Chemical agents (eg, moth balls, aniline dyes, henna compounds)",
"     </li>",
"     <li>",
"      Diabetic ketoacidosis",
"     </li>",
"     <li>",
"      Ingestion of fava beans (see",
"      <a class=\"local\" href=\"#H11\">",
"       'Foods: fava beans and bitter melon'",
"      </a>",
"      above)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Clinical manifestations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clinical manifestations of G6PD deficiency depend upon the severity of the deficiency as well as the inciting event:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Chronic hemolysis",
"      </strong>",
"      &mdash; Patients with class I deficiency usually have chronic hemolysis. Some drugs with relatively mild oxidant potential that are safe in patients with class II or class III G6PD variants may increase hemolysis in patients with class I variants. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Congenital nonspherocytic hemolytic anemia'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <strong>",
"       Acute hemolysis",
"      </strong>",
"      &mdash; Almost all individuals with the most prevalent G6PD variants are asymptomatic in the steady state and are not anemic. Two to four days after oxidant drug ingestion, there is the sudden onset of jaundice, pallor, and dark urine, with or without abdominal and back pain, and an abrupt fall in the hemoglobin concentration of 3 to 4",
"      <span class=\"nowrap\">",
"       g/dL.",
"      </span>",
"      (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Acute hemolytic anemia'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <strong>",
"       Favism",
"      </strong>",
"      &mdash; Manifestations of favism begin within 5 to 24 hours after fava bean ingestion and include headache, nausea, back pain, chills, and fever, followed by hemoglobinuria and jaundice. The fall in hemoglobin concentration is acute, often severe, and, in the absence of transfusion, can be fatal. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Foods: fava beans and bitter melon'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Glader B. Hereditary hemolytic anemias due to red blood cell enzyme disorders. In: Wintrobe's Clinical Hematology, Greer JP, Foerster J, Rodgers GM, et al. (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2009. p.933.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/25/4505/abstract/2\">",
"      Mason PJ, Bautista JM, Gilsanz F. G6PD deficiency: the genotype-phenotype association. Blood Rev 2007; 21:267.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/25/4505/abstract/3\">",
"      Cappellini MD, Fiorelli G. Glucose-6-phosphate dehydrogenase deficiency. Lancet 2008; 371:64.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/25/4505/abstract/4\">",
"      ALVING AS, CARSON PE, FLANAGAN CL, ICKES CE. Enzymatic deficiency in primaquine-sensitive erythrocytes. Science 1956; 124:484.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/25/4505/abstract/5\">",
"      Hsia YE, Miyakawa F, Baltazar J, et al. Frequency of glucose-6-phosphate dehydrogenase (G6PD) mutations in Chinese, Filipinos, and Laotians from Hawaii. Hum Genet 1993; 92:470.",
"     </a>",
"    </li>",
"    <li>",
"     Beutler E. The molecular biology of enzymes of erythrocyte metabolism. In: The Molecular Basis of Blood Disease, Stamatoyannopoulos G, Nienhus AW, Majerus PW, et al. (Eds), WB Saunders, Philadelphia 1993.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/25/4505/abstract/7\">",
"      Brewer GJ, et al. The hemolytic effect of primaquine. XII. Shortened erythrocyte life span in primaquine-sensitive male negroes in the absence of drug administration. J Lab Clin Med 1961; 58:217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/25/4505/abstract/8\">",
"      Corash L, Spielberg S, Bartsocas C, et al. Reduced chronic hemolysis during high-dose vitamin E administration in Mediterranean-type glucose-6-phosphate dehydrogenase deficiency. N Engl J Med 1980; 303:416.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/25/4505/abstract/9\">",
"      DERN RJ, BEUTLER E, ALVING AS. The hemolytic effect of primaquine. II. The natural course of the hemolytic anemia and the mechanism of its self-limited character. J Lab Clin Med 1954; 44:171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/25/4505/abstract/10\">",
"      Piomelli S, Corash LM, Davenport DD, et al. In vivo lability of glucose-6-phosphate dehydrogenase in GdA- and GdMediterranean deficiency. J Clin Invest 1968; 47:940.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/25/4505/abstract/11\">",
"      Yoshida A, Stamatoyannopoulos G, Motulsky AG. Negro variant of glucose-6-phosphate dehydrogenase deficiency (A-) in man. Science 1967; 155:97.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/25/4505/abstract/12\">",
"      Pannacciulli I, Salvidio E, Tizianello A, Parravidino G. Hemolytic effects of standard single dosages of primaquine and chloroquine on G-6-PD-deficient caucasians. J Lab Clin Med 1969; 74:653.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/25/4505/abstract/13\">",
"      George JN, Sears DA, McCurdy PR, Conrad ME. Primaquine sensitivity in Caucasians: hemolytic reactions induced by primaquine in G-6-PD deficient subjects. J Lab Clin Med 1967; 70:80.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/25/4505/abstract/14\">",
"      Pamba A, Richardson ND, Carter N, et al. Clinical spectrum and severity of hemolytic anemia in glucose 6-phosphate dehydrogenase-deficient children receiving dapsone. Blood 2012; 120:4123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/25/4505/abstract/15\">",
"      Beutler E. G6PD deficiency. Blood 1994; 84:3613.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/25/4505/abstract/16\">",
"      Beutler E. Glucose-6-phosphate dehydrogenase deficiency. N Engl J Med 1991; 324:169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/25/4505/abstract/17\">",
"      Youngster I, Arcavi L, Schechmaster R, et al. Medications and glucose-6-phosphate dehydrogenase deficiency: an evidence-based review. Drug Saf 2010; 33:713.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/25/4505/abstract/18\">",
"      Markowitz N, Saravolatz LD. Use of trimethoprim-sulfamethoxazole in a glucose-6-phosphate dehydrogenase-deficient population. Rev Infect Dis 1987; 9 Suppl 2:S218.",
"     </a>",
"    </li>",
"    <li>",
"     Beutler E. Disorders of red cells resulting from enzyme abnormalities. In: Williams' Hematology, 7th ed, Lichtman MA, Beutler E, Kipps TJ, et al (Eds), McGraw-Hill, 2006. p.603.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/25/4505/abstract/20\">",
"      Raupp P, Hassan JA, Varughese M, Kristiansson B. Henna causes life threatening haemolysis in glucose-6-phosphate dehydrogenase deficiency. Arch Dis Child 2001; 85:411.",
"     </a>",
"    </li>",
"    <li>",
"     www.g6pd.org and www.g6pddeficiency.org (Accessed on October 27, 2009).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/25/4505/abstract/22\">",
"      Burka ER, Weaver Z III, Marks PA. Clinical spectrum of hemolytic anemia associated with glucose-6-phosphate dehydrogenase deficiency. Ann Intern Med 1966; 64:817.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/25/4505/abstract/23\">",
"      Shannon K, Buchanan GR. Severe hemolytic anemia in black children with glucose-6-phosphate dehydrogenase deficiency. Pediatrics 1982; 70:364.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/25/4505/abstract/24\">",
"      Whelton A, Donadio JV Jr, Elisberg BL. Acute renal failure complicating rickettsial infections in glucose-6-phosphate dehydrogenase-deficient individuals. Ann Intern Med 1968; 69:323.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/25/4505/abstract/25\">",
"      Phillips SM, Silvers NP. Glucose-6 phosphate dehydrogenase deficiency, infectious hepatitis, acute hemolysis, and renal failure. Ann Intern Med 1969; 70:99.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/25/4505/abstract/26\">",
"      Chan TK, Chesterman CN, McFadzean AJ, Todd D. The survival of glucose-6-phosphate dehydrogenase--deficient erythrocytes in patients with typhoid fever on chloramphenicol therapy. J Lab Clin Med 1971; 77:177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/25/4505/abstract/27\">",
"      Constantopoulos A, Economopoulos P, Kandylas J. Fulminant diarrhoea and acute haemolysis due to G.-6-P.D. deficiency in salmonellosis. Lancet 1973; 1:1522.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/25/4505/abstract/28\">",
"      Hersko C, Vardy PA. Haemolysis in typhoid fever in children with G-6-PD deficiency. Br Med J 1967; 1:214.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/25/4505/abstract/29\">",
"      Mengel CE, Metz E, Yancey WS. Anemia during actue infections. Role of glucose-6-phosphate dehydrogenase deficiency in Negroes. Arch Intern Med 1967; 119:287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/25/4505/abstract/30\">",
"      Salen G, Goldstein F, Haurani F, Wirts CW. Acute hemolytic anemia complicating viral hepatitis in patients with glucose-6-phosphate dehydrogenase deficiency. Ann Intern Med 1966; 65:1210.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/25/4505/abstract/31\">",
"      Baehner RL, Nathan DG, Castle WB. Oxidant injury of caucasian glucose-6-phosphate dehydrogenase-deficient red blood cells by phagocytosing leukocytes during infection. J Clin Invest 1971; 50:2466.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/25/4505/abstract/32\">",
"      Gellady AM, Greenwood RD. G-6-PD hemolytic anemia complicating diabetic ketoacidosis. J Pediatr 1972; 80:1037.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/25/4505/abstract/33\">",
"      Shalev O, Wollner A, Menczel J. Diabetic ketoacidosis does not precipitate haemolysis in patients with the Mediterranean variant of glucose-6-phosphate dehydrogenase deficiency. Br Med J (Clin Res Ed) 1984; 288:179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/25/4505/abstract/34\">",
"      Glader BE. Role of elevated glucose concentrations in the hemolysis of glucose-6-phosphate dehydrogenase deficient erythroycytes (38474). Proc Soc Exp Biol Med 1975; 148:50.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/25/4505/abstract/35\">",
"      Kattamis CA, Kyriazakou M, Chaidas S. Favism: clinical and biochemical data. J Med Genet 1969; 6:34.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/25/4505/abstract/36\">",
"      Luisada A. Favism. Medicine (Baltimore) 1941; 20:229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/25/4505/abstract/37\">",
"      SZEINBERG A, ASHER Y, SHEBA C. Studies on glutathione stability in erythrocytes of cases with past history of favism or sulfa-drug-induced hemolysis. Blood 1958; 13:348.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/25/4505/abstract/38\">",
"      Stamatoyannopoulos G, Fraser GR, Motulsky AC, et al. On the familial predisposition to favism. Am J Hum Genet 1966; 18:253.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/25/4505/abstract/39\">",
"      Cutillo S, Costa S, Vintuleddu MC, Meloni T. Salicylamide-Glucuronide formation in children with favism and in their parents. Acta Haematol 1976; 55:296.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/25/4505/abstract/40\">",
"      Chevion M, Navok T, Glaser G, Mager J. The chemistry of favism-inducing compounds. The properties of isouramil and divicine and their reaction with glutathione. Eur J Biochem 1982; 127:405.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/25/4505/abstract/41\">",
"      Razin A, Hershko A, Glaser G, Mager J. The oxidant effect of isouramil on red cell glutathione and its synergistic enhancement by ascorbic acid or 3,4-dihydroxyphenylalanine. Possible relation to the pathogenesis of favism. Isr J Med Sci 1968; 4:852.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/25/4505/abstract/42\">",
"      Gaetani GF, Rolfo M, Arena S, et al. Active involvement of catalase during hemolytic crises of favism. Blood 1996; 88:1084.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/25/4505/abstract/43\">",
"      Galiano S, Gaetani GF, Barabino A, et al. Favism in the African type of glucose-6-phosphate dehydrogenase deficiency (A-). BMJ 1990; 300:236.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/25/4505/abstract/44\">",
"      Beutler E, Mathai CK, Smith JE. Biochemical variants of glucose-6-phosphate dehydrogenase giving rise to congenital nonspherocytic hemolytic disease. Blood 1968; 31:131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/25/4505/abstract/45\">",
"      Beutler E, Grooms AM, Morgan SK, Trinidad F. Chronic severe hemolytic anemia due to G-6-PD Charleston: a new deficient variant. J Pediatr 1972; 80:1005.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/25/4505/abstract/46\">",
"      Feldman R, Gromisch DS, Luhby AL, Beutler E. Congenital nonspherocytic hemolytic anemia due to glucose-6-phosphate dehydrogenase East Harlem: a new deficient variant. J Pediatr 1977; 90:89.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/25/4505/abstract/47\">",
"      Grossman A, Ramanathan K, Justice P, et al. Congenital nonspherocytic hemolytic anemia associated with erythrocyte glucose-6-phosphate dehydrogenase deficiency in a Negro family. Pediatrics 1966; 37:624.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/25/4505/abstract/48\">",
"      Rattazzi MC, Corash LM, van Zanen GE, et al. G6PD deficiency and chronic hemolysis: four new mutants--relationships between clinical syndrome and enzyme kinetics. Blood 1971; 38:205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/25/4505/abstract/49\">",
"      Benbassat J, Ben-Ishay D. Hereditary hemolytic anemia associated with glucose-6-phosphate dehydrogenase deficiency (Mediterranean type). Isr J Med Sci 1969; 5:1053.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/25/4505/abstract/50\">",
"      Vives Corrons JL, Feliu E, Pujades MA, et al. Severe-glucose-6-phosphate dehydrogenase (G6PD) deficiency associated with chronic hemolytic anemia, granulocyte dysfunction, and increased susceptibility to infections: description of a new molecular variant (G6PD Barcelona). Blood 1982; 59:428.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/25/4505/abstract/51\">",
"      Kaplan M, Hammerman C. Glucose-6-phosphate dehydrogenase deficiency: a hidden risk for kernicterus. Semin Perinatol 2004; 28:356.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/25/4505/abstract/52\">",
"      Johnson L, Bhutani VK, Karp K, et al. Clinical report from the pilot USA Kernicterus Registry (1992 to 2004). J Perinatol 2009; 29 Suppl 1:S25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/25/4505/abstract/53\">",
"      Sansone G, Perroni L, Yoshida A. Glucose-6-phosphate dehydrogenase variants from Italian subjects associated with severe neonatal jaundice. Br J Haematol 1975; 31:159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/25/4505/abstract/54\">",
"      Kaplan M, Abramov A. Neonatal hyperbilirubinemia associated with glucose-6-phosphate dehydrogenase deficiency in Sephardic-Jewish neonates: incidence, severity, and the effect of phototherapy. Pediatrics 1992; 90:401.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/25/4505/abstract/55\">",
"      Huang CS, Hung KL, Huang MJ, et al. Neonatal jaundice and molecular mutations in glucose-6-phosphate dehydrogenase deficient newborn infants. Am J Hematol 1996; 51:19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/25/4505/abstract/56\">",
"      Brown WR, Boon WH. Hyperbilirubinemia and kernicterus in glucose-6-phosphate dehydrogenase-deficient infants in Singapore. Pediatrics 1968; 41:1055.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/25/4505/abstract/57\">",
"      Perkins RP. The significance of glucose-6-phosphate dehydrogenase deficiency in pregnancy. Am J Obstet Gynecol 1976; 125:215.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/25/4505/abstract/58\">",
"      Slusher TM, Vreman HJ, McLaren DW, et al. Glucose-6-phosphate dehydrogenase deficiency and carboxyhemoglobin concentrations associated with bilirubin-related morbidity and death in Nigerian infants. J Pediatr 1995; 126:102.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/25/4505/abstract/59\">",
"      Gibbs WN, Gray R, Lowry M. Glucose-6-phosphate dehydrogenase deficiency and neonatal jaundice in Jamaica. Br J Haematol 1979; 43:263.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/25/4505/abstract/60\">",
"      Oyebola DD. Care of the neonate and management of neonatal jaundice as practised by Yoruba traditional healers of Nigeria. J Trop Pediatr 1983; 29:18.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/25/4505/abstract/61\">",
"      MacDonald MG. Hidden risks: early discharge and bilirubin toxicity due to glucose 6-phosphate dehydrogenase deficiency. Pediatrics 1995; 96:734.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/25/4505/abstract/62\">",
"      Kaplan M, Hammerman C. The need for neonatal glucose-6-phosphate dehydrogenase screening: a global perspective. J Perinatol 2009; 29 Suppl 1:S46.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/25/4505/abstract/63\">",
"      Valaes T. Severe neonatal jaundice associated with glucose-6-phosphate dehydrogenase deficiency: pathogenesis and global epidemiology. Acta Paediatr Suppl 1994; 394:58.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/25/4505/abstract/64\">",
"      Valaes T. Pathophysiology of spontaneous neonatal bilirubinemia associated with glucose-6-phosphate dehydrogenase deficiency. J Pediatr 1996; 128:863.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/25/4505/abstract/65\">",
"      Drew JH, Kitchen WH. Jaundice in infants of Greek parentage: the unknown factor may be environmental. J Pediatr 1976; 89:248.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/25/4505/abstract/66\">",
"      Drew JH, Smith MB, Kitchen WH. Glucose-6-phosphate dehydrogenase deficiency in immigrant greek infants. J Pediatr 1977; 90:659.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/25/4505/abstract/67\">",
"      Brown AK, Cevik N. Hemolysis and jaundice in the newborn following maternal treatment with sulfamethoxypyridazine (kynex). Pediatrics 1965; 36:742.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/25/4505/abstract/68\">",
"      Mentzer WC, Collier E. Hydrops fetalis associated with erythrocyte G-6-PD deficiency and maternal ingestion of fava beans and ascorbic acid. J Pediatr 1975; 86:565.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/25/4505/abstract/69\">",
"      Kaplan M, Vreman HJ, Hammerman C, et al. Contribution of haemolysis to jaundice in Sephardic Jewish glucose-6-phosphate dehydrogenase deficient neonates. Br J Haematol 1996; 93:822.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/25/4505/abstract/70\">",
"      Seidman DS, Shiloh M, Stevenson DK, et al. Role of hemolysis in neonatal jaundice associated with glucose-6 phosphate dehydrogenase deficiency. J Pediatr 1995; 127:804.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/25/4505/abstract/71\">",
"      Kaplan M, Rubaltelli FF, Hammerman C, et al. Conjugated bilirubin in neonates with glucose-6-phosphate dehydrogenase deficiency. J Pediatr 1996; 128:695.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7111 Version 10.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0602-201.211.0.116-C9B4E1D095-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_25_4505=[""].join("\n");
var outline_f4_25_4505=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H15\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      OVERVIEW",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Clinical spectrum",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Disease variants",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      ACUTE HEMOLYTIC ANEMIA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Clinical course",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Drugs and chemicals",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Lists of safe and unsafe drugs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Infections",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Diabetic ketoacidosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Foods: fava beans and bitter melon",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      CONGENITAL NONSPHEROCYTIC HEMOLYTIC ANEMIA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Neutrophil dysfunction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      NEONATAL HYPERBILIRUBINEMIA",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Diagnosis of G6PD deficiency",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1807524\">",
"      Enzyme variants",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1807531\">",
"      Clinical syndromes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Inciting events",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Clinical manifestations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"HEME/7111\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/7111|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?28/29/29149\" title=\"figure 1\">",
"      G6PD mutations and class",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?18/40/19085\" title=\"figure 2\">",
"      Physiology of G6PD",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/7111|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?25/28/26054\" title=\"picture 1\">",
"      Heinz body hemolytic anemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/7111|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?19/22/19821\" title=\"table 1\">",
"      Drugs and G6PD deficiency",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/18/27943?source=related_link\">",
"      Bilirubin metabolism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/54/22377?source=related_link\">",
"      Clinical manifestations and pathogenesis of human parvovirus B19 infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/50/39719?source=related_link\">",
"      Diagnosis and treatment of glucose-6-phosphate dehydrogenase deficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/46/4841?source=related_link\">",
"      Genetics and pathogenesis of methemoglobinemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/62/13289?source=related_link\">",
"      Genetics and pathophysiology of glucose-6-phosphate dehydrogenase deficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/60/14280?source=related_link\">",
"      Myeloperoxidase deficiency and other enzymatic WBC defects causing immunodeficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/31/6650?source=related_link\">",
"      Neutrophil functions other than movement",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/2/2088?source=related_link\">",
"      Newborn screening",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/3/39992?source=related_link\">",
"      Pathogenesis and etiology of unconjugated hyperbilirubinemia in the newborn",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?12/41/12946?source=related_link\">",
"      Patient information: Glucose-6-phosphate dehydrogenase deficiency (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/59/21434?source=related_link\">",
"      Treatment of unconjugated hyperbilirubinemia in term and late preterm infants",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/38/616?source=related_link\">",
"      Unstable hemoglobin variants",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f4_25_4506="Epidemiology, presentation, and diagnosis of type 2 diabetes mellitus in children and adolescents";
var content_f4_25_4506=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Epidemiology, presentation, and diagnosis of type 2 diabetes mellitus in children and adolescents",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/25/4506/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/25/4506/contributors\">",
"     Lori Laffel, MD, MPH",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/25/4506/contributors\">",
"     Britta Svoren, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/25/4506/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/25/4506/contributors\">",
"     Joseph I Wolfsdorf, MB, BCh",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/25/4506/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/25/4506/contributors\">",
"     Alison G Hoppin, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?4/25/4506/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 5, 2011.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Since the early 1990s, the incidence of type 2 diabetes has increased in children and adolescents and is linked to the rise in childhood obesity. Type 2 diabetes and its co-morbidities are risk factors for vascular disease later in life. As a result, it is imperative for health care providers to identify and treat children and adolescents with this disorder. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/5/32858?source=see_link\">",
"     \"Definition; epidemiology; and etiology of obesity in children and adolescents\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The epidemiology, presentation, and diagnosis of type 2 diabetes mellitus in children and adolescents are presented here. The pathogenesis of type 2 diabetes, and the management, co-morbidities, and complications of type 2 diabetes in children and adolescents are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/31/36346?source=see_link\">",
"     \"Pathogenesis of type 2 diabetes mellitus\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/30/36329?source=see_link\">",
"     \"Management of type 2 diabetes mellitus in children and adolescents\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/28/34249?source=see_link\">",
"     \"Comorbidities and complications of type 2 diabetes mellitus in children and adolescents\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     DEFINITIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Type 2 diabetes is closely linked to an increase in excess weight. Several classifications, based upon body mass index (BMI), are used to define overweight and obesity (",
"    <a class=\"graphic graphic_table graphicRef78725 \" href=\"UTD.htm?23/40/24203\">",
"     table 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef60784 graphicRef68478 \" href=\"UTD.htm?10/0/10247\">",
"     figure 1A-B",
"    </a>",
"    ). BMI provides a guideline for weight in relation to height and is equal to the body weight in kilograms divided by the height in meters squared (",
"    <a class=\"graphic graphic_table graphicRef71431 \" href=\"UTD.htm?0/28/459\">",
"     table 2",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/5/32858?source=see_link&amp;anchor=H2#H2\">",
"     \"Definition; epidemiology; and etiology of obesity in children and adolescents\", section on 'Definitions'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In this review the following terminology is used to describe states of excess weight in childhood and adolescence:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Overweight &mdash; BMI &ge;85th and &lt;95th percentile",
"     </li>",
"     <li>",
"      Obesity &mdash; BMI &ge;95th percentile",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The rise in type 2 diabetes is occurring worldwide in parallel with an increasing prevalence of obesity in children [",
"    <a class=\"abstract\" href=\"UTD.htm?4/25/4506/abstract/1\">",
"     1",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/5/32858?source=see_link&amp;anchor=H3#H3\">",
"     \"Definition; epidemiology; and etiology of obesity in children and adolescents\", section on 'Epidemiology'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In the absence of routine screening, the true prevalence and incidence of childhood onset type 2 diabetes are unknown. However, the incidence of type 2 diabetes is increasing in many countries, coinciding with increasing rates of obesity:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Japan &mdash; A population-based study from Tokyo of school-aged children (ages 6 to 15 years of age) demonstrated an increased incidence of type 2 diabetes after 1981 compared to before 1981 (2.76 versus 1.73 per 100,000), which corresponded to an increase in obese children during the same time period [",
"      <a class=\"abstract\" href=\"UTD.htm?4/25/4506/abstract/2\">",
"       2",
"      </a>",
"      ]. The incidence of type 2 diabetes was greater in adolescents (13 to 15 years of age) compared to younger children (&le;12 years of age), 6.43 versus 1.73 per 100,000. In another report, type 2 diabetes appears to account for 80 percent of all diabetic cases in Japan [",
"      <a class=\"abstract\" href=\"UTD.htm?4/25/4506/abstract/3\">",
"       3",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Thailand &mdash; A review of patients cared for at a pediatric endocrinology center reported the proportion of new diabetic cases due to type 2 diabetes rose from 5 percent to 18 percent between the periods of 1986 to 1995 and 1996 to 1999 [",
"      <a class=\"abstract\" href=\"UTD.htm?4/25/4506/abstract/4\">",
"       4",
"      </a>",
"      ]. The prevalence of obesity in children also increased from 5.8 to 13.3 percent between 1990 and 1996.",
"     </li>",
"     <li>",
"      Argentina &mdash; In a review of patients from a tertiary center, the percentage of new cases of type 2 diabetes rose from 0 to 4.3 percent between 1992 and 2001 [",
"      <a class=\"abstract\" href=\"UTD.htm?4/25/4506/abstract/1\">",
"       1",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      United States &mdash; In the United States, several centers have reported an increase in type 2 diabetes that parallels the increasing rate of obesity [",
"      <a class=\"abstract\" href=\"UTD.htm?4/25/4506/abstract/5-8\">",
"       5-8",
"      </a>",
"      ]. In one retrospective study from Cincinnati, the incidence of type 2 diabetes in adolescents aged 10 to 19 years rose 10-fold from 0.7 per 100,000 in 1982 to 7.2 per 100,000 in 1994 [",
"      <a class=\"abstract\" href=\"UTD.htm?4/25/4506/abstract/5\">",
"       5",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Population-based surveys suggest that the true prevalence of type 2 diabetes may be lower than that suggested by the clinic-based reports cited above. Population surveys in the United States report prevalence rates of 0.18 per 1000 individuals among non-Hispanic white youth 10-19 years old, with rates of 1.06 and 1.45 per 1000 individuals in African-American and Navajo youth, respectively (",
"    <a class=\"graphic graphic_table graphicRef51817 \" href=\"UTD.htm?21/60/22476\">",
"     table 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/25/4506/abstract/9-13\">",
"     9-13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    These findings suggest that the overall incidence of type 2 diabetes in adolescents has not increased as sharply as the increases in obesity in the same age group. This is probably because of a substantial latency period between the onset of obesity and the related risk for type 2 diabetes [",
"    <a class=\"abstract\" href=\"UTD.htm?4/25/4506/abstract/14\">",
"     14",
"    </a>",
"    ]. Consistent with this model, studies have shown sharp increases in type 2 diabetes among young adults [",
"    <a class=\"abstract\" href=\"UTD.htm?4/25/4506/abstract/15\">",
"     15",
"    </a>",
"    ]. Thus, the consequence of the rise in obesity among adolescents may be a marked increase in type 2 diabetes when the cohort reaches adulthood.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Risk factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following factors are associated with an increased risk for childhood onset type 2 diabetes:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Obesity",
"     </li>",
"     <li>",
"      Positive family history",
"     </li>",
"     <li>",
"      Specific ethnic groups",
"     </li>",
"     <li>",
"      Female gender",
"     </li>",
"     <li>",
"      Conditions with insulin resistance",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Obesity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Excess weight is the most important risk factor for the development of type 2 diabetes. As an example, in a retrospective study of 50 patients (age range, 8 to 19 years) with type 2 diabetes, all but one patient had a BMI &ge;85th percentile [",
"    <a class=\"abstract\" href=\"UTD.htm?4/25/4506/abstract/6\">",
"     6",
"    </a>",
"    ]. In another study of 54 adolescents (age range, 10 to 19 years), 47 patients had a BMI &ge;90th percentile [",
"    <a class=\"abstract\" href=\"UTD.htm?4/25/4506/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Obesity predisposes to type 2 diabetes by increasing peripheral resistance to insulin-mediated glucose uptake. The role of obesity in the pathogenesis of type 2 diabetes is discussed in greater detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/31/36346?source=see_link&amp;anchor=H17#H17\">",
"     \"Pathogenesis of type 2 diabetes mellitus\", section on 'Role of diet, obesity, and inflammation'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    As in adults, the distribution of excess weight in an abdominal obesity pattern (also called central adiposity, visceral, android, or male-type obesity) increases insulin resistance and the likelihood of type 2 diabetes in children [",
"    <a class=\"abstract\" href=\"UTD.htm?4/25/4506/abstract/16,17\">",
"     16,17",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/30/29162?source=see_link\">",
"     \"Prediction and prevention of type 2 diabetes mellitus\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The HEALTHY Study reported on a comprehensive, multi-component,&nbsp;middle-school based intervention aimed at reducing childhood",
"    <span class=\"nowrap\">",
"     overweight/obesity",
"    </span>",
"    in order to reduce progression to prediabetes and diabetes in childhood [",
"    <a class=\"abstract\" href=\"UTD.htm?4/25/4506/abstract/18\">",
"     18",
"    </a>",
"    ]. The school-based program did not yield&nbsp;a greater decrease in the combined prevalence of overweight and obesity compared with control schools. However, the intervention&nbsp;did reduce BMI z-score and several other measures of adiposity in general and particularly among youth who were overweight or obese at study entry. These findings have potential implications for&nbsp;reducing the risk of childhood-onset type 2 diabetes.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Genetic susceptibility",
"    </span>",
"    &nbsp;&mdash;&nbsp;Type 2 diabetes in adults appears to be caused by a complex interaction of environmental and genetic factors in a susceptible individual. In the majority of patients with type 2 diabetes, genetic susceptibility appears to be due to the expression of multiple genes (polygenic). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/31/36346?source=see_link&amp;anchor=H8#H8\">",
"     \"Pathogenesis of type 2 diabetes mellitus\", section on 'Genetic susceptibility'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Evidence for a strong genetic component for type 2 disease is based upon observations that the risk of diabetes is significantly increased in close relatives of an affected patient.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In several studies reviewed by the American Diabetes Association (ADA), 40 to 80 percent of children and adolescents with type 2 diabetes had at least one affected parent [",
"      <a class=\"abstract\" href=\"UTD.htm?4/25/4506/abstract/19\">",
"       19",
"      </a>",
"      ]. In the previously mentioned review of 54 adolescents with type 2 diabetes, 65 percent had one first-degree relative with the condition, and 85 percent had at least one first- or second-degree relative [",
"      <a class=\"abstract\" href=\"UTD.htm?4/25/4506/abstract/5\">",
"       5",
"      </a>",
"      ]. In the baseline data from the TODAY Study (Treatment Options for Type 2 Diabetes in Adolescents and Youth), 60 percent of study participants had a positive family history of diabetes in a first degree relative while 89 percent had a positive family history of diabetes with the addition of grandparents [",
"      <a class=\"abstract\" href=\"UTD.htm?4/25/4506/abstract/20\">",
"       20",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The offspring of a parent with type 2 diabetes has an estimated risk of 40 percent of developing diabetes. This risk increases to 60 percent if both parents are affected [",
"      <a class=\"abstract\" href=\"UTD.htm?4/25/4506/abstract/21\">",
"       21",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In monozygotic twins with one affected twin, the other twin has a 90 percent chance of developing diabetes [",
"      <a class=\"abstract\" href=\"UTD.htm?4/25/4506/abstract/22\">",
"       22",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Gene identification has been difficult because of the complex inheritance patterns and interactions with the environment [",
"    <a class=\"abstract\" href=\"UTD.htm?4/25/4506/abstract/23\">",
"     23",
"    </a>",
"    ]. A number of candidate genes have been linked to type 2 diabetes and they are discussed in greater detail separately (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/31/36346?source=see_link&amp;anchor=H8#H8\">",
"     \"Pathogenesis of type 2 diabetes mellitus\", section on 'Genetic susceptibility'",
"    </a>",
"    ). Studies of genetic susceptibility are ongoing with the inclusion of patients with a young age of onset of type 2 diabetes under 18 years old.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Ethnicity",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the United States, type 2 diabetes is more common in Native American, African American, Hispanic, Asian-American, and Pacific Islander children than in the general population (",
"    <a class=\"graphic graphic_table graphicRef51817 \" href=\"UTD.htm?21/60/22476\">",
"     table 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/25/4506/abstract/9-13,24-28\">",
"     9-13,24-28",
"    </a>",
"    ]. In the age range 15 to 19 years, incidence rates are 17 to 50 per 100,000 person-years among these groups [",
"    <a class=\"abstract\" href=\"UTD.htm?4/25/4506/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Native Americans &mdash; Pima Indian adolescents (15 to 19 years of age) have the highest reported prevalence of type 2 diabetes among youth, 51 per 1000 [",
"      <a class=\"abstract\" href=\"UTD.htm?4/25/4506/abstract/25\">",
"       25",
"      </a>",
"      ]. The prevalence rate for all North American Indians was 4.5 per 1000.",
"     </li>",
"     <li>",
"      Non-Hispanic black &mdash; Several case series have demonstrated that type 2 diabetes disproportionately affects non-Hispanic blacks [",
"      <a class=\"abstract\" href=\"UTD.htm?4/25/4506/abstract/5,6,8\">",
"       5,6,8",
"      </a>",
"      ]. As an example, at a tertiary center in Arkansas, non-Hispanic blacks represented 74 percent of children with type 2 diabetes whereas they comprised only 16 percent of the state's general population [",
"      <a class=\"abstract\" href=\"UTD.htm?4/25/4506/abstract/6\">",
"       6",
"      </a>",
"      ]. In a case series from Cincinnati, 69 percent of adolescents with type 2 diabetes were black compared to 14.5 percent of the general population served by the study center [",
"      <a class=\"abstract\" href=\"UTD.htm?4/25/4506/abstract/5\">",
"       5",
"      </a>",
"      ]. Similar results were seen from a Chicago-based diabetes registry in which 76 percent of cases of type 2 diabetes in children occurred in non-Hispanic blacks [",
"      <a class=\"abstract\" href=\"UTD.htm?4/25/4506/abstract/8\">",
"       8",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      Several studies have reported that insulin resistance is greater in black compared to white children [",
"      <a class=\"abstract\" href=\"UTD.htm?4/25/4506/abstract/30-35\">",
"       30-35",
"      </a>",
"      ], which may in part explain the overrepresentation of non-Hispanic black children in the above case series.",
"     </li>",
"     <li>",
"      Hispanic &mdash; In case series, Hispanic children appear to be at increased risk for type 2 diabetes compared to the general population [",
"      <a class=\"abstract\" href=\"UTD.htm?4/25/4506/abstract/8,24\">",
"       8,24",
"      </a>",
"      ]. In the previously mentioned report from a Chicago-based diabetes registry, 20 percent of the children with type 2 diabetes were Hispanic. Among 101 children with type 2 diabetes at a referral center in Texas, 83 percent of patients were Hispanic and 17 percent were white. Hispanic children have been reported to have lower insulin sensitivity [",
"      <a class=\"abstract\" href=\"UTD.htm?4/25/4506/abstract/36,37\">",
"       36,37",
"      </a>",
"      ] and reduced pancreatic beta cell function (decreased insulin secretion) [",
"      <a class=\"abstract\" href=\"UTD.htm?4/25/4506/abstract/38\">",
"       38",
"      </a>",
"      ], both of which increase the risk of diabetes.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Gender",
"    </span>",
"    &nbsp;&mdash;&nbsp;Girls are 1.3 to 1.7 times more likely than boys to develop type 2 diabetes during childhood [",
"    <a class=\"abstract\" href=\"UTD.htm?4/25/4506/abstract/5,6,24,29\">",
"     5,6,24,29",
"    </a>",
"    ]. Although the reason for this increased risk in girls is not clear, it may be related to an increased risk of insulin resistance as seen in adolescent girls with polycystic ovarian syndrome (PCOS). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/46/24297?source=see_link&amp;anchor=H16#H16\">",
"     \"Treatment of polycystic ovary syndrome in adolescents\", section on 'Obesity and insulin resistance'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/9/34970?source=see_link&amp;anchor=H11771185#H11771185\">",
"     \"Definition, pathogenesis, and etiology of polycystic ovary syndrome in adolescents\", section on 'Insulin resistant hyperinsulinism'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     In-utero programming",
"    </span>",
"    &nbsp;&mdash;&nbsp;One hypothesis suggests that in-utero programming due to prenatal undernutrition or gestational diabetes causes metabolic and hormonal changes that promote obesity and insulin resistance and increase type 2 diabetes risk in adult offspring.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Low birth weight &mdash; Low birth weight for gestational age resulting from intrauterine undernutrition is associated with insulin resistance. The combination of low birth weight and increasing weight gain in adult middle age increases insulin resistance and the risk for type 2 diabetes (",
"      <a class=\"graphic graphic_figure graphicRef52859 \" href=\"UTD.htm?17/56/18318\">",
"       figure 2",
"      </a>",
"      ). Individuals with the lowest birth weight and the highest prepubertal body weight appear to be at the greatest risk for insulin resistance and type 2 diabetes [",
"      <a class=\"abstract\" href=\"UTD.htm?4/25/4506/abstract/39\">",
"       39",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?35/31/36346?source=see_link&amp;anchor=H32#H32\">",
"       \"Pathogenesis of type 2 diabetes mellitus\", section on 'Role of intrauterine development'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Gestational diabetes &mdash; The abnormal intrauterine metabolic environment of a diabetic pregnancy appears to increase the risk of type 2 diabetes. Intrauterine exposure to hyperglycemia and hyperinsulinemia may affect the development of adipose tissue and pancreatic beta cells, leading to future obesity and altered glucose metabolism. The effects of gestational diabetes on the risk of developing type 2 diabetes in the offspring are discussed separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?43/48/44809?source=see_link&amp;anchor=H27#H27\">",
"       \"Infant of a diabetic mother\", section on 'Diabetes'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Other insulin resistant states",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Puberty &mdash; Most patients with pediatric type 2 diabetes present at the onset of puberty (mean age of 13.5 years) [",
"      <a class=\"abstract\" href=\"UTD.htm?4/25/4506/abstract/5,6\">",
"       5,6",
"      </a>",
"      ], a stage of development when there is increased insulin resistance [",
"      <a class=\"abstract\" href=\"UTD.htm?4/25/4506/abstract/40,41\">",
"       40,41",
"      </a>",
"      ]. During puberty, insulin sensitivity decreases by approximately 30 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?4/25/4506/abstract/40\">",
"       40",
"      </a>",
"      ] and is related to the increased activity of growth hormone and insulin-like growth factor-1.",
"     </li>",
"     <li>",
"      Polycystic ovary syndrome (PCOS) &mdash; Insulin resistance is a component of PCOS and may play a role in its pathogenesis. Patients with PCOS are at increased risk for developing type 2 diabetes. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?38/13/39130?source=see_link&amp;anchor=H34#H34\">",
"       \"Clinical features and diagnosis of polycystic ovary syndrome in adolescents\", section on 'Additional evaluation of PCOS patients'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?34/9/34970?source=see_link&amp;anchor=H11771185#H11771185\">",
"       \"Definition, pathogenesis, and etiology of polycystic ovary syndrome in adolescents\", section on 'Insulin resistant hyperinsulinism'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     CLINICAL PRESENTATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Childhood type 2 diabetes can present in several ways [",
"    <a class=\"abstract\" href=\"UTD.htm?4/25/4506/abstract/42\">",
"     42",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Diabetic ketoacidosis (DKA) or with only ketonuria",
"     </li>",
"     <li>",
"      Symptomatic presentation without ketonuria or acidosis",
"     </li>",
"     <li>",
"      Asymptomatic presentation",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Diabetic ketoacidosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Children with type 2 diabetes can present with DKA (hyperglycemia, ketonuria, and acidosis). Symptoms are due to hyperglycemia and include polyuria (due to the glucose osmotic diuresis), polydipsia (due to increased urinary losses), fatigue, and lethargy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/32/41480?source=see_link&amp;anchor=H9#H9\">",
"     \"Clinical features and diagnosis of diabetic ketoacidosis in children\", section on 'Signs and symptoms'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The reported frequency of diabetic ketoacidosis (DKA) as the initial presentation for childhood type 2 diabetes varies from 5 to 25 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?4/25/4506/abstract/6,43\">",
"     6,43",
"    </a>",
"    ]. In a retrospective review of 69 patients (between 9 and 18 years of age) who presented with DKA at a tertiary center, 13 percent had type 2 diabetes [",
"    <a class=\"abstract\" href=\"UTD.htm?4/25/4506/abstract/43\">",
"     43",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/32/41480?source=see_link&amp;anchor=H3#H3\">",
"     \"Clinical features and diagnosis of diabetic ketoacidosis in children\", section on 'Epidemiology'",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H19\">",
"     'Type 2 versus type 1 diabetes'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Non-Hispanic black and Hispanic children with type 2 diabetes are more likely to present with DKA or ketonuria than white children [",
"    <a class=\"abstract\" href=\"UTD.htm?4/25/4506/abstract/6,44,45\">",
"     6,44,45",
"    </a>",
"    ]. In one case series of 42 adolescents with type 2 diabetes, of the 28 non-Hispanic black patients, 7 presented with DKA and another 12 with ketonuria without acidosis [",
"    <a class=\"abstract\" href=\"UTD.htm?4/25/4506/abstract/44\">",
"     44",
"    </a>",
"    ]. In contrast, none of the 12 white patients had ketonuria or DKA. In an observational study of 21 Mexican American children with type 2 diabetes, about one-third presented with ketonuria [",
"    <a class=\"abstract\" href=\"UTD.htm?4/25/4506/abstract/45\">",
"     45",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Children with DKA require hospitalization, rehydration, and insulin replacement therapy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/28/7626?source=see_link\">",
"     \"Treatment and complications of diabetic ketoacidosis in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Hyperosmolar hyperglycemic state",
"    </span>",
"    &nbsp;&mdash;&nbsp;A hyperosmolar hyperglycemic state (HHS) is a condition similar to DKA, characterized by marked hyperglycemia (plasma glucose &gt;600",
"    <span class=\"nowrap\">",
"     mg/dL)",
"    </span>",
"    and severe dehydration but little or no ketonuria. It is usually seen in adult patients with poorly controlled type 2 diabetes, but has been reported in adolescents [",
"    <a class=\"abstract\" href=\"UTD.htm?4/25/4506/abstract/46-48\">",
"     46-48",
"    </a>",
"    ]. Recognition of HHS is important because it is characterized by more severe dehydration than DKA, with high morbidity and mortality if not adequately treated. Management of HHS is discussed in a separate topic review. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/48/15114?source=see_link&amp;anchor=H8#H8\">",
"     \"Treatment of diabetic ketoacidosis and hyperosmolar hyperglycemic state in adults\", section on 'Fluid replacement'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Symptomatic",
"    </span>",
"    &nbsp;&mdash;&nbsp;Symptoms are due to hyperglycemia and commonly include polyuria, polydipsia, and nocturia similar to that seen in patients with type 1 diabetes. Recent weight loss is less frequently reported in children who present with type 2 diabetes compared to those with type 1 diabetes [",
"    <a class=\"abstract\" href=\"UTD.htm?4/25/4506/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In adolescent girls, vaginal discharge or vulvovaginitis due to monilial infection can be the initial chief complaint [",
"    <a class=\"abstract\" href=\"UTD.htm?4/25/4506/abstract/5,49\">",
"     5,49",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/1/15386?source=see_link&amp;anchor=H4#H4\">",
"     \"Candida vulvovaginitis\", section on 'Risk factors'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Asymptomatic",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many patients with type 2 diabetes are identified by screening and are asymptomatic at presentation. This occurs as a result of screening specifically for type 2 diabetes or because of a positive urinalysis test for glycosuria obtained as part of a routine physical examination [",
"    <a class=\"abstract\" href=\"UTD.htm?4/25/4506/abstract/5\">",
"     5",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H21\">",
"     'Screening'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Type 2 diabetes is one of many different types of diabetes mellitus. The initial step is to diagnose diabetes, and then differentiate type 2 diabetes from other causes of diabetes based upon the clinical presentation of the patient. (See",
"    <a class=\"local\" href=\"#H19\">",
"     'Type 2 versus type 1 diabetes'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H20\">",
"     'Other causes of diabetes'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Diabetes mellitus",
"    </span>",
"    &nbsp;&mdash;&nbsp;A diagnosis of diabetes mellitus in a child or adolescent is made in one of four ways (",
"    <a class=\"graphic graphic_table graphicRef61853 \" href=\"UTD.htm?28/3/28731\">",
"     table 4",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/25/4506/abstract/50\">",
"     50",
"    </a>",
"    ]. The diagnostic criteria, based upon the guidelines of the American Diabetes Association (ADA), are the same as those used in adults. Unless unequivocal hyperglycemia is present, the diagnosis should be confirmed by repeat testing on a different day. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/54/38758?source=see_link\">",
"     \"Diagnosis of diabetes mellitus\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Fasting plasma glucose &ge;126",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (7",
"      <span class=\"nowrap\">",
"       mmol/L).",
"      </span>",
"      Fasting is defined as no caloric intake for at least eight hours.",
"     </li>",
"     <li>",
"      Symptoms of hyperglycemia and a random venous plasma glucose &ge;200",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (11.1",
"      <span class=\"nowrap\">",
"       mmol/L)",
"      </span>",
"     </li>",
"     <li>",
"      Abnormal oral glucose tolerance test (OGTT) defined as a plasma glucose &ge;200",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (11.1",
"      <span class=\"nowrap\">",
"       mmol/L)",
"      </span>",
"      measured two hours after a glucose load of 1.75",
"      <span class=\"nowrap\">",
"       g/kg",
"      </span>",
"      (maximum dose of 75 g)",
"     </li>",
"     <li>",
"      Hemoglobin A1C &ge; 6.5 percent. The test should be performed in a laboratory using a method that is certified by the National Glycohemoglobin Standardization Program (NGSP)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Because of improved assay standardization and validation against other diagnostic methods, diagnosis of diabetes based on the level of hemoglobin A1C (glycated hemoglobin) was recommended by an international consensus statement and endorsed by the American Diabetes Association. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/54/38758?source=see_link&amp;anchor=H7#H7\">",
"     \"Diagnosis of diabetes mellitus\", section on 'Hemoglobin A1C'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Glycosuria is suggestive of diabetes, but not diagnostic. For example, patients with renal glucosuria or Fanconi syndrome will present with glycosuria but will be normoglycemic.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Impaired glucose tolerance",
"    </span>",
"    &nbsp;&mdash;&nbsp;Both impaired fasting glucose (IFG) and impaired glucose tolerance (IGT) have been officially termed \"pre-diabetes\". &nbsp;Both categories, IFG and IGT, are risk factors for future diabetes. The diagnostic criteria used to establish these diagnoses in children are the same as those used in adults.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Impaired fasting glucose &mdash; Fasting plasma glucose 100",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (5.6",
"      <span class=\"nowrap\">",
"       mmol/L)",
"      </span>",
"      to 125",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (6.9",
"      <span class=\"nowrap\">",
"       mmol/L)",
"      </span>",
"     </li>",
"     <li>",
"      Impaired glucose tolerance &mdash; Two-hour plasma glucose 140",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (7.8",
"      <span class=\"nowrap\">",
"       mmol/L)",
"      </span>",
"      to 199",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (11.0",
"      <span class=\"nowrap\">",
"       mmol/L)",
"      </span>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Hemoglobin A1C values between 5.7 and 6.4 percent have also been considered to indicate risk for diabetes and have been viewed as pre-diabetes in adults; additional studies are needed in pediatric patients.",
"   </p>",
"   <p>",
"    It has been suggested that the oral glucose tolerance test (OGTT) may reliably identify asymptomatic obese children who are at high risk for diabetes. One study, however, has shown poor reproducibility of results in 60 overweight children who had two OGTTs performed 1 to 25 days apart [",
"    <a class=\"abstract\" href=\"UTD.htm?4/25/4506/abstract/51\">",
"     51",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Type 2 versus type 1 diabetes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because long term management differs for patients with type 2 versus type 1 diabetes, it is important to distinguish between the two diseases. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/33/14874?source=see_link\">",
"     \"Classification of diabetes mellitus and genetic diabetic syndromes\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although clinical presentation, history, and laboratory studies are used to differentiate between the two diseases, some patients have clinical and biochemical features of both types, which can make specific diagnosis difficult or even impossible. In general, the following features may be helpful to distinguish between the two types of diabetes (",
"    <a class=\"graphic graphic_table graphicRef59370 \" href=\"UTD.htm?31/15/31997\">",
"     table 5",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Body habitus &mdash; Patients with type 2 diabetes are generally overweight with body mass index &ge;85th percentile for age and gender. In contrast, children with type 1 diabetes are usually not overweight and often have a recent history of weight loss. However, in the current epidemic of childhood overweight and obesity, as many as one third of youth with type 1 diabetes will be overweight or obese [",
"      <a class=\"abstract\" href=\"UTD.htm?4/25/4506/abstract/52\">",
"       52",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Age &mdash; Patients with type 2 diabetes generally present after the onset of puberty at a mean age of 13.5 years. Age of presentation of type 1 disease is bimodal with a peak between four and six years of age and a second before the onset of or in early puberty, 10 to 14 years of age.",
"     </li>",
"     <li>",
"      Insulin resistance &mdash; Patients with type 2 diabetes usually have clinical features associated with insulin resistance such as acanthosis nigricans, hypertension, dyslipidemia, and polycystic ovary syndrome, which are not commonly seen in children with type 1 disease.",
"     </li>",
"     <li>",
"      Family history &mdash; Patients with either type 1 or type 2 diabetes can have an affected close relative; however, it is more common with type 2 diabetes.",
"     </li>",
"     <li>",
"      Ethnicity &mdash; In the United States, most pediatric patients with type 2 diabetes belong to minority ethnic groups including non-Hispanic black, Hispanic, Native American, Asian American, and Pacific islanders.",
"     </li>",
"     <li>",
"      Ketoacidosis &mdash; Patients with type 1 diabetes are somewhat more likely to present with ketoacidosis, due to insufficient insulin production, but this presentation is not uncommon in type 2 diabetes.",
"     </li>",
"     <li>",
"      Type 1 diabetes is suggested by the presence of pancreatic (islet) autoantibodies. These include autoantibodies to insulin (IAA), islet cell cytoplasm (ICA), glutamic acid decarboxylase (GAD), tyrosine phosphatase (IA-2), and a beta cell-specific autoantibody to zinc transporter 8 (ZnT8) [",
"      <a class=\"abstract\" href=\"UTD.htm?4/25/4506/abstract/53\">",
"       53",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Type 1 diabetes also is usually suggested by reduced insulin and c-peptide levels.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    On occasion patients may have mixed features, and are difficult to classify. This is because type 2 diabetes may have atypical characteristics, including a presentation with ketosis (\"ketosis-prone type 2 diabetes\") or ketoacidosis. The presence of serum autoantibodies suggests type 1 diabetes, but can also occur in patients with clinically diagnosed type 2 diabetes, particularly those presenting with atypical features. As an example, among 1206 youths clinically diagnosed with type 2 diabetes and screened for participation in the TODAY study, 9.8 percent were found to have positive antibodies to either GAD or IA2 (other antibodies were not tested) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/25/4506/abstract/54\">",
"     54",
"    </a>",
"    ]. Furthermore, fasting serum insulin levels and C-peptide levels have not been standardized to distinguish between type 1 and 2 diabetes [",
"    <a class=\"abstract\" href=\"UTD.htm?4/25/4506/abstract/55\">",
"     55",
"    </a>",
"    ]. Finally, the pathophysiologic features of both types of diabetes may coexist in the same patient, particularly if the patient has obesity.",
"   </p>",
"   <p>",
"    The challenges of categorizing types of diabetes were illustrated in a multicenter study in which pediatric diabetes was classified based upon the presence or absence of beta cell autoimmunity and the presence or absence of insulin sensitivity. Over 70 percent of patients fell into traditional categories of autoimmune and insulin sensitive type 1 diabetes (55 percent) or nonautoimmune and insulin resistant type 2 diabetes (16 percent). An additional 20 percent had both autoimmunity and insulin resistance, a pattern typical for obese patients with type 1 diabetes. The final 10 percent of patients were insulin sensitive in the absence of beta cell autoimmunity, suggesting that these patients need additional evaluation for the possibility of monogenic diabetes [",
"    <a class=\"abstract\" href=\"UTD.htm?4/25/4506/abstract/56\">",
"     56",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/33/14874?source=see_link&amp;anchor=H6#H6\">",
"     \"Classification of diabetes mellitus and genetic diabetic syndromes\", section on 'Distinguishing type 1 from type 2 diabetes'",
"    </a>",
"    .) &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Other causes of diabetes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Type 2 diabetes is differentiated from other causes of diabetes by patient characteristics, history, and laboratory studies. This approach is similar to that used to differentiate type 1 from type 2 diabetes discussed above. (See",
"    <a class=\"local\" href=\"#H19\">",
"     'Type 2 versus type 1 diabetes'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The following diseases that cause diabetes are discussed in greater detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/33/14874?source=see_link\">",
"     \"Classification of diabetes mellitus and genetic diabetic syndromes\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Diseases of the exocrine system &mdash; Cystic fibrosis, hereditary hemochromatosis, and chronic pancreatitis.",
"     </li>",
"     <li>",
"      Endocrine abnormalities in glucose regulation &mdash; Cushing's syndrome, glucagon-secreting tumors, catecholamine excess in pheochromocytoma.",
"     </li>",
"     <li>",
"      Drug-induced diabetes &mdash; A number of drugs (eg, glucocorticoids, HIV protease inhibitors, and",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/24/34176?source=see_link\">",
"       cyclosporine",
"      </a>",
"      ) can impair glucose tolerance by inhibiting insulin secretion, increasing hepatic glucose production, or causing insulin resistance (",
"      <a class=\"graphic graphic_table graphicRef67257 \" href=\"UTD.htm?10/40/10891\">",
"       table 6",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     SCREENING",
"    </span>",
"    &nbsp;&mdash;&nbsp;Data from screening programs in Japan and Taiwan indicate that the cost of screening an unselected general school population for type 2 diabetes is approximately $10,000 (US) for every identified case. This estimated cost remains too high for universal screening and therefore, screening has been focused on high-risk populations.",
"   </p>",
"   <p>",
"    A multi-center study of predominantly minority eighth-grade students in the United States found that approximately 0.5 and 43 percent of students met criteria for diabetes and prediabetes, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?4/25/4506/abstract/37\">",
"     37",
"    </a>",
"    ]. Although these data suggest that middle schools might be appropriate venues for lifestyle intervention programs, screening efforts remain controversial because there are no data from controlled trials showing that earlier diagnosis in children improves long-term outcome.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Indications",
"    </span>",
"    &nbsp;&mdash;&nbsp;The ADA recommends screening children every three years beginning at 10 years of age or at onset of puberty (whichever comes first) if they are overweight or obese (BMI &ge;85th percentile) and have two or more of the following additional risk factors&nbsp;(",
"    <a class=\"graphic graphic_table graphicRef56279 \" href=\"UTD.htm?39/46/40683\">",
"     table 7",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/25/4506/abstract/50\">",
"     50",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Type 2 DM in a first- or second-degree relative",
"     </li>",
"     <li>",
"      Member of a high-risk ethnic group: Native American, non-Hispanic black, Hispanic, Asian American, or Pacific islander",
"     </li>",
"     <li>",
"      Signs of insulin resistance or conditions associated with insulin resistance (eg, hypertension, dyslipidemia, acanthosis nigricans, and polycystic ovary syndrome, or small for gestational age birth weight)",
"     </li>",
"     <li>",
"      Maternal history of diabetes or gestational diabetes during the child's gestation",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Test",
"    </span>",
"    &nbsp;&mdash;&nbsp;Screening for diabetes can be done by measuring hemoglobin A1C (A1C), fasting plasma glucose (FPG), or performing an oral glucose tolerance test (OGTT). Among candidates for screening who have not fasted overnight, A1C is the preferred test. Abnormal results should be confirmed either by repeating the initial test on another day, or performing a different test.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h3\">",
"     Hemoglobin A1C",
"    </span>",
"    &nbsp;&mdash;&nbsp;Until recently, hemoglobin A1C (glycated hemoglobin) was not recommended as a screening test for diabetes mellitus, in part because of widely divergent methodologies used for the assay. Because of improved assay standardization and validation against other diagnostic methods, diagnosis of diabetes based on the level of hemoglobin A1C is now recommended by an international consensus statement and endorsed by the American Diabetes Association.",
"   </p>",
"   <p>",
"    An A1C level &ge;6.5 percent (on two occasions) can now be used to diagnose diabetes in adults, using an assay that is certified by the National Glycohemoglobin Standardization Program [",
"    <a class=\"abstract\" href=\"UTD.htm?4/25/4506/abstract/50\">",
"     50",
"    </a>",
"    ]. The same diagnostic criteria are used for pediatric patients. However, these recommendations were based on studies in adults. A subsequent report in a population-based sample of adolescents concluded that a single measurement of A1C &ge;6.5 percent had high specificity (99 percent) but only 75 percent sensitivity for detecting diabetes mellitus; however, this study was based on only four cases of type 2 diabetes in a sample of 1156 youth [",
"    <a class=\"abstract\" href=\"UTD.htm?4/25/4506/abstract/57\">",
"     57",
"    </a>",
"    ]. This study used data from the National Health and Nutrition Examination Surveys (NHANES), and a single measurement of FPG &ge;126",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    OR two-hour plasma glucose &ge;200",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    on an oral glucose tolerance test was used as the gold standard for diagnosing diabetes mellitus. Thus, while an elevated A1C (on two occasions, using a certified laboratory assay) can be used to diagnose diabetes, glucose tolerance testing should be performed in youth with normal A1C levels and clinical concerns of type 2 diabetes. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/54/38758?source=see_link&amp;anchor=H7#H7\">",
"     \"Diagnosis of diabetes mellitus\", section on 'Hemoglobin A1C'",
"    </a>",
"    .) &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h3\">",
"     Fasting plasma glucose",
"    </span>",
"    &nbsp;&mdash;&nbsp;FPG is more convenient, less expensive, and less invasive than the oral glucose tolerance test (OGTT) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/25/4506/abstract/37\">",
"     37",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      An FPG &ge;126 mg per dL (7.0",
"      <span class=\"nowrap\">",
"       mmol/L)",
"      </span>",
"      is consistent with the diagnosis of diabetes.",
"     </li>",
"     <li>",
"      An FPG 100",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (5.6",
"      <span class=\"nowrap\">",
"       mmol/L)",
"      </span>",
"      to 125",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (6.9",
"      <span class=\"nowrap\">",
"       mmol/L)",
"      </span>",
"      demonstrates impaired fasting glucose (IFG) and is consistent with the diagnosis of pre-diabetes. Patients with IFG should undergo an OGTT.",
"     </li>",
"     <li>",
"      Patients who have a normal fasting plasma glucose but in whom the clinical suspicion for type 2 diabetes remains high also should undergo an OGTT or be referred to an endocrinologist for further evaluation. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Diagnosis'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?37/54/38758?source=see_link\">",
"       \"Diagnosis of diabetes mellitus\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Children with FPG values in the upper half of the normal range (between 86 and 99",
"    <span class=\"nowrap\">",
"     mg/dL)",
"    </span>",
"    have 2.1 times the risk for developing diabetes during adulthood, and 3.4 times the risk for developing pre-diabetes, independent of the child's weight status [",
"    <a class=\"abstract\" href=\"UTD.htm?4/25/4506/abstract/58\">",
"     58",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h3\">",
"     Oral glucose tolerance test",
"    </span>",
"    &nbsp;&mdash;&nbsp;The OGTT is a more sensitive test than FPG, because OGTT detects patients with diabetes early in the development of their disease when the FPG may not be elevated [",
"    <a class=\"abstract\" href=\"UTD.htm?4/25/4506/abstract/59\">",
"     59",
"    </a>",
"    ]. Evidence from adult patients with diabetes shows that approximately 30 percent of individuals will have a nondiabetic fasting glucose concentration when their OGTT is diagnostic for diabetes [",
"    <a class=\"abstract\" href=\"UTD.htm?4/25/4506/abstract/60\">",
"     60",
"    </a>",
"    ]. This false negative rate increases with more frequent screening.",
"   </p>",
"   <p>",
"    For these reasons, we recommend that OGTT be used as part of the screening process, particularly when clinical suspicion for diabetes remains high despite a FPG that is non-diagnostic. It should be noted, however, that it is currently unknown whether the diagnostic cut points used for adults are applicable to children. Furthermore, although the glucose load of 1.75",
"    <span class=\"nowrap\">",
"     g/kg",
"    </span>",
"    (maximum dose, 75 g) is the standard dose employed when performing an OGTT in children, the available evidence to support this dose is not strong and its validity has been challenged [",
"    <a class=\"abstract\" href=\"UTD.htm?4/25/4506/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h3\">",
"     Our approach",
"    </span>",
"    &nbsp;&mdash;&nbsp;In our practice, we screen children by measuring either fasting plasma glucose (FPG) or hemoglobin A1C (A1C). Screening is typically performed every three years beginning at 10 years of age or at the onset of puberty, whichever occurs first, in children who are overweight (eg, BMI &ge;85th percentile) and have two or more additional risk factors (affected first or second-degree relative, member of high-risk ethnic group, or signs of insulin resistance) (",
"    <a class=\"graphic graphic_table graphicRef56279 \" href=\"UTD.htm?39/46/40683\">",
"     table 7",
"    </a>",
"    ). (See",
"    <a class=\"local\" href=\"#H22\">",
"     'Indications'",
"    </a>",
"    above.) We screen more frequently in patients with marked obesity or strong evidence of insulin resistance.",
"   </p>",
"   <p>",
"    Asymptomatic individuals with FPG&ge;126",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    or A1C&ge;6.5 percent may have diabetes, and should undergo repeat testing to confirm the diagnosis. (See",
"    <a class=\"local\" href=\"#H16\">",
"     'Diagnosis'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    We perform an oral glucose tolerance test, which is more expensive but more sensitive than fasting plasma glucose, in patients with intermediate values (FPG 100-125",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    or A1C 5.7-6.4 percent), or with discordant results for either of these tests. An oral glucose tolerance test should also be performed in patients who have a normal fasting plasma glucose concentration, but in whom the clinical suspicion for type 2 diabetes is high. (See",
"    <a class=\"local\" href=\"#H16\">",
"     'Diagnosis'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Pre-diabetes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with pre-diabetes (impaired fasting glucose or impaired glucose tolerance), or A1C 5.7-6.4 percent, are at increased risk for future development of diabetes. We suggest annually re-screening these patients for the development of diabetes. Such patients should be engaged in intensive lifestyle intervention similar to the non-pharmacologic therapy recommended for patients with established type 2 diabetes. For most such patients, weight reduction is an important goal. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/30/36329?source=see_link&amp;anchor=H6#H6\">",
"     \"Management of type 2 diabetes mellitus in children and adolescents\", section on 'Nonpharmacologic therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    It has not been established whether",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?12/59/13238?source=see_link\">",
"     metformin",
"    </a>",
"    should be used in adolescents with pre-diabetes or with other evidence of insulin resistance. Available data from a few trials suggest that treatment with metformin improves markers of insulin sensitivity and slightly reduces BMI [",
"    <a class=\"abstract\" href=\"UTD.htm?4/25/4506/abstract/61\">",
"     61",
"    </a>",
"    ]. However, the improvements are modest, and there are no data showing that metformin affects long-term risks for developing pre-diabetes or diabetes.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Since the early 1990s, the incidence of type 2 diabetes has dramatically increased worldwide and is linked to the rise in childhood obesity. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Epidemiology'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?32/5/32858?source=see_link&amp;anchor=H3#H3\">",
"       \"Definition; epidemiology; and etiology of obesity in children and adolescents\", section on 'Epidemiology'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The risk of type 2 diabetes is increased in children and adolescents who are overweight or obese, have an affected close relative, or are a member of a high-risk ethnic group (eg, Non-Hispanic blacks, Native American, Hispanic, Pacific Islanders, and Asian Americans). Conditions that increase insulin resistance such as polycystic ovary disease are also associated with type 2 diabetes. Girls are 1.3 to 1.7 times more likely than boys to develop type 2 diabetes in childhood. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Risk factors'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Puberty increases insulin resistance. As a result most cases of childhood type 2 diabetes present at the onset of puberty (mean age, 13.5 years). (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Other insulin resistant states'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Children and adolescents with type 2 diabetes can present with diabetic ketoacidosis or with symptoms of hyperglycemia but without ketonuria. Symptoms result from hyperglycemia and include polyuria, polydipsia, fatigue, and lethargy. Patients can also be identified by screening for the disease or by urinalysis obtained during a routine physical examination. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Clinical presentation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnosis of diabetes is based upon one of four detected abnormalities of glucose metabolism (",
"      <a class=\"graphic graphic_table graphicRef61853 \" href=\"UTD.htm?28/3/28731\">",
"       table 4",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Diagnosis'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?37/54/38758?source=see_link\">",
"       \"Diagnosis of diabetes mellitus\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Fasting plasma glucose &ge;126",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (7",
"      <span class=\"nowrap\">",
"       mmol/L)",
"      </span>",
"     </li>",
"     <li>",
"      Symptoms of hyperglycemia and a plasma glucose &ge;200",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (11.1",
"      <span class=\"nowrap\">",
"       mmol/L)",
"      </span>",
"     </li>",
"     <li>",
"      Abnormal oral glucose tolerance test (OGTT), glucose &ge;200",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (11.1",
"      <span class=\"nowrap\">",
"       mmol/L)",
"      </span>",
"      two hours after glucose load",
"     </li>",
"     <li>",
"      Hemoglobin A1C &ge;6.5 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Type 2 diabetes is distinguished from other causes of diabetes, such as type 1 diabetes, by the clinical presentation and history. Although there is no single diagnostic test, type 2 diabetes is suggested by the presence of excessive weight, signs",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      symptoms of insulin resistance (such as acanthosis nigricans, hypertension, dyslipidemia, and polycystic ovary syndrome), a positive family history, and being a member of a high-risk ethnic group. (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Type 2 versus type 1 diabetes'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H20\">",
"       'Other causes of diabetes'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Universal screening for type 2 diabetes is not cost-effective. Targeted screening of children at increased risk for type 2 diabetes has been recommended by the American Academy of Pediatrics and the American Diabetes Association. (See",
"      <a class=\"local\" href=\"#H21\">",
"       'Screening'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      At-risk children are those with a BMI &ge;85th percentile and two or more additional risk factors (affected first or second-degree relative, member of high-risk ethnic group, or signs of insulin resistance); screening is typically performed every three years beginning at 10 years of age or at the onset of puberty (whichever occurs first) (",
"      <a class=\"graphic graphic_table graphicRef56279 \" href=\"UTD.htm?39/46/40683\">",
"       table 7",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H22\">",
"       'Indications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest screening at-risk children by measuring fasting plasma glucose concentration or hemoglobin A1C (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H23\">",
"       'Test'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest performing an oral glucose tolerance test (OGTT) in patients with intermediate values (FPG 100-125",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      or A1C 5.7-6.4 percent), or with discordant results for either of these tests, or those with a normal fasting plasma glucose but in whom the clinical suspicion for type 2 diabetes remains high (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). The OGTT is more expensive but more sensitive for detecting impaired glucose tolerance than fasting plasma glucose. (See",
"      <a class=\"local\" href=\"#H27\">",
"       'Our approach'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/25/4506/abstract/1\">",
"      Pinhas-Hamiel O, Zeitler P. The global spread of type 2 diabetes mellitus in children and adolescents. J Pediatr 2005; 146:693.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/25/4506/abstract/2\">",
"      Urakami T, Kubota S, Nitadori Y, et al. Annual incidence and clinical characteristics of type 2 diabetes in children as detected by urine glucose screening in the Tokyo metropolitan area. Diabetes Care 2005; 28:1876.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/25/4506/abstract/3\">",
"      Cockram CS. The epidemiology of diabetes mellitus in the Asia-Pacific region. Hong Kong Med J 2000; 6:43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/25/4506/abstract/4\">",
"      Likitmaskul S, Kiattisathavee P, Chaichanwatanakul K, et al. Increasing prevalence of type 2 diabetes mellitus in Thai children and adolescents associated with increasing prevalence of obesity. J Pediatr Endocrinol Metab 2003; 16:71.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/25/4506/abstract/5\">",
"      Pinhas-Hamiel O, Dolan LM, Daniels SR, et al. Increased incidence of non-insulin-dependent diabetes mellitus among adolescents. J Pediatr 1996; 128:608.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/25/4506/abstract/6\">",
"      Scott CR, Smith JM, Cradock MM, Pihoker C. Characteristics of youth-onset noninsulin-dependent diabetes mellitus and insulin-dependent diabetes mellitus at diagnosis. Pediatrics 1997; 100:84.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/25/4506/abstract/7\">",
"      Silverstein JH, Rosenbloom AL. Treatment of type 2 diabetes mellitus in children and adolescents. J Pediatr Endocrinol Metab 2000; 13 Suppl 6:1403.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/25/4506/abstract/8\">",
"      Lipton RB, Drum M, Burnet D, et al. Obesity at the onset of diabetes in an ethnically diverse population of children: what does it mean for epidemiologists and clinicians? Pediatrics 2005; 115:e553.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/25/4506/abstract/9\">",
"      Bell RA, Mayer-Davis EJ, Beyer JW, et al. Diabetes in non-Hispanic white youth: prevalence, incidence, and clinical characteristics: the SEARCH for Diabetes in Youth Study. Diabetes Care 2009; 32 Suppl 2:S102.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/25/4506/abstract/10\">",
"      Dabelea D, DeGroat J, Sorrelman C, et al. Diabetes in Navajo youth: prevalence, incidence, and clinical characteristics: the SEARCH for Diabetes in Youth Study. Diabetes Care 2009; 32 Suppl 2:S141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/25/4506/abstract/11\">",
"      Mayer-Davis EJ, Beyer J, Bell RA, et al. Diabetes in African American youth: prevalence, incidence, and clinical characteristics: the SEARCH for Diabetes in Youth Study. Diabetes Care 2009; 32 Suppl 2:S112.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/25/4506/abstract/12\">",
"      Liu LL, Yi JP, Beyer J, et al. Type 1 and Type 2 diabetes in Asian and Pacific Islander U.S. youth: the SEARCH for Diabetes in Youth Study. Diabetes Care 2009; 32 Suppl 2:S133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/25/4506/abstract/13\">",
"      Lawrence JM, Mayer-Davis EJ, Reynolds K, et al. Diabetes in Hispanic American youth: prevalence, incidence, demographics, and clinical characteristics: the SEARCH for Diabetes in Youth Study. Diabetes Care 2009; 32 Suppl 2:S123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/25/4506/abstract/14\">",
"      Lee JM. Why young adults hold the key to assessing the obesity epidemic in children. Arch Pediatr Adolesc Med 2008; 162:682.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/25/4506/abstract/15\">",
"      Lee JM, Okumura MJ, Freed GL, et al. Trends in hospitalizations for diabetes among children and young adults: United States, 1993 2004. Diabetes Care 2007; 30:3035.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/25/4506/abstract/16\">",
"      Freedman DS, Srinivasan SR, Burke GL, et al. Relation of body fat distribution to hyperinsulinemia in children and adolescents: the Bogalusa Heart Study. Am J Clin Nutr 1987; 46:403.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/25/4506/abstract/17\">",
"      Caprio S, Hyman LD, Limb C, et al. Central adiposity and its metabolic correlates in obese adolescent girls. Am J Physiol 1995; 269:E118.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/25/4506/abstract/18\">",
"      HEALTHY Study Group, Foster GD, Linder B, et al. A school-based intervention for diabetes risk reduction. N Engl J Med 2010; 363:443.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/25/4506/abstract/19\">",
"      Type 2 diabetes in children and adolescents. American Diabetes Association. Diabetes Care 2000; 23:381.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/25/4506/abstract/20\">",
"      Copeland KC, Zeitler P, Geffner M, et al. Characteristics of adolescents and youth with recent-onset type 2 diabetes: the TODAY cohort at baseline. J Clin Endocrinol Metab 2011; 96:159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/25/4506/abstract/21\">",
"      Tattersal RB, Fajans SS. Prevalence of diabetes and glucose intolerance in 199 offspring of thirty-seven conjugal diabetic parents. Diabetes 1975; 24:452.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/25/4506/abstract/22\">",
"      Barnett AH, Eff C, Leslie RD, Pyke DA. Diabetes in identical twins. A study of 200 pairs. Diabetologia 1981; 20:87.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/25/4506/abstract/23\">",
"      Alberti G, Zimmet P, Shaw J, et al. Type 2 diabetes in the young: the evolving epidemic: the international diabetes federation consensus workshop. Diabetes Care 2004; 27:1798.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/25/4506/abstract/24\">",
"      Fagot-Campagna A, Pettitt DJ, Engelgau MM, et al. Type 2 diabetes among North American children and adolescents: an epidemiologic review and a public health perspective. J Pediatr 2000; 136:664.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/25/4506/abstract/25\">",
"      Dean HJ, Young TK, Flett B, Wood-Steiman P. Screening for type-2 diabetes in aboriginal children in northern Canada. Lancet 1998; 352:1523.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/25/4506/abstract/26\">",
"      Kim C, McHugh C, Kwok Y, Smith A. Type 2 diabetes mellitus in Navajo adolescents. West J Med 1999; 170:210.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/25/4506/abstract/27\">",
"      Savage PJ, Bennett PH, Senter RG, Miller M. High prevalence of diabetes in young Pima Indians: evidence of phenotypic variation in a genetically isolated population. Diabetes 1979; 28:937.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/25/4506/abstract/28\">",
"      Gahagan S, Silverstein J, American Academy of Pediatrics Committee on Native American Child Health, American Academy of Pediatrics Section on Endocrinology. Prevention and treatment of type 2 diabetes mellitus in children, with special emphasis on American Indian and Alaska Native children. American Academy of Pediatrics Committee on Native American Child Health. Pediatrics 2003; 112:e328.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/25/4506/abstract/29\">",
"      Writing Group for the SEARCH for Diabetes in Youth Study Group, Dabelea D, Bell RA, et al. Incidence of diabetes in youth in the United States. JAMA 2007; 297:2716.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/25/4506/abstract/30\">",
"      Arslanian S, Suprasongsin C. Differences in the in vivo insulin secretion and sensitivity of healthy black versus white adolescents. J Pediatr 1996; 129:440.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/25/4506/abstract/31\">",
"      Arslanian SA. Metabolic differences between Caucasian and African-American children and the relationship to type 2 diabetes mellitus. J Pediatr Endocrinol Metab 2002; 15 Suppl 1:509.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/25/4506/abstract/32\">",
"      Wong WW, Butte NF, Ellis KJ, et al. Pubertal African-American girls expend less energy at rest and during physical activity than Caucasian girls. J Clin Endocrinol Metab 1999; 84:906.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/25/4506/abstract/33\">",
"      Danadian K, Balasekaran G, Lewy V, et al. Insulin sensitivity in African-American children with and without family history of type 2 diabetes. Diabetes Care 1999; 22:1325.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/25/4506/abstract/34\">",
"      Svec F, Nastasi K, Hilton C, et al. Black-white contrasts in insulin levels during pubertal development. The Bogalusa Heart Study. Diabetes 1992; 41:313.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/25/4506/abstract/35\">",
"      Banerji MA. Impaired beta-cell and alpha-cell function in African-American children with type 2 diabetes mellitus--\"Flatbush diabetes\". J Pediatr Endocrinol Metab 2002; 15 Suppl 1:493.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/25/4506/abstract/36\">",
"      Cruz ML, Weigensberg MJ, Huang TT, et al. The metabolic syndrome in overweight Hispanic youth and the role of insulin sensitivity. J Clin Endocrinol Metab 2004; 89:108.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/25/4506/abstract/37\">",
"      Baranowski T, Cooper DM, Harrell J, et al. Presence of diabetes risk factors in a large U.S. eighth-grade cohort. Diabetes Care 2006; 29:212.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/25/4506/abstract/38\">",
"      Goran MI, Bergman RN, Avila Q, et al. Impaired glucose tolerance and reduced beta-cell function in overweight Latino children with a positive family history for type 2 diabetes. J Clin Endocrinol Metab 2004; 89:207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/25/4506/abstract/39\">",
"      Fors&eacute;n T, Eriksson J, Tuomilehto J, et al. The fetal and childhood growth of persons who develop type 2 diabetes. Ann Intern Med 2000; 133:176.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/25/4506/abstract/40\">",
"      Amiel SA, Sherwin RS, Simonson DC, et al. Impaired insulin action in puberty. A contributing factor to poor glycemic control in adolescents with diabetes. N Engl J Med 1986; 315:215.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/25/4506/abstract/41\">",
"      Ball GD, Huang TT, Gower BA, et al. Longitudinal changes in insulin sensitivity, insulin secretion, and beta-cell function during puberty. J Pediatr 2006; 148:16.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/25/4506/abstract/42\">",
"      Gungor N, Hannon T, Libman I, et al. Type 2 diabetes mellitus in youth: the complete picture to date. Pediatr Clin North Am 2005; 52:1579.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/25/4506/abstract/43\">",
"      Sapru A, Gitelman SE, Bhatia S, et al. Prevalence and characteristics of type 2 diabetes mellitus in 9-18 year-old children with diabetic ketoacidosis. J Pediatr Endocrinol Metab 2005; 18:865.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/25/4506/abstract/44\">",
"      Pinhas-Hamiel O, Dolan LM, Zeitler PS. Diabetic ketoacidosis among obese African-American adolescents with NIDDM. Diabetes Care 1997; 20:484.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/25/4506/abstract/45\">",
"      Neufeld ND, Raffel LJ, Landon C, et al. Early presentation of type 2 diabetes in Mexican-American youth. Diabetes Care 1998; 21:80.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/25/4506/abstract/46\">",
"      Rosenbloom AL. Hyperglycemic hyperosmolar state: an emerging pediatric problem. J Pediatr 2010; 156:180.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/25/4506/abstract/47\">",
"      Carchman RM, Dechert-Zeger M, Calikoglu AS, Harris BD. A new challenge in pediatric obesity: pediatric hyperglycemic hyperosmolar syndrome. Pediatr Crit Care Med 2005; 6:20.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/25/4506/abstract/48\">",
"      Bhowmick SK, Levens KL, Rettig KR. Hyperosmolar hyperglycemic crisis: an acute life-threatening event in children and adolescents with type 2 diabetes mellitus. Endocr Pract 2005; 11:23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/25/4506/abstract/49\">",
"      Curran J, Hayward J, Sellers E, Dean H. Severe vulvovaginitis as a presenting problem of type 2 diabetes in adolescent girls: a case series. Pediatrics 2011; 127:e1081.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/25/4506/abstract/50\">",
"      American Diabetes Association. Standards of medical care in diabetes--2011. Diabetes Care 2011; 34 Suppl 1:S11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/25/4506/abstract/51\">",
"      Libman IM, Barinas-Mitchell E, Bartucci A, et al. Reproducibility of the oral glucose tolerance test in overweight children. J Clin Endocrinol Metab 2008; 93:4231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/25/4506/abstract/52\">",
"      Liu LL, Lawrence JM, Davis C, et al. Prevalence of overweight and obesity in youth with diabetes in USA: the SEARCH for Diabetes in Youth study. Pediatr Diabetes 2010; 11:4.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/25/4506/abstract/53\">",
"      Wenzlau JM, Moua O, Sarkar SA, et al. SlC30A8 is a major target of humoral autoimmunity in type 1 diabetes and a predictive marker in prediabetes. Ann N Y Acad Sci 2008; 1150:256.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/25/4506/abstract/54\">",
"      Klingensmith GJ, Pyle L, Arslanian S, et al. The presence of GAD and IA-2 antibodies in youth with a type 2 diabetes phenotype: results from the TODAY study. Diabetes Care 2010; 33:1970.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/25/4506/abstract/55\">",
"      Silverstein J, Klingensmith G, Copeland K, et al. Care of children and adolescents with type 1 diabetes: a statement of the American Diabetes Association. Diabetes Care 2005; 28:186.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/25/4506/abstract/56\">",
"      Dabelea D, Pihoker C, Talton JW, et al. Etiological approach to characterization of diabetes type: the SEARCH for Diabetes in Youth Study. Diabetes Care 2011; 34:1628.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/25/4506/abstract/57\">",
"      Lee JM, Wu EL, Tarini B, et al. Diagnosis of diabetes using hemoglobin A1c: should recommendations in adults be extrapolated to adolescents? J Pediatr 2011; 158:947.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/25/4506/abstract/58\">",
"      Nguyen QM, Srinivasan SR, Xu JH, et al. Fasting plasma glucose levels within the normoglycemic range in childhood as a predictor of prediabetes and type 2 diabetes in adulthood: the Bogalusa Heart Study. Arch Pediatr Adolesc Med 2010; 164:124.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/25/4506/abstract/59\">",
"      DeFronzo RA. Lilly lecture 1987. The triumvirate: beta-cell, muscle, liver. A collusion responsible for NIDDM. Diabetes 1988; 37:667.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/25/4506/abstract/60\">",
"      Shaw JE, Zimmet PZ, McCarty D, de Courten M. Type 2 diabetes worldwide according to the new classification and criteria. Diabetes Care 2000; 23 Suppl 2:B5.",
"     </a>",
"    </li>",
"    <li>",
"     Quinn SM, Baur LA, Garnett SP, Cowell CT. Treatment of clinical insulin resistance in children: a systematic review. Obes Rev 2009; :. [epub ahead of print].",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5820 Version 10.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-61.234.146.186-9CEA1CDAAA-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_25_4506=[""].join("\n");
var outline_f4_25_4506=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H29\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      DEFINITIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Risk factors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Obesity",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Genetic susceptibility",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Ethnicity",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Gender",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - In-utero programming",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Other insulin resistant states",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      CLINICAL PRESENTATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Diabetic ketoacidosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Hyperosmolar hyperglycemic state",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Symptomatic",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Asymptomatic",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Impaired glucose tolerance",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Type 2 versus type 1 diabetes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Other causes of diabetes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      SCREENING",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Indications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Test",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      - Hemoglobin A1C",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      - Fasting plasma glucose",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      - Oral glucose tolerance test",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      - Our approach",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Pre-diabetes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/5820\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/5820|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?37/23/38257\" title=\"figure 1A\">",
"      CDC BMI for age boys 2 to 20 years",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?40/2/40993\" title=\"figure 1B\">",
"      CDC BMI for age girls 2 to 20 years",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?17/56/18318\" title=\"figure 2\">",
"      Birth wt and insulin resistance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/5820|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/40/24203\" title=\"table 1\">",
"      Weight categories",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?0/28/459\" title=\"table 2\">",
"      Calculation of BMI",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?21/60/22476\" title=\"table 3\">",
"      Diab prevalence youth",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?28/3/28731\" title=\"table 4\">",
"      ADA criteria for diagnosis diabetes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?31/15/31997\" title=\"table 5\">",
"      Type 1 vs type 2 DM",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?10/40/10891\" title=\"table 6\">",
"      Drug induced diabetes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?39/46/40683\" title=\"table 7\">",
"      Screening for type 2 diabetes mellitus in children",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/1/15386?source=related_link\">",
"      Candida vulvovaginitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/33/14874?source=related_link\">",
"      Classification of diabetes mellitus and genetic diabetic syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/32/41480?source=related_link\">",
"      Clinical features and diagnosis of diabetic ketoacidosis in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/13/39130?source=related_link\">",
"      Clinical features and diagnosis of polycystic ovary syndrome in adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/28/34249?source=related_link\">",
"      Comorbidities and complications of type 2 diabetes mellitus in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/9/34970?source=related_link\">",
"      Definition, pathogenesis, and etiology of polycystic ovary syndrome in adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/5/32858?source=related_link\">",
"      Definition; epidemiology; and etiology of obesity in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/54/38758?source=related_link\">",
"      Diagnosis of diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/48/44809?source=related_link\">",
"      Infant of a diabetic mother",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/30/36329?source=related_link\">",
"      Management of type 2 diabetes mellitus in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/31/36346?source=related_link\">",
"      Pathogenesis of type 2 diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/30/29162?source=related_link\">",
"      Prediction and prevention of type 2 diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/28/7626?source=related_link\">",
"      Treatment and complications of diabetic ketoacidosis in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/48/15114?source=related_link\">",
"      Treatment of diabetic ketoacidosis and hyperosmolar hyperglycemic state in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/46/24297?source=related_link\">",
"      Treatment of polycystic ovary syndrome in adolescents",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f4_25_4507="Strategies increase adherence";
var content_f4_25_4507=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F52715&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F52715&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Psychologic strategies to help patients deal with threats to adherence",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        Counter-conditioning - Substitute other activities or experiences when",
"tempted by cravings or stress (eg, relaxed abdominal breathing when",
"driving in stressful traffic).",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Stimulus control - Avoid situations that are likely to produce",
"temptations or pressures (eg, avoid lunch with friends who smoke; do",
"not walk by the bakery section in the supermarket).",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Reinforcement management - Provide yourself with rewards (eg, a movie,",
"a shopping trip) when you do well at sticking with the desired changes.",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from Turk, D, Meichenbaum, D. In: Handbook of Clinical Psychology in Medical Settings, Sweet, JJ, Rozensky, RH, Tovian, SM (Eds), Plenum Press, New York, 1991.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_25_4507=[""].join("\n");
var outline_f4_25_4507=null;
var title_f4_25_4508="Major causes of TTP-HUS";
var content_f4_25_4508=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F69868&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F69868&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Thrombotic thrombocytopenic purpura-hemolytic uremic syndrome (TTP-HUS): a classification of clinical syndromes",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Childhood HUS",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Typical HUS: caused by Shiga toxin-producing E. coli , typically E. coli O157:H7. Children present with abdominal pain and diarrhea, typically bloody, and acute kidney injury. 90 percent of childhood HUS.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Atypical HUS: acute kidney injury without preceding diarrhea. Some cases may be familial, caused by congenital abnormalities of complement regulation. 10 percent of childhood HUS.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Adult TTP-HUS syndromes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Idiopathic: a non-specific term indicating that none of the syndromes listed below was apparent. Many, but not all, of the patients have severe ADAMTS13 deficiency.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Drug-induced",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Immune mediated",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Quinine is most common cause. Among drugs suspected to be the cause of acute TTP-HUS, drug-dependent antibodies have only been documented for quinine. Other drugs may cause immune-mediated TTP-HUS but are rare.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Dose-dependent toxicity",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Cancer chemotherapy (mitomycin C, gemcitabine, possibly others)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Immunosuppressive agents (cyclosporine, tacrolimus, sirolimus)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Following bloody diarrhea caused by Shiga toxin-producing E. coli",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pregnancy or postpartum: May be indistinguishable from severe preeclampsia, eclampsia, and the HELLP syndromes. May trigger acute episodes of TTP-HUS caused by severe ADAMTS13 deficiency.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Autoimmune disorders",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Systemic lupus erythematosus (SLE) can mimic all features of TTP-HUS.&nbsp;Patients may have both SLE and TTP-HUS caused by severe ADAMTS13 deficiency.",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_25_4508=[""].join("\n");
var outline_f4_25_4508=null;
var title_f4_25_4509="Complications Rx CMV retinitis";
var content_f4_25_4509=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F70634&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F70634&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Management of toxic effects of intravenous drugs used in the treatment of cytomegalovirus retinitis",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Drug",
"       </td>",
"       <td class=\"subtitle1\">",
"        Management of toxic effects",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ganciclovir/Valganciclovir",
"       </td>",
"       <td class=\"sublist1_start\" colspan=\"1\" rowspan=\"2\">",
"        If absolute neutrophil count is &lt;500/mm3,",
"coadminister granulocyte colony-stimulating factor (G-CSF), titrating",
"dose to maintain",
"count between 500 and 1500/mm3; if platelet count is",
"&lt;20,000/mm3,",
"discontinue drug.",
"        <br/>",
"        Reduce dose if estimated creatinine clearance",
"&lt;60-70 mL/min (see package insert for details).",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Standard dose*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Foscarnet",
"       </td>",
"       <td class=\"sublist1_start\" colspan=\"1\" rowspan=\"2\">",
"        Slow the infusion",
"if symptoms of ionized hypocalcemia",
"occur (eg, paresthesias, headache or nausea); replace potassium,",
"magnesium,",
"calcium, or phosphorous if serum concentrations are low&Delta;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Standard dose&bull;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ganciclovir*",
"and foscarnet&bull;",
"       </td>",
"       <td>",
"        Same as for intravenous ganciclovir alone or",
"intravenous foscarnet alone",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cidofovir&loz;",
"       </td>",
"       <td>",
"        If absolute neutrophil count is &lt;500/mm3,",
"coadminister G-CSF, titrating dose to maintain count between 500 and",
"1500/mm3; monitor",
"intraocular pressure monthly and discontinue cidofovir if pressure is",
"below 50 percent of",
"baseline value or if uveitis develops; syptomatic treatment for probenecid toxicity:",
"diphenhydramine or",
"loratadine for rash, acetaminophen for fever, and prochlorperazine or",
"ondansetron for nausea",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <p>",
"     &nbsp;",
"    </p>",
"    <div class=\"footnotes\">",
"     * IV Ganciclovir is given as a 1-hour infusion. Dose should be reduced if estimated creatinine clearance &lt;60-70 mL/min (see package insert for details).",
"     <br>",
"      &bull; Foscarnet is given as a 2-hour IV infusion administered by pump to control the rate; dilute to 12 mg/mL with 5 percent dextrose or normal saline if administered through a peripheral vein (to prevent thrombophlebitis). Foscarnet should not be mixed with any other drug or supplement. Dose must be reduced if estimated creatinine clearance is &lt;1.4 ml/min/kg (see package insert for details). Hydration may reduce the risk of nephrotoxicity. It is recommended that 750-1000 mL of normal saline or 5 percent dextrose solution should be given prior to the first infusion of foscarnet to establish diuresis. With subsequent infusions, 750-1000 mL of hydration fluid should be given with 90-120 mg/kg of foscarnet. Hydration fluid may need to be decreased if clinically warranted. After the first dose, the hydration fluid should be administered concurrently with each infusion of foscarnet.",
"      <br>",
"       &Delta; Replacement regimens are as follows: for hypokalemia, 20 to 40 mmol potassium chloride orally 3 times daily, depending on severity (or 10 mmol/hr IV 1 to 4 times daily, if symptoms are very severe); for hypomagnesemia, 500 mg magnesium gluconate orally 2 to 4 times daily; for hypophosphatemia, 250 mg sodium or potassium phosphate orally 2 to 3 times daily; for hypocalcemia, 650 to 1300 mg calcium carbonate orally 3 times daily (or IV calcium gluconate if symptoms are severe).",
"       <br>",
"        &loz; Given as a 1-hour IV infusion. Administer 2 g probenecid orally 3 hrs before infusion and 1 L normal saline 1 hr before infusion. Administer 1 L normal saline with cidofovir. Administer 1 g probenecid orally 2 and 8 hrs after infusion has been completed. Cidofovir is contraindicated if baseline urinary protein level is &ge;2+, serum creatinine level is &gt;1.5 mg/dL, or (133 &micro;mol/L) estimated creatinine clearance is &le;55 mL/min. Dose should be reduced from 5 to 3 mg/kg if serum creatinine level increases by 0.3 to 0.4 mg/dL over baseline value. Drug must be discontinued if serum creatinine level increases by &gt;0.5 mg/dL (44 &micro;mol/L) over baseline value or if urinary protein level is &gt;3+. Cidofovir should not be administered concurrently with or within 7 days of other nephrotoxic drugs (eg, foscarnet, aminoglycosides, amphotericin B, nonsteroidal antiinflammatory drugs, or parenteral pentamidine).",
"       </br>",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from Jacobson MA. N Engl J Med 1997; 337:105.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_25_4509=[""].join("\n");
var outline_f4_25_4509=null;
var title_f4_25_4510="Ciliary choroid thickness";
var content_f4_25_4510=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F77041&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F77041&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 565px\">",
"   <div class=\"ttl\">",
"    Classification for ciliary body and choroid uveal melanoma based on thickness and diameter",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 545px; height: 236px; background-image: url(data:image/gif;base64,R0lGODlhIQLsAOYAAP/////gwczp9f+ystHB0YCAgGZ0egAAAH9wYH9ZWWhgaIiIiERERDMzM3d3d+7u7qqqqhEREVVVVd3d3WZmZiIiIru7u8zMzJartJmZmZmOmUAtLVU7OyIeGt3Cp7+okbHK1N2amsyOjjMtJ1VKQHdpWruljhEPDYmco0BAQCIYGODg4HdTU29nb4h3Z0Q8M5mGdGZaTe7RtG18glJdYg4QEHuMkplra+6mphEMDDMkJEQvL7uDgw4NDrWntVNNUzM6PUA4MDQwNL+GhpmvuMDAwKBwcJ2RnWBUSN/EqSAXFwAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAACH5BAAAAAAALAAAAAAhAuwAAAf/gACCg4SFhoeIiYqLjI2Oj5CRkpOUlZaXmJmam5ydnp+goaKjpKWmp6ipqqusra6vsLGys7S1tre4ubq7vL2+v8DBwsPExcbHyMnKy8zNzs/Q0dLT1NXW19jZ2tvc3d7f4OHi4+Tl5ufo6err7O3u7/Dx8vP09fb3+Pn6+/z9/v8ABRUYSLCgwYMIEypcyLChw4cQI0qcSLGixYsYM2rcyLGjx4hFuilMAcSAyZMoU6pcybKly5cwY8qcSbOmzZs4c+rcybOnz59Ag6IEUsBcAQMCkipdyrSp06dQo0qdSrWq1atYs2rdyrWr169gw4odS3apgaLljpZdy7at27dw/+PKnUu3LtWzRpHa3cu3r9+/gAML/oo3rd7BiBMrXsy4sWMBhcmpfUy5suXLmDObRSv5sObPoEOLHg028rjJpFOrXs36s2lxqFvLnk27dt3XuxYgmhDBgqAJB4If0E2IQXAKiWLbXs6c7IwDGCg/j/54+ljcuhwccFBoQXDfAIBPOLSgwgPeEBApb86+fVYbwak3hg/9MX35pTn7ekDhAIUHhBwAHnDBSVCIBNwBwABxhqzn3oMQOoVCDSjU19iEFeKnGIYWhoVdLxUcECB4g1wQAYMKEscAcoc4GOGLD2IAHQgdKiYjBjRqiNiNOV6nXy/8+QfgIAIasiAhCApyZP+LnsHopHs0CBcfY1FKqaNgVQp35VYf4qJdgoUUCcAC3JnoWwW6lXdeBOkx+eSbEfb4mJyO0ZkfMCgO4t1xAFgQ4naCoKkkn+o1CeehttnJmKKLMdpVlyIZiuiklFa6FqTcuGjpppx2eteP4Wjq6aikdorpNqKWquqqb56qTaqsxiore65mA+usuObKWq3Y3Krrr8Bqxus1vgZr7LGMDWtNscg266xfylbD7LPUVgtXtNQUUJJQ3Hbr7bfghivuuCwRYSy20xQQBALstuvuu/DGK++89NZr77345qvvvvz26++/AAcsML5BSDorutIUgEAADDfs8MMQRyzxxBRXbPH/xRhnrPHGHHfs8ccghywyxggYLCvC0Sg88sost+zyyzDHLPPMHZd8LqjgqEzzzjz37PPPQAf9sM3BogyNzkInrfTSTDftM9HAGv0M0k5XbfXVWGfNMNS/Su0M1VqHLfbYZI/Mta5eNwN22Wy37bbbZ+eaNjNrv2333XgvHTeuc08CgYiCZBBBcBkc0kCeg/A2oJR5GudfcgvnLfnkE78Q3AkmjG35AZi7vHdX1lVXI2E4m+L4IA4UvkAEhVgQHOJjfvfbAeMZoiZ66kVO+e68M1zCCGz/7rnJWt1n35Ri9S2J64ZAwLqRsAsiJoEHGIhkgks2qHvv3OdNQgxsfz+8/1gcbilY+T66wjwhE1TQZiFL9ve49CQKYiKKS66Ye/f82w3DAR3wANn+F8DxgYVHo9vRjBL4qNJBYgISaIAEGwCJ9dkvAoU7RPYMIabioChJKdpf/0bYNhd0gG0mNOBXsoQ8xbCQgVxy4CMcJ5whNcKC5blA4jq4wTCBh0wAMBMABHU7NomQhEjEmgdGIMASnEBsS2ziE1v2Oa44KjFXjCEmGNCAB3jRhoygYeH+RDjg+MZ1wamA7YSDHD8FJ0GCUhChWrS9JNqRaTIgQXA6kLmw5XGPfWRZFbeSxcEUMitSu4D7IMBIZNTtjpCM5NUGySqp7amGx3ikJDfJyaBRcv9VUmtABBxASjAVQ5OdTKUqY/ZJVUnNARRcBipXSctagqyVpbLkASYYS2PM0pbADKbFcEmqV0rpAGAcxi+Fycxmbo14lZThI77oRUfW0ZnYzCYxRyU1CPLSmtkMZzi36Smp0TA4yRTGMsXJzk2S01TSbAQXqQnOdtrTlu/kVCIX2chMXvOeAJUkArZFrpyY6zG6lFI6g7HOgDqUex8YmETrVTDKhHKUpaznQzfK0Zfl8zbxZAQs6fbPjpr0pBr7KF10+U1/ovSlMCUZNANjTIW6NKY4zanDVDoXr1FzoQwtqU6HylGeykV5yWgoUZc6zpkCBqkaZapUHWrUuED1plP/zeo9q3qtkJrCjRg0XPQUZ78GzHEQjmMRHVO5uc6Jra2B1BpcNXe5uGZtrlR06lVC5yGvNuIBPYTEifqETEKgEXZ7Ak8GynQAHerJPLhb6yqFVzbKks2yY8Os2DQrMq4qxXjJ82sjBleBDELiAcMRhBHhFz0AdFAQqHWsIEAYWIEIFZLiK1tuybbbsfVWbL/trF6pgr7QdsICQJTEngb3PrQSR35qfa2CTBlCBam1EErtHgEFOLbtDhCA3BWbd7sLXhV6BYHm04rUIMAdCjCgdpa4QGOhl4gOPqAB150t9qKXXf6lsGz/JVuAxzZgsRVYuGF5YXqxIjUJLCg4DLjE/wQaEGEzOre+4LFAWAdBRMiuVnudjGIAnAhFJo54iloTMYnDpmIUZ63F5gXLIRksWkQ0wAH98Q5QGZGBAgHIwmg8gBq7w0YAyI9PcUwr5Dr5RwDa9WpN5qPYovxkq1F5ynp0coy/MuOrmDOCDfjbjn3RX62auZOedYvUerwdCgzZl7c9s5xpmea2eG0BaTLtKeM85z5zss5sWW973xtVPxtalYC+VI0P4eA9RRirh470n4fbl1DieDiFhbOkN+1OSvPlyxIUM6Q5TWoSJrosa36jmwtd6lZz79RkuXOeWe3qWk8O1unLBAQmYAH47tnWwN4dro17CRO1uZenXNdEl//N7GY7+9nQjna8koDTYfcVExKIAAMcIGpfbiAB4A63uMdN7nKb+9zoTre6183udrv73fCOt7znLW8lfKDant6LpUnZ4zH3ogAJGIDAB07wghv84AhPuMIXzvCGO/zhEI+4xCdO8YpTfAP3jqm173SJCEoAzI4MuMVHTvKSm/zkKE+5yiGOcXxbdNGG4I1w9EwMgK/85jjPuc53zvOGt1zj+baL1yZApvqdUuQ9T7rSl870phv85zDdOOkyQaaMZhLpTs+61rfOdYlD/aVS90pNMelLrHf97GhPe9a/jtKwNxAToswAI5tbc7Or/e54zzvK2X5St3NFahRAdsj1Tvj/whs+4nw3qd+1eIkel5K6l7CAWQFXCAc8uhATfqORzopdu1ucBcFRgQgID/oDiJ70oR+93kt/+r1nfGR4DVvsVwZovnLcEtqxaSaAk18iHeDySDJQ+5pbRLoPwuYn58DoOcABwit/AMx3/vKbr/fnR9/1L+Os1rR/y6BDBbTXlvDc+5kJyytiAcAfRAOsB0L9Kom/nic5C6hf+Pkf3v6Gx//JEx+y4GrN/91HPhQCQ4xnCfXTWpLAAIOzS74mCOgXOGnUJ38ySh6kJL0nEPFncTyQAyFgeBvYgYX3gR7IgSnHfx4zXuJVXnkVFuiVa7j3Hw8gAZmGbcSBX7aTfoYw/1iDQFvwl3I30HqE94OqF4RAqHdCqHIm+DEHpjVLGIBgoWDEZgk9Jkq/twkL0EUAcGNDxCAPmAgKCCAdtibGh4EotwM6gAOGZ4ZoWHhqmIZnuHJJqDEwxmImtmKC5H1Q0WVW4TXOo4ObIIO/B4bEISUNSCAN4FhJxnmEgHwlFwLHBIJ354hSAolqJ4nCQYlpZ4nBgYkjF4cZc2V+lGVStoJjoYdVgTJVh2MRQAGQp04ZeHiwGIt554kBtXjqBXPqd0zodHWy2Iu+OIuvB3Z42FO4KAgWMH5zN3i/uIzMqHW0CFC2iEjFOAgZcIjTpYzNmI3auHPPuFXDeFTTqCTWo/9jvLiN5niO2Ad0Lwd3CdJtR4eO8BiPFxeMbfeNVhWORnYiECBB2CiP/viPCNeN9hSNNIYJMkc4/QiQCgmQAtlOBOll+AgAD1B0SfWKC3mR2tiQ7PSQeziNC8BIj9eKDGWRGFmSv6iR4sSRpziNN5Z7ZHdK30ZvMjmTNFmTNnmT6jYEsLgBSCBtE0WPYaOSn2KAEzAByOhIQqAASrmUTNmUTvmUUBmVUjmVVFmVVnmVWJmVWomVQkCSZ2cEOBmW4bYBfOY0QjkVd/Z4jqQABNCWbvmWcBmXcjmXdFmXdnmXeJmXermXfNmXe6kAXmmSJJcAZdk0ZykVY7eLvsSWftn/mI75mJAZmZI5mXEJmIK5c4TJNocZFRcld+R3SoxJmaI5mqRZmqY5l5Z5mTmXmWWzmVABeIKXSaF5mrRZm7Z5m3SZmqp5c6xJNq75FKh4aWopm7hZnMZ5nKOpm7upcr05Nr/pFCgzecfkb7xQALOJnNiZndqZm4G5nBLXnGLznE2BMseIjGPIUNe5neq5nsepnN55cuAZlPbYVQbYAEa3luyZn/p5m+75niUXn1ojnkyBMn9znpgQZDgIAOZ3CJIXHJs3Py2SnpDpAz2gAfs5lxRqoRcalxmanN3ZcKw3hHgXoikHoB4ze2Yzn0the1NXCX+DIMPJCZHlewnKe+Th/2HnaZ2i2QLBoaEb6pY8egA++qMEEKRDKpn9aXHWR394t6QlWpgaw30fU2fgd3t+o4szqAny1YBjkqALagg8qB4SCplCSqRwWaZm6pZoSplJKn9MunpvOphQmjEAOKUqKgDFFX6U8KIh2QkhgliPxmZqpIDB0QC+lj8XCAA6OpprmqaNaqaPGpltqoEkGIKVCp9zajEoSHsq2oJReKUGqgkPUFo3yGg1eF1hGqGkGak/yqob6qqOOakUd4SFR6soZ6Ig04R2mmDHtGAQWZ/3qQkUoBu8oRtx1KXkgYVaGIYzil1j+piwup/Rqp/T2peyKnFtyIZvyJyZOjFzeIdkYf+KQ4kLGfAn1hNHhAimECaIgwKhDfKsfhmkB/ADaSqv9Gqm9iqa1wpxmngAnHh2/fqvFYerGwOK4FqKBHiLRgGvadqwDruv/hlxBGs1AroZC+uwGJuxbwmxEftwE1s1FasUV7WYGluyD/uhHbtwH2uWd2pnEak2DGuyMqudHJuyDLeyhtmygfaydBOzM/uzxlmzNqtwOMs0IZsUIwuaQLu06ym0Q4twRas3OqtoF8u0VoudTvu0Bhe1SnO0kMGzsuSzVzu2bIqyWltwXJs0Xpu0NSe2ZPu2j5m1ZztwaSs0awu2yrCocLu3pCm3czsAdetJU4tqeJtUbsu3iIuXChD/k2KJkzp5eAmgbD4ZMBWFUIWLn4mbuZB5BFvZuZ6rlF0Ji0PQuGG5AYMba5dLnJq7upnrt3ObAKfrgqdxuKxbuxrrumcLu+uYFrRru76bprirtbpruVX7u8YLtMH7tMPrGGyrTL17vNDLnsk7tMvbGM2rTs8bvdqbndNrs9WbLKlLsts7vsBrtn8LuLH7qbCRveTbvrXZvSn7vYtxvamAoA+aqIrKvhhaoQ7boQ3rv2kKwJMJvwNAoquXeiWqsywqduGbChmwQc1afGK6oz3asEZqwRVcrxlctijnpNU3fQk8FlXaosUwAf0hAUa3pdfzfhPMqEdKpNXKnjG8njOs/5cEPHD6R3pxOnLyyxV5aqXC0GNvRgh/yloW2MKiWcPbqcTaycTZ6cR2ecMDIIKWKrAD26kL5Ku/agwmXD1GN6p6lqrvuqov3Kpl/KpnfKFQXJc3bKtGWIQm18NaAYV6egwPrBvDGh6Dxawf5qxkjLFrfJyBbJyDLJcEnK2Eh8i3qrPiipYNTApsJhy6Ua4FEigqoojHp79xma/4Khz3SqScDMqerK/mi3ABm3enDJ+MnLDSWLzu+8pNW8qvm751vL6wfMvqKcXvKceIQb/AoLe4HMxBK8u5S8tAHCqaLMzK/JfELLzGTMKzu8zS/L7NrLzPzMCuPM3azMHnK7HX/P92vLvN4szN3eyx3/x3j+y847zOkKnL3snLg+HLvwDM7FzPNlzN1HvOBRjN9tzPeenOywnPgiHPtTASSfm5CJ3QCr3QDN3QDv3QVykEjEu6FF3R8rYBBFVQNUEUIpEQKZACHxHSHx3SHzHSJN0RJn3SG5HSKp0RLN3SGPHSME0RIG0U6ZwJA/FvN40JOV2dO30JPe3TQp0WP20JQa0LR50LSY0LS30LTe3URU0JT+0NU00LVT0LVy0LWR0LWw0LXe3VUT0JX00sYS3WZS0JY90Kac0Ka70Kbe3WZw0Jb50wcS3Xdf0Ic40KeX0Ke20Kfe3Xd90If602gS3Yhc0Igz3/CoktCosdCo3t2IetCI/tSJEt2ZWdHJetHpndIpvdIJ3t2UMtGZ+9iKN9fKUtEKetqKk92Z/A2pzg2qe02rKt07Qd2rsA25qA28OwAivQC7zt273NC78t3MG9C8NN3MgdELHzOpg3eTTHCQ+wgIZqCF/aOpN3vzLqOPdZ3YkzeZCnZBLm3YfA3YRwOLDlOFhICHuS3pFg3hKJ3ulE3qhzeUdGeQ5YqNRZ3gxCRjgo34LwpctFc+ud34swVr1hjH9CXZl3AM+t3IlwhfXjjgDwcQAg4aCghQFShTHnro8lhptQAeyd4QlK4cOn3jjaccLnPmGi4a3D3OHBAF50rEE0/18Y/giH9RswPqp5AmGIwOOCQAEXKF86VOOLcOOB0uCuxeIr/miolR4OMMRCnoUiCQlfQmRiooV/42sUbuEO3joySAENWB6FsFrS5QlgXKrUnaATvl+a4Dw71oWFsH7ut4NsbglyvuZorkGI494OGEtwDgmBxed6oubI+uNpdIB+Tuh6zmGFyqV/3h2XVwESMJHW0+cOqOjT1B//MSI/foh+AkZkHqxdbmQcHh6yw+muheTCquSDPjvBMQGEyoAVaF2asDrBceCQ7uq040YHQIEXRusGOIGQ14WC+ut6InhdKOYJmCdXSB6PRj218+j5qN6PpuyO0EP3Vemtbuqvfv/px84AFXCA1T7EmBAiqC55OeZD0qPqXW4BX96AKjwIoU4KEtB70j7hp7rC1YUJXfjkeY4Ifojn+44JAe/tiLBBgZdMzV7okYDwIb7tzm4IFjQmiQ7oiCPt927w8gUgrmNDC5/xkRAkm04k4GFE0d1c8z7q52efCuIbf3MBFrblWcoJGWA9cu5eEK/eyjpoY3LimWAiOjRSOG/wBx8BAILzEpwJX7iFOW/E4WGDg4DzUU7kM0QcE3ZdQ8/weW6NON9jMz7kU77ofZLj5p31IN+F8pUe/eb1Ux/2jlDlHFTyZWJEgiLzBO4P9V0kl0SsRbLg7F5skzfdQ5+uB7KuRvb/aOBd64WqQ4MvHIW4+D+O+JgcCYaIiIPo+C0egZEsZId/37t098YoHGq0+WrU+N2+4t0OiNbo9cv98IkQZGq04DDe+Ul++hne7QEOAKw/4PxOHkWmYZrH9H6v8sRf/MZ//Mif/Mq//Mzf/M7//NAf/dI//dRf/dZ//dif/dq//dzf/d7//eAf/uI//uRf/uZ//uif/uq//uzf/u7//vAf/49gVrJFCd4BO/IVm/K//9sACAsHDgCFhoeIiYqKEgcQiA0HF4uUiYILihcHDQCRk5WghYKEoaWmp6ipqqusra6vsLGys7S1trWjt4eNj4eer5eZm7S5usbHyMnKy8zN/87PrcWFEQfVEgAQmw0NEwwHEdQPD40HFY8Z1N+C1ZyGkeQZAOQHDBMP3tULmtUHmMGGFyp8G9bowr58nQ6QW+CtwQMAGQQqPHjgQURr2LS1Q5RtG711mN7la/gQmsmTKFOqXMnylLRDAi1kY9cIUzheE8o9+DbBEC9Ikh6A29XPwQEKiTRFAPCvkECDBCUB/JbQgoVyACgcyKCJk9YMubpm3TpzWKJsDAB4y5CzQtWrbr+2nEu3rt27eCu9NMoPQrZrAKhNCpeO3wOtGH/6khpugcRBAatFuDBhXsWmO5eKLViZX0VPYo0uWMfPQS7S1Rz8pbSaV+aEUDmJzku7tv/t27hjSROUltdqtY4CV2wUD5HQA52Lu5MEVynTQYaMUqgp/EHTwBEeXOVUkHo40MNEizUkCOn4Qr8Db8x4zTVV8LL75Z5Pv779vKizR4oQya/CQhdE0kA44/AzmYGYXEDNepFUU8Ek5ETiwDz1KLhJY/IZMpOA8khi4YCfeRiefBfl80CDFj22wG9XYaLhf+4tBR8As91n44045kgXXDre4liPQAYp5JApldXAJ0S+wgApSTbp5JNQRinllFRWaeWVWGap5ZZcdunll2CGKeaYZJZp5plopqnmmmy26eabcMYp55x01mnnnXjmqeeefPbp55+ABirooIQWauihiCYXquiijDbq6KOQRirppJRWaumlmGZKZyAAOw==);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Used with the permission of the American Joint Committee on Cancer (AJCC), Chicago, Illinois. The original source for this material is the AJCC Cancer Staging Manual, Seventh Edition (2010) published by Springer New York, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_25_4510=[""].join("\n");
var outline_f4_25_4510=null;
var title_f4_25_4511="Contents: Cirrhosis";
var content_f4_25_4511=[" <script type=\"text/javascript\">",
"  $$.inlineInitCustomer(",
"	false);",
"	var quirksmode = document.compatMode == \"CSS1Compat\";",
"	if (quirksmode) {",
"		$(\"html\").addClass(\"ie-standards\");",
"	}",
" </script>",
" <div id=\"message-wrap\">",
"  <div id=\"message-bg\">",
"  </div>",
"  <iframe id=\"message-bk\">",
"  </iframe>",
"  <dl id=\"message-container\">",
"   <dt id=\"message-title\">",
"   </dt>",
"   <dd id=\"message-body\">",
"   </dd>",
"   <dd id=\"message-controls\">",
"   </dd>",
"  </dl>",
" </div>",
" <div id=\"topPanel\">",
"  <div id=\"header\">",
"   <div id=\"header_container\">",
"    <h2 id=\"logo\">",
"     <a href=\"./toc\">",
"      Wolters Kluwer Health UpToDate",
"     </a>",
"    </h2>",
"    <div id=\"header_right\">",
"     <div id=\"searchpanel\">",
"      <a href=\"/login\" id=\"loginbutton\">",
"       Log in",
"      </a>",
"      <div id=\"cmsSearchBox\">",
"       <div class=\"header-search\">",
"        <form action=\"./search\" id=\"cmssearch\" method=\"get\" name=\"SearchForm\">",
"         <div class=\"header-search-left\">",
"          <input autocomplete=\"off\" class=\"searchfield\" id=\"cmsTxtBox\" name=\"search\" placeholder=\"Search UpToDate\" type=\"text\"/>",
"         </div>",
"         <div class=\"header-search-right\">",
"          <input alt=\"Search\" id=\"cmsSearchSubmit\" src=\"/sites/all/themes/uptodate/images/search_button.png\" type=\"image\"/>",
"         </div>",
"         <div class=\"clear\">",
"         </div>",
"        </form>",
"       </div>",
"      </div>",
"      <div id=\"cms_lang_dropdown\">",
"       <form accept-charset=\"UTF-8\" action=\"/\" id=\"lang-dropdown-form\" method=\"post\">",
"        <div class=\"form-item form-type-select form-item-lang-dropdown-select\">",
"         <select class=\"lang-dropdown-select-element form-select\" id=\"edit-lang-dropdown-select\" name=\"lang_dropdown_select\" style=\"width:100px\">",
"          <option selected=\"selected\" value=\"en\">",
"           English",
"          </option>",
"          <option value=\"ja\">",
"           ���������������������������",
"          </option>",
"         </select>",
"        </div>",
"        <input name=\"lang_dropdown_type\" type=\"hidden\" value=\"language\">",
"         <input name=\"en\" type=\"hidden\" value=\"/\">",
"          <input name=\"ja\" type=\"hidden\" value=\"/ja\">",
"           <noscript>",
"            <div>",
"             <input class=\"form-submit\" id=\"edit-submit\" name=\"op\" type=\"submit\" value=\"Go\"/>",
"            </div>",
"           </noscript>",
"           <input name=\"form_build_id\" type=\"hidden\" value=\"form-on4lUWpxHun_wp6revUkjCG6rK2IBuCGME9Cw0HXeok\">",
"            <input name=\"form_id\" type=\"hidden\" value=\"lang_dropdown_form\">",
"            </input>",
"           </input>",
"          </input>",
"         </input>",
"        </input>",
"       </form>",
"      </div>",
"      <div class=\"clear\">",
"      </div>",
"     </div>",
"     <ul id=\"utility\">",
"      <li class=\"first\">",
"       <a href=\"/home/about-us\">",
"        About Us",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/news-events\">",
"        News &amp; Events",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/contact-us\">",
"        Contact Us",
"       </a>",
"      </li>",
"      <li class=\"last\">",
"       <a href=\"/help\">",
"        Help",
"       </a>",
"      </li>",
"     </ul>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"nav\">",
"    <ul>",
"     <li id=\"productTab\">",
"      <a href=\"/home/product\">",
"       Product",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"editoralTab\">",
"      <a href=\"/home/editorial\">",
"       Editorial",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"whyUptodateTab\">",
"      <a href=\"/home/why-uptodate\">",
"       Why UpToDate",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"supscriptionOptionsTab\">",
"      <a href=\"/home/subscription-options\">",
"       Subscription Options",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"/store\">",
"       Subscribe",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"wkhcsTab\">",
"      <a href=\"/home/wolters-kluwer-health-clinical-solutions\">",
"       Wolters Kluwer Health Clinical Solutions",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"    </ul>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"greyBar\">",
"    <div id=\"greyBarTitle\">",
"     <span class=\"emphasis\">",
"      <a href=\"UTD.htm?3/3/3134\">",
"       Contents",
"      </a>",
"     </span>",
"     <img src=\"./../images/space_arrows.myextg\">",
"      <a href=\"UTD.htm?3/12/3278\">",
"       Gastroenterology and Hepatology",
"      </a>",
"      <img src=\"./../images/space_arrows.myextg\">",
"       Cirrhosis",
"      </img>",
"     </img>",
"    </div>",
"    <div id=\"greyBarButtons\">",
"     <div id=\"printGB\">",
"      <a class=\"icontxt\" href=\"?view=print\">",
"       <img align=\"middle\" alt=\"Print this page\" border=\"0\" height=\"20\" src=\"./../images/icn_print.myextg\" width=\"24\"/>",
"      </a>",
"      <a class=\"icontxt\" href=\"?view=print\" title=\"Print this page\">",
"       Print",
"      </a>",
"     </div>",
"    </div>",
"   </div>",
"   <!-- menuMessage.jsp -->",
"   <!-- /menuMessage.jsp -->",
"  </div>",
"  <!-- header -->",
" </div>",
" <!-- topPanel -->",
" <div id=\"leftPanel\">",
"  <ul>",
"   <li>",
"    <a href=\"UTD.htm?3/45/3806\">",
"     Specialties",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?18/22/18798\">",
"     Patient Information",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?3/13/3294\">",
"     What's New",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/37/606\">",
"     Calculators",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/40/654\">",
"     Authors and Editors",
"    </a>",
"   </li>",
"  </ul>",
" </div>",
" <!-- leftPanel -->",
" <div id=\"rightPanel\">",
"  <noscript>",
"   <div id=\"javascriptDisabled\">",
"    It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"   </div>",
"  </noscript>",
"  <div id=\"printHeader\">",
"   <div id=\"printHeaderLogo\">",
"    <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"    </img>",
"   </div>",
"   <div id=\"printHeaderText\">",
"    Official reprint from UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"    <a href=\"file://www.uptodate.com\">",
"     www.uptodate.com",
"    </a>",
"    <br>",
"     &copy;2013 UpToDate",
"     <sup>",
"      &reg;",
"     </sup>",
"    </br>",
"   </div>",
"   <div id=\"printHeaderLinks\">",
"    <a href=\"#\" id=\"printHeaderPrint\" rel=\"\" title=\"Click here to print\">",
"     Print",
"    </a>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"     Back",
"    </a>",
"   </div>",
"  </div>",
"  <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" id=\"tocTable\" width=\"100%\">",
"   <trs>",
"    <tds>",
"     <h1>",
"      Contents:",
"			Cirrhosis",
"     </h1>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds valign=\"top\">",
"     <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">",
"      <trs>",
"       <tds>",
"        <strong>",
"         Ascites",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?0/10/168\">",
"           Chylous, bloody, and pancreatic ascites",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?7/0/7172\">",
"           Clinical manifestations of spontaneous bacterial peritonitis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?12/0/12296\">",
"           Diagnosis of spontaneous bacterial peritonitis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?15/12/15560\">",
"           Diagnostic and therapeutic abdominal paracentesis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?13/43/14010\">",
"           Evaluation of adults with ascites",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?17/12/17608\">",
"           Hyponatremia in patients with cirrhosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?33/35/34359\">",
"           Indications for the use of transjugular intrahepatic portosystemic shunts",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?18/44/19145\">",
"           Initial therapy of ascites in patients with cirrhosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?38/63/39928\">",
"           Malignancy-related ascites",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?21/1/21527\">",
"           Pathogenesis of ascites in patients with cirrhosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?33/25/34197\">",
"           Pathogenesis of spontaneous bacterial peritonitis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?39/22/40292\">",
"           Spontaneous bacterial peritonitis variants",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?4/1/4121\">",
"           Treatment and prophylaxis of spontaneous bacterial peritonitis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?34/40/35465\">",
"           Treatment of diuretic-resistant ascites in patients with cirrhosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?0/40/650\">",
"           Treatment of refractory edema in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?35/48/36614\">",
"           Tuberculous peritonitis",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Etiology",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?28/4/28744\">",
"           Alcoholic hepatitis: Clinical manifestations and diagnosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?0/43/698\">",
"           Alcoholic hepatitis: Natural history and management",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?20/42/21162\">",
"           Clinical manifestations and diagnosis of alcoholic fatty liver disease and alcoholic cirrhosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?27/60/28617\">",
"           Clinical manifestations of hereditary hemochromatosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?12/45/13018\">",
"           Clinical manifestations, diagnosis, and natural history of Wilson disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?40/42/41641\">",
"           Clinical manifestations, diagnosis, and natural history of primary biliary cirrhosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?22/41/23194\">",
"           Diagnostic approach to the patient with cirrhosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?13/37/13910\">",
"           Epidemiology and pathogenesis of Wilson disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?2/13/2266\">",
"           Genetics of hereditary hemochromatosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?17/46/18149\">",
"           Hypercholesterolemia and atherosclerosis in primary biliary cirrhosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?37/60/38856\">",
"           Iron overload syndromes other than hereditary hemochromatosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?29/8/29830\">",
"           Metabolic bone disease in primary biliary cirrhosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?5/38/5737\">",
"           Pathogenesis of primary biliary cirrhosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?21/37/22104\">",
"           Prognosis and management of alcoholic fatty liver disease and alcoholic cirrhosis",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Hepatic encephalopathy",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?33/22/34153\">",
"           Clinical manifestations and diagnosis of hepatic encephalopathy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?15/5/15448\">",
"           Complications of transjugular intrahepatic portosystemic shunts",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?4/15/4346\">",
"           Hepatic encephalopathy in adults: Treatment",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?14/10/14506\">",
"           Hepatic encephalopathy: Pathogenesis",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Hepatorenal syndrome",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?15/5/15448\">",
"           Complications of transjugular intrahepatic portosystemic shunts",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?28/50/29482\">",
"           Hepatorenal syndrome",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?33/35/34359\">",
"           Indications for the use of transjugular intrahepatic portosystemic shunts",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Other",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?12/35/12858\">",
"           Assessing surgical risk in patients with liver disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?39/54/40805\">",
"           Effects of anesthesia and surgery on the liver",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?12/59/13242\">",
"           Emerging therapies for hepatic fibrosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?4/15/4346\">",
"           Hepatic encephalopathy in adults: Treatment",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?29/35/30263\">",
"           Hepatic hydrothorax",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?35/58/36774\">",
"           Hepatopulmonary syndrome: Natural history, treatment, and outcomes",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?3/35/3640\">",
"           Hepatopulmonary syndrome: Prevalence, causes, clinical manifestations, and diagnosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?9/49/10007\">",
"           Management of pain in patients with cirrhosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?15/25/15770\">",
"           Model for End-stage Liver Disease (MELD)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?29/59/30650\">",
"           Noninvasive assessment of hepatic fibrosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?16/59/17337\">",
"           Overview of the complications, prognosis, and management of cirrhosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?33/19/34105\">",
"           Overview of the treatment of primary biliary cirrhosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?32/30/33258\">",
"           Pathogenesis of hepatic fibrosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?34/15/35064\">",
"           Portopulmonary hypertension",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?12/15/12535\">",
"           Screening for hereditary hemochromatosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?13/48/14088\">",
"           Tests used in the diagnosis of Wilson disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?18/32/18952\">",
"           Treatment of hereditary hemochromatosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?42/32/43526\">",
"           Ursodeoxycholic acid in the treatment of primary biliary cirrhosis",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Portal-hypertensive bleeding",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?34/54/35689\">",
"           Endoscopic variceal ligation",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?1/56/1928\">",
"           General principles of the management of variceal hemorrhage",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?33/35/34359\">",
"           Indications for the use of transjugular intrahepatic portosystemic shunts",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?20/60/21446\">",
"           Prediction of variceal hemorrhage in patients with cirrhosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?17/23/17786\">",
"           Prevention of recurrent variceal hemorrhage in patients with cirrhosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?26/49/27418\">",
"           Primary and pre-primary prophylaxis against variceal hemorrhage in patients with cirrhosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?23/19/23863\">",
"           Pruritus associated with cholestasis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?38/37/39511\">",
"           Role of transjugular intrahepatic portosystemic shunts in the treatment of variceal bleeding",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?22/61/23514\">",
"           Treatment of active variceal hemorrhage",
"          </a>",
"         </li>",
"        </ul>",
"       </tds>",
"      </trs>",
"     </div>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"     <img height=\"10\" src=\"./../images/spacer.myextg\" width=\"1\"/>",
"    </tds>",
"   </trs>",
"  </div>",
"  <div id=\"footer\">",
"   <div id=\"footerNav\">",
"    <ul>",
"     <li>",
"      <a href=\"file://www.wolterskluwerhealth.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Wolters Kluwer Health",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.factsandcomparisons.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Facts &amp; Comparisons&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medispan.com\" rel=\"nofollow\" target=\"_blank\">",
"       Medi-Span&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationordersets.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Order Sets",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationmedical.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Medical",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://pharmacyonesource.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Pharmacy OneSource&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medicom.com.cn/\" rel=\"nofollow\" target=\"_blank\">",
"       Medicom",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.lexi.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Lexicomp",
"      </a>",
"     </li>",
"     <li class=\"last\">",
"      <a href=\"/home/privacy-policy\">",
"       Privacy Policy",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"   <div id=\"footerLogo\">",
"    <a href=\"./toc\">",
"     Wolters Kluwer Health | UpToDate",
"    </a>",
"   </div>",
"   <div id=\"supportFooter\">",
"    <span class=\"sfInfo\">",
"     &copy; 2013 UpToDate, Inc. All rights reserved.",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Release: 21.3 - C21.34",
"    </span>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <span class=\"sfInfo\">",
"     <a href=\"/home/terms-use\">",
"      Terms of Use",
"     </a>",
"    </span>",
"    <br/>",
"    <span class=\"sfInfo\">",
"     Licensed to:",
"     <span class=\"emphasis\">",
"      UpToDate Marketing Professional",
"     </span>",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Support Tag: [0605-95.154.198.148-4D068604C3-14]",
"     <br/>",
"    </span>",
"   </div>",
"  </div>",
" </div>",
" <!-- rightPanel -->",
"</body>"].join("\n");
var script_f4_25_4511=[""].join("\n");
var outline_f4_25_4511=null;
